HRP20230340T1 - 1-h-pirolo[2,3-c]piridin-7(6h)-oni i pirazolo[3,4-c]piridin-7(6h)-oni kao inhibitori bet proteina - Google Patents
1-h-pirolo[2,3-c]piridin-7(6h)-oni i pirazolo[3,4-c]piridin-7(6h)-oni kao inhibitori bet proteina Download PDFInfo
- Publication number
- HRP20230340T1 HRP20230340T1 HRP20230340TT HRP20230340T HRP20230340T1 HR P20230340 T1 HRP20230340 T1 HR P20230340T1 HR P20230340T T HRP20230340T T HR P20230340TT HR P20230340 T HRP20230340 T HR P20230340T HR P20230340 T1 HRP20230340 T1 HR P20230340T1
- Authority
- HR
- Croatia
- Prior art keywords
- dihydro
- methyl
- oxo
- pyridin
- pyrrolo
- Prior art date
Links
- 239000003112 inhibitor Substances 0.000 title claims 4
- CIRNDJMEVJYOAW-UHFFFAOYSA-N 1,6-dihydropyrrolo[2,3-c]pyridin-7-one Chemical class O=C1NC=CC2=C1NC=C2 CIRNDJMEVJYOAW-UHFFFAOYSA-N 0.000 title 1
- QWXPWACMFNEWOR-UHFFFAOYSA-N 5,6-dihydropyrazolo[3,4-c]pyridin-7-one Chemical class O=C1NCC=C2C=NN=C12 QWXPWACMFNEWOR-UHFFFAOYSA-N 0.000 title 1
- 229940088617 BET protein inhibitor Drugs 0.000 claims 35
- 239000002246 antineoplastic agent Substances 0.000 claims 19
- 229940127089 cytotoxic agent Drugs 0.000 claims 19
- -1 alemtuzumab Chemical compound 0.000 claims 15
- 239000003814 drug Substances 0.000 claims 15
- 229940124597 therapeutic agent Drugs 0.000 claims 15
- VZSAMEOETVNDQH-UHFFFAOYSA-N CC1(OC2=C(N(C1=O)C)C=C(C=C2C=2C1=C(C(N(C2)C)=O)NC=C1)S(=O)(=O)C)C Chemical compound CC1(OC2=C(N(C1=O)C)C=C(C=C2C=2C1=C(C(N(C2)C)=O)NC=C1)S(=O)(=O)C)C VZSAMEOETVNDQH-UHFFFAOYSA-N 0.000 claims 8
- 150000003839 salts Chemical class 0.000 claims 8
- YMXDUJHQMMRCDQ-UHFFFAOYSA-N 2-[6-methoxy-8-(6-methyl-7-oxo-1H-pyrrolo[2,3-c]pyridin-4-yl)-3-oxo-2-propan-2-yl-1,4-benzoxazin-4-yl]acetic acid Chemical compound C(C)(C)C1OC2=C(N(C1=O)CC(=O)O)C=C(C=C2C=2C1=C(C(N(C2)C)=O)NC=C1)OC YMXDUJHQMMRCDQ-UHFFFAOYSA-N 0.000 claims 6
- RHYOGQKAKBDMMP-UHFFFAOYSA-N 4,5-dimethyl-8-(6-methyl-7-oxo-3aH-pyrrolo[2,3-c]pyridin-4-yl)-6-piperidin-1-ylsulfonyl-2-propan-2-yl-1,4-benzoxazin-3-one Chemical compound CC1=C(C=C(C2=C1N(C(=O)C(O2)C(C)C)C)C3=CN(C(=O)C4=NC=CC34)C)S(=O)(=O)N5CCCCC5 RHYOGQKAKBDMMP-UHFFFAOYSA-N 0.000 claims 6
- CUTSJIQRJNXWGF-UHFFFAOYSA-N 8-(6-methyl-7-oxo-1H-pyrrolo[2,3-c]pyridin-4-yl)-2-propan-2-yl-6-propan-2-ylsulfonyl-4H-1,4-benzoxazin-3-one Chemical compound C(C)(C)C1OC2=C(NC1=O)C=C(C=C2C=2C1=C(C(N(C2)C)=O)NC=C1)S(=O)(=O)C(C)C CUTSJIQRJNXWGF-UHFFFAOYSA-N 0.000 claims 6
- COVZYZSDYWQREU-UHFFFAOYSA-N Busulfan Chemical compound CS(=O)(=O)OCCCCOS(C)(=O)=O COVZYZSDYWQREU-UHFFFAOYSA-N 0.000 claims 6
- BHRFIRJQNJWMER-UHFFFAOYSA-N C(C)(=O)C=1C=C(C2=C(N(C(C(O2)(C)C)=O)C)C1)C=1C2=C(C(N(C1)C)=O)NC=C2 Chemical compound C(C)(=O)C=1C=C(C2=C(N(C(C(O2)(C)C)=O)C)C1)C=1C2=C(C(N(C1)C)=O)NC=C2 BHRFIRJQNJWMER-UHFFFAOYSA-N 0.000 claims 6
- GBDDCVVMMBUQSS-UHFFFAOYSA-N C(C)(=O)C=1C=C(C2=C(NC(C(O2)(C)C)=O)C1)C=1C2=C(C(N(C1)C)=O)NC=C2 Chemical compound C(C)(=O)C=1C=C(C2=C(NC(C(O2)(C)C)=O)C1)C=1C2=C(C(N(C1)C)=O)NC=C2 GBDDCVVMMBUQSS-UHFFFAOYSA-N 0.000 claims 6
- KMEAPQYZZXHZGP-UHFFFAOYSA-N C(C)(=O)C=1C=C(C2=C(NC(C(O2)C(C)C)=O)C1)C=1C2=C(C(N(C1)C)=O)NC=C2 Chemical compound C(C)(=O)C=1C=C(C2=C(NC(C(O2)C(C)C)=O)C1)C=1C2=C(C(N(C1)C)=O)NC=C2 KMEAPQYZZXHZGP-UHFFFAOYSA-N 0.000 claims 6
- RKMKZCHLXSZZSO-UHFFFAOYSA-N C(C)(C)C1OC2=C(N(C1)C)C=C(C=C2C=2C1=C(C(N(C2)C)=O)NC=C1)OC Chemical compound C(C)(C)C1OC2=C(N(C1)C)C=C(C=C2C=2C1=C(C(N(C2)C)=O)NC=C1)OC RKMKZCHLXSZZSO-UHFFFAOYSA-N 0.000 claims 6
- BZDMBDBFOSIAJM-UHFFFAOYSA-N C(C)(C)C1OC2=C(N(C1=O)C(C)C)C=C(C=C2C=2C1=C(C(N(C2)C)=O)NC=C1)OC Chemical compound C(C)(C)C1OC2=C(N(C1=O)C(C)C)C=C(C=C2C=2C1=C(C(N(C2)C)=O)NC=C1)OC BZDMBDBFOSIAJM-UHFFFAOYSA-N 0.000 claims 6
- MWRTXNSJFNRWGB-UHFFFAOYSA-N C(C)(C)C1OC2=C(N(C1=O)C)C=C(C=C2C=2C1=C(C(N(C2)C)=O)NC=C1)C#N Chemical compound C(C)(C)C1OC2=C(N(C1=O)C)C=C(C=C2C=2C1=C(C(N(C2)C)=O)NC=C1)C#N MWRTXNSJFNRWGB-UHFFFAOYSA-N 0.000 claims 6
- VCVIXEIJKSXPNT-UHFFFAOYSA-N C(C)(C)C1OC2=C(N(C1=O)C)C=C(C=C2C=2C1=C(C(N(C2)C)=O)NC=C1)C(=O)N Chemical compound C(C)(C)C1OC2=C(N(C1=O)C)C=C(C=C2C=2C1=C(C(N(C2)C)=O)NC=C1)C(=O)N VCVIXEIJKSXPNT-UHFFFAOYSA-N 0.000 claims 6
- SXYZTRGYEAVJIW-UHFFFAOYSA-N C(C)(C)C1OC2=C(N(C1=O)C)C=C(C=C2C=2C1=C(C(N(C2)C)=O)NC=C1)OC Chemical compound C(C)(C)C1OC2=C(N(C1=O)C)C=C(C=C2C=2C1=C(C(N(C2)C)=O)NC=C1)OC SXYZTRGYEAVJIW-UHFFFAOYSA-N 0.000 claims 6
- WGOXPRDASYHAQQ-UHFFFAOYSA-N C(C)(C)C1OC2=C(N(C1=O)C)C=C(C=C2C=2C1=C(C(N(C2)C)=O)NC=C1)S(=O)(=O)C Chemical compound C(C)(C)C1OC2=C(N(C1=O)C)C=C(C=C2C=2C1=C(C(N(C2)C)=O)NC=C1)S(=O)(=O)C WGOXPRDASYHAQQ-UHFFFAOYSA-N 0.000 claims 6
- ACIXQIIPFSJIFH-UHFFFAOYSA-N C(C)(C)C1OC2=C(N(C1=O)C)C=C(C=C2C=2C1=C(C(N(C2)C)=O)NC=C1)S(=O)(=O)C(C)C Chemical compound C(C)(C)C1OC2=C(N(C1=O)C)C=C(C=C2C=2C1=C(C(N(C2)C)=O)NC=C1)S(=O)(=O)C(C)C ACIXQIIPFSJIFH-UHFFFAOYSA-N 0.000 claims 6
- WFWRYNWEIWQCDH-UHFFFAOYSA-N C(C)(C)C1OC2=C(N(C1=O)C)C=C(C=C2C=2C1=C(C(N(C2)C)=O)NC=C1)S(=O)(=O)N(C)C Chemical compound C(C)(C)C1OC2=C(N(C1=O)C)C=C(C=C2C=2C1=C(C(N(C2)C)=O)NC=C1)S(=O)(=O)N(C)C WFWRYNWEIWQCDH-UHFFFAOYSA-N 0.000 claims 6
- RSTKTMLTNCOEFQ-UHFFFAOYSA-N C(C)(C)C1OC2=C(N(C1=O)CC(=O)N)C=C(C=C2C=2C1=C(C(N(C2)C)=O)NC=C1)OC Chemical compound C(C)(C)C1OC2=C(N(C1=O)CC(=O)N)C=C(C=C2C=2C1=C(C(N(C2)C)=O)NC=C1)OC RSTKTMLTNCOEFQ-UHFFFAOYSA-N 0.000 claims 6
- DTJGBPPBPZKKBJ-UHFFFAOYSA-N C(C)(C)C1OC2=C(N(C1=O)CC(=O)N1CCN(CC1)C)C=C(C=C2C=2C1=C(C(N(C2)C)=O)NC=C1)OC Chemical compound C(C)(C)C1OC2=C(N(C1=O)CC(=O)N1CCN(CC1)C)C=C(C=C2C=2C1=C(C(N(C2)C)=O)NC=C1)OC DTJGBPPBPZKKBJ-UHFFFAOYSA-N 0.000 claims 6
- JAVNUIONZCKOSO-UHFFFAOYSA-N C(C)(C)C1OC2=C(N(C1=O)CC(=O)NC)C=C(C=C2C=2C1=C(C(N(C2)C)=O)NC=C1)OC Chemical compound C(C)(C)C1OC2=C(N(C1=O)CC(=O)NC)C=C(C=C2C=2C1=C(C(N(C2)C)=O)NC=C1)OC JAVNUIONZCKOSO-UHFFFAOYSA-N 0.000 claims 6
- XMCVATSPPKKRPO-UHFFFAOYSA-N C(C)(C)C1OC2=C(NC1=O)C=C(C=C2C=2C1=C(C(N(C2)C)=O)NC=C1)C#N Chemical compound C(C)(C)C1OC2=C(NC1=O)C=C(C=C2C=2C1=C(C(N(C2)C)=O)NC=C1)C#N XMCVATSPPKKRPO-UHFFFAOYSA-N 0.000 claims 6
- VJPORROVNJWNTH-UHFFFAOYSA-N C(C)(C)C1OC2=C(NC1=O)C=C(C=C2C=2C1=C(C(N(C2)C)=O)NC=C1)C(=O)N Chemical compound C(C)(C)C1OC2=C(NC1=O)C=C(C=C2C=2C1=C(C(N(C2)C)=O)NC=C1)C(=O)N VJPORROVNJWNTH-UHFFFAOYSA-N 0.000 claims 6
- XLCCRKYGUWVTNE-UHFFFAOYSA-N C(C)(C)C1OC2=C(NC1=O)C=C(C=C2C=2C1=C(C(N(C2)C)=O)NC=C1)C(=O)N(C)C Chemical compound C(C)(C)C1OC2=C(NC1=O)C=C(C=C2C=2C1=C(C(N(C2)C)=O)NC=C1)C(=O)N(C)C XLCCRKYGUWVTNE-UHFFFAOYSA-N 0.000 claims 6
- PZEAIFBAKMIROG-UHFFFAOYSA-N C(C)(C)C1OC2=C(NC1=O)C=C(C=C2C=2C1=C(C(N(C2)C)=O)NC=C1)C(=O)N1CCOCC1 Chemical compound C(C)(C)C1OC2=C(NC1=O)C=C(C=C2C=2C1=C(C(N(C2)C)=O)NC=C1)C(=O)N1CCOCC1 PZEAIFBAKMIROG-UHFFFAOYSA-N 0.000 claims 6
- HABYNDWUMBDLSU-UHFFFAOYSA-N C(C)(C)C1OC2=C(NC1=O)C=C(C=C2C=2C1=C(C(N(C2)C)=O)NC=C1)C(=O)NC Chemical compound C(C)(C)C1OC2=C(NC1=O)C=C(C=C2C=2C1=C(C(N(C2)C)=O)NC=C1)C(=O)NC HABYNDWUMBDLSU-UHFFFAOYSA-N 0.000 claims 6
- WEBIPQYYGQULER-UHFFFAOYSA-N C(C)(C)C1OC2=C(NC1=O)C=C(C=C2C=2C1=C(C(N(C2)C)=O)NC=C1)C=1C=NN(C1)C Chemical compound C(C)(C)C1OC2=C(NC1=O)C=C(C=C2C=2C1=C(C(N(C2)C)=O)NC=C1)C=1C=NN(C1)C WEBIPQYYGQULER-UHFFFAOYSA-N 0.000 claims 6
- ZOIAALYHIWXWIE-UHFFFAOYSA-N C(C)(C)C1OC2=C(NC1=O)C=C(C=C2C=2C1=C(C(N(C2)C)=O)NC=C1)CNC(C)=O Chemical compound C(C)(C)C1OC2=C(NC1=O)C=C(C=C2C=2C1=C(C(N(C2)C)=O)NC=C1)CNC(C)=O ZOIAALYHIWXWIE-UHFFFAOYSA-N 0.000 claims 6
- WSYTXPXMORQZPT-UHFFFAOYSA-N C(C)(C)C1OC2=C(NC1=O)C=C(C=C2C=2C1=C(C(N(C2)C)=O)NC=C1)CNS(=O)(=O)CC Chemical compound C(C)(C)C1OC2=C(NC1=O)C=C(C=C2C=2C1=C(C(N(C2)C)=O)NC=C1)CNS(=O)(=O)CC WSYTXPXMORQZPT-UHFFFAOYSA-N 0.000 claims 6
- KTPJSJZLDJHYMM-UHFFFAOYSA-N C(C)(C)C1OC2=C(NC1=O)C=C(C=C2C=2C1=C(C(N(C2)C)=O)NC=C1)COC Chemical compound C(C)(C)C1OC2=C(NC1=O)C=C(C=C2C=2C1=C(C(N(C2)C)=O)NC=C1)COC KTPJSJZLDJHYMM-UHFFFAOYSA-N 0.000 claims 6
- KRJWGRKYQVYBNX-UHFFFAOYSA-N C(C)(C)C1OC2=C(NC1=O)C=C(C=C2C=2C1=C(C(N(C2)C)=O)NC=C1)OC Chemical compound C(C)(C)C1OC2=C(NC1=O)C=C(C=C2C=2C1=C(C(N(C2)C)=O)NC=C1)OC KRJWGRKYQVYBNX-UHFFFAOYSA-N 0.000 claims 6
- MQXCZCZVDCBXEP-UHFFFAOYSA-N C(C)(C)C1OC2=C(NC1=O)C=C(C=C2C=2C1=C(C(N(C2)C)=O)NC=C1)S(=O)(=O)C Chemical compound C(C)(C)C1OC2=C(NC1=O)C=C(C=C2C=2C1=C(C(N(C2)C)=O)NC=C1)S(=O)(=O)C MQXCZCZVDCBXEP-UHFFFAOYSA-N 0.000 claims 6
- NEPDDSPFRJKQIG-UHFFFAOYSA-N C(C)(C)C1OC2=C(NC1=O)C=C(C=C2C=2C1=C(C(N(C2)C)=O)NC=C1)S(=O)(=O)N(C)C Chemical compound C(C)(C)C1OC2=C(NC1=O)C=C(C=C2C=2C1=C(C(N(C2)C)=O)NC=C1)S(=O)(=O)N(C)C NEPDDSPFRJKQIG-UHFFFAOYSA-N 0.000 claims 6
- RQCFRYCIVSTQQX-UHFFFAOYSA-N C(C)(C)C1OC2=C(NC1=O)C=C(C=C2C=2C1=C(C(N(C2)C)=O)NC=C1)S(=O)(=O)NC Chemical compound C(C)(C)C1OC2=C(NC1=O)C=C(C=C2C=2C1=C(C(N(C2)C)=O)NC=C1)S(=O)(=O)NC RQCFRYCIVSTQQX-UHFFFAOYSA-N 0.000 claims 6
- BJFXRUBKKJTYMK-UHFFFAOYSA-N C(C)(C)C1OC2=C(NC1=O)C=C(C=C2C=2C1=C(C(N(C2)C)=O)NC=C1)[N+](=O)[O-] Chemical compound C(C)(C)C1OC2=C(NC1=O)C=C(C=C2C=2C1=C(C(N(C2)C)=O)NC=C1)[N+](=O)[O-] BJFXRUBKKJTYMK-UHFFFAOYSA-N 0.000 claims 6
- BHCQUZIQSDHQBI-UHFFFAOYSA-N C(C)(C)C1OC2=C(NC1=O)C=C(C=C2C=2C1=C(C(N(C2)C)=O)NN=C1)OC Chemical compound C(C)(C)C1OC2=C(NC1=O)C=C(C=C2C=2C1=C(C(N(C2)C)=O)NN=C1)OC BHCQUZIQSDHQBI-UHFFFAOYSA-N 0.000 claims 6
- PSGASZJXHIZBPE-UHFFFAOYSA-N C(C)(C)C1OC2=C(NC1=O)C=C(C=C2C=2C1=C(C(N(C2)C)=O)NN=C1)S(=O)(=O)C Chemical compound C(C)(C)C1OC2=C(NC1=O)C=C(C=C2C=2C1=C(C(N(C2)C)=O)NN=C1)S(=O)(=O)C PSGASZJXHIZBPE-UHFFFAOYSA-N 0.000 claims 6
- FACZPYRLHYCURA-UHFFFAOYSA-N C(C)(C)NS(=O)(=O)C=1C=C(C2=C(NC(C(O2)(C)C)=O)C1)C=1C2=C(C(N(C1)C)=O)NC=C2 Chemical compound C(C)(C)NS(=O)(=O)C=1C=C(C2=C(NC(C(O2)(C)C)=O)C1)C=1C2=C(C(N(C1)C)=O)NC=C2 FACZPYRLHYCURA-UHFFFAOYSA-N 0.000 claims 6
- HNQLCPAQQAHVOG-UHFFFAOYSA-N C(C)(C)S(=O)(=O)C=1C=C(C2=C(N(C(C(O2)(C)C)=O)C)C1)C=1C2=C(C(N(C1)C)=O)NC=C2 Chemical compound C(C)(C)S(=O)(=O)C=1C=C(C2=C(N(C(C(O2)(C)C)=O)C)C1)C=1C2=C(C(N(C1)C)=O)NC=C2 HNQLCPAQQAHVOG-UHFFFAOYSA-N 0.000 claims 6
- IFMPPLILXDJTER-UHFFFAOYSA-N C(C)(C)S(=O)(=O)C=1C=C(C2=C(NC(C(O2)(C)C)=O)C1)C=1C2=C(C(N(C1)C)=O)NC=C2 Chemical compound C(C)(C)S(=O)(=O)C=1C=C(C2=C(NC(C(O2)(C)C)=O)C1)C=1C2=C(C(N(C1)C)=O)NC=C2 IFMPPLILXDJTER-UHFFFAOYSA-N 0.000 claims 6
- SSYAJZNGKRVZDT-MRXNPFEDSA-N C(C)(C)[C@@H]1C(NC2=CC(=CC(=C2N1)C=1C2=C(C(N(C1)C)=O)NC=C2)S(=O)(=O)C)=O Chemical compound C(C)(C)[C@@H]1C(NC2=CC(=CC(=C2N1)C=1C2=C(C(N(C1)C)=O)NC=C2)S(=O)(=O)C)=O SSYAJZNGKRVZDT-MRXNPFEDSA-N 0.000 claims 6
- SSYAJZNGKRVZDT-INIZCTEOSA-N C(C)(C)[C@H]1C(NC2=CC(=CC(=C2N1)C=1C2=C(C(N(C1)C)=O)NC=C2)S(=O)(=O)C)=O Chemical compound C(C)(C)[C@H]1C(NC2=CC(=CC(=C2N1)C=1C2=C(C(N(C1)C)=O)NC=C2)S(=O)(=O)C)=O SSYAJZNGKRVZDT-INIZCTEOSA-N 0.000 claims 6
- FCOINXWHXDCOAG-UHFFFAOYSA-N C(C)C1OC2=C(N(C1=O)C)C=CC=C2C=2C1=C(C(N(C2)C)=O)NC=C1 Chemical compound C(C)C1OC2=C(N(C1=O)C)C=CC=C2C=2C1=C(C(N(C2)C)=O)NC=C1 FCOINXWHXDCOAG-UHFFFAOYSA-N 0.000 claims 6
- NJXCTPVBHMBLOD-UHFFFAOYSA-N C(C)N1C(C(OC2=C1C=C(C=C2C=2C1=C(C(N(C2)C)=O)NC=C1)S(=O)(=O)C)C(C)C)=O Chemical compound C(C)N1C(C(OC2=C1C=C(C=C2C=2C1=C(C(N(C2)C)=O)NC=C1)S(=O)(=O)C)C(C)C)=O NJXCTPVBHMBLOD-UHFFFAOYSA-N 0.000 claims 6
- SAFVBAUCLGDZHX-UHFFFAOYSA-N C(C)S(=O)(=O)C=1C=C(C2=C(N(C(C(O2)(C)C)=O)C)C1)C=1C2=C(C(N(C1)C)=O)NC=C2 Chemical compound C(C)S(=O)(=O)C=1C=C(C2=C(N(C(C(O2)(C)C)=O)C)C1)C=1C2=C(C(N(C1)C)=O)NC=C2 SAFVBAUCLGDZHX-UHFFFAOYSA-N 0.000 claims 6
- AOFYESONCWVXOM-UHFFFAOYSA-N C(C)S(=O)(=O)C=1C=C(C2=C(N(C(C(O2)C(C)C)=O)C)C1)C=1C2=C(C(N(C1)C)=O)NC=C2 Chemical compound C(C)S(=O)(=O)C=1C=C(C2=C(N(C(C(O2)C(C)C)=O)C)C1)C=1C2=C(C(N(C1)C)=O)NC=C2 AOFYESONCWVXOM-UHFFFAOYSA-N 0.000 claims 6
- UUZKTBMPOCFCII-UHFFFAOYSA-N C(C)S(=O)(=O)C=1C=C(C2=C(NC(C(O2)(C)C)=O)C1)C=1C2=C(C(N(C1)C)=O)NC=C2 Chemical compound C(C)S(=O)(=O)C=1C=C(C2=C(NC(C(O2)(C)C)=O)C1)C=1C2=C(C(N(C1)C)=O)NC=C2 UUZKTBMPOCFCII-UHFFFAOYSA-N 0.000 claims 6
- FXNXKAYEZZOSLM-UHFFFAOYSA-N C(C)S(=O)(=O)C=1C=C(C2=C(NC(C(O2)C(C)C)=O)C1)C=1C2=C(C(N(C1)C)=O)NC=C2 Chemical compound C(C)S(=O)(=O)C=1C=C(C2=C(NC(C(O2)C(C)C)=O)C1)C=1C2=C(C(N(C1)C)=O)NC=C2 FXNXKAYEZZOSLM-UHFFFAOYSA-N 0.000 claims 6
- YFEHNICKIWSDPK-UHFFFAOYSA-N C1(CC1)C1OC2=C(NC1=O)C=C(C=C2C=2C1=C(C(N(C2)C)=O)NC=C1)OC Chemical compound C1(CC1)C1OC2=C(NC1=O)C=C(C=C2C=2C1=C(C(N(C2)C)=O)NC=C1)OC YFEHNICKIWSDPK-UHFFFAOYSA-N 0.000 claims 6
- FYVGXSSFEOIVOH-UHFFFAOYSA-N C1(CC1)CN1C(C(OC2=C1C=C(C=C2C=2C1=C(C(N(C2)C)=O)NC=C1)S(=O)(=O)C)C(C)C)=O Chemical compound C1(CC1)CN1C(C(OC2=C1C=C(C=C2C=2C1=C(C(N(C2)C)=O)NC=C1)S(=O)(=O)C)C(C)C)=O FYVGXSSFEOIVOH-UHFFFAOYSA-N 0.000 claims 6
- APVTWFGLNNDNFT-UHFFFAOYSA-N C1(CCCC1)C1OC2=C(NC1=O)C=C(C=C2C=2C1=C(C(N(C2)C)=O)NC=C1)OC Chemical compound C1(CCCC1)C1OC2=C(NC1=O)C=C(C=C2C=2C1=C(C(N(C2)C)=O)NC=C1)OC APVTWFGLNNDNFT-UHFFFAOYSA-N 0.000 claims 6
- ZQNWOJLLSNTBOT-UHFFFAOYSA-N C1(CCCC1)C1OC2=C(NC1=O)C=C(C=C2C=2C1=C(C(N(C2)C)=O)NN=C1)OC Chemical compound C1(CCCC1)C1OC2=C(NC1=O)C=C(C=C2C=2C1=C(C(N(C2)C)=O)NN=C1)OC ZQNWOJLLSNTBOT-UHFFFAOYSA-N 0.000 claims 6
- GEOFFFTZVWEORK-UHFFFAOYSA-N CC1(C(NC2=CC(=CC(=C2N1)C=1C2=C(C(N(C1)C)=O)NC=C2)S(=O)(=O)C)=O)C Chemical compound CC1(C(NC2=CC(=CC(=C2N1)C=1C2=C(C(N(C1)C)=O)NC=C2)S(=O)(=O)C)=O)C GEOFFFTZVWEORK-UHFFFAOYSA-N 0.000 claims 6
- AOCBNYMNFJBMMG-UHFFFAOYSA-N CC1(OC2=C(NC1=O)C=C(C=C2C=2C1=C(C(N(C2)C)=O)NC=C1)S(=O)(=O)C)C Chemical compound CC1(OC2=C(NC1=O)C=C(C=C2C=2C1=C(C(N(C2)C)=O)NC=C1)S(=O)(=O)C)C AOCBNYMNFJBMMG-UHFFFAOYSA-N 0.000 claims 6
- WQVKFRLTBDFPLL-UHFFFAOYSA-N CC1(OC2=C(NC1=O)C=C(C=C2C=2C1=C(C(N(C2)C)=O)NC=C1)S(=O)(=O)N1CCCCC1)C Chemical compound CC1(OC2=C(NC1=O)C=C(C=C2C=2C1=C(C(N(C2)C)=O)NC=C1)S(=O)(=O)N1CCCCC1)C WQVKFRLTBDFPLL-UHFFFAOYSA-N 0.000 claims 6
- HBMRYZMTMNSJHQ-UHFFFAOYSA-N CN(S(=O)(=O)C=1C=C(C2=C(N(C(C(O2)(C)C)=O)C)C1)C=1C2=C(C(N(C1)C)=O)NC=C2)C Chemical compound CN(S(=O)(=O)C=1C=C(C2=C(N(C(C(O2)(C)C)=O)C)C1)C=1C2=C(C(N(C1)C)=O)NC=C2)C HBMRYZMTMNSJHQ-UHFFFAOYSA-N 0.000 claims 6
- XDULBZUBUWDUQX-UHFFFAOYSA-N CN(S(=O)(=O)C=1C=C(C2=C(NC(C(O2)(C)C)=O)C1)C=1C2=C(C(N(C1)C)=O)NC=C2)C Chemical compound CN(S(=O)(=O)C=1C=C(C2=C(NC(C(O2)(C)C)=O)C1)C=1C2=C(C(N(C1)C)=O)NC=C2)C XDULBZUBUWDUQX-UHFFFAOYSA-N 0.000 claims 6
- HNVGNTKAVBOFFJ-UHFFFAOYSA-N CN1C(C2(OC3=C1C=C(C=C3C=3C1=C(C(N(C3)C)=O)NC=C1)S(=O)(=O)C)CC2)=O Chemical compound CN1C(C2(OC3=C1C=C(C=C3C=3C1=C(C(N(C3)C)=O)NC=C1)S(=O)(=O)C)CC2)=O HNVGNTKAVBOFFJ-UHFFFAOYSA-N 0.000 claims 6
- DCRSESOZHPEKDC-UHFFFAOYSA-N CN1C(C2(OC3=C1C=C(C=C3C=3C1=C(C(N(C3)C)=O)NN=C1)S(=O)(=O)C)CC2)=O Chemical compound CN1C(C2(OC3=C1C=C(C=C3C=3C1=C(C(N(C3)C)=O)NN=C1)S(=O)(=O)C)CC2)=O DCRSESOZHPEKDC-UHFFFAOYSA-N 0.000 claims 6
- OTAWOJQJKMLEIJ-UHFFFAOYSA-N CN1C(C2=C(C(=C1)C1=CC(=CC=3NC(C(OC31)C3=CC=CC=C3)=O)S(=O)(=O)C)C=CN2)=O Chemical compound CN1C(C2=C(C(=C1)C1=CC(=CC=3NC(C(OC31)C3=CC=CC=C3)=O)S(=O)(=O)C)C=CN2)=O OTAWOJQJKMLEIJ-UHFFFAOYSA-N 0.000 claims 6
- PSNFDUYWYRHDGG-UHFFFAOYSA-N CN1C(C2=C(C(=C1)C1=CC(=CC=3NC(C4(OC31)CC4)=O)S(=O)(=O)C)C=CN2)=O Chemical compound CN1C(C2=C(C(=C1)C1=CC(=CC=3NC(C4(OC31)CC4)=O)S(=O)(=O)C)C=CN2)=O PSNFDUYWYRHDGG-UHFFFAOYSA-N 0.000 claims 6
- BJNFZKYTEAIKRD-UHFFFAOYSA-N CN1C(C2=C(C(=C1)C1=CC(=CC=3NC(C4(OC31)CC4)=O)S(=O)(=O)C)C=NN2)=O Chemical compound CN1C(C2=C(C(=C1)C1=CC(=CC=3NC(C4(OC31)CC4)=O)S(=O)(=O)C)C=NN2)=O BJNFZKYTEAIKRD-UHFFFAOYSA-N 0.000 claims 6
- BHNIBBIFICVZCH-UHFFFAOYSA-N CN1C(C2=C(C(=C1)C1=CC=CC=3NC(C(OC31)C3CCOCC3)=O)C=CN2)=O Chemical compound CN1C(C2=C(C(=C1)C1=CC=CC=3NC(C(OC31)C3CCOCC3)=O)C=CN2)=O BHNIBBIFICVZCH-UHFFFAOYSA-N 0.000 claims 6
- WYJVNKCWTPZLLE-UHFFFAOYSA-N CN1C(C2=C(C(=C1)C1=CC=CC=3NC(C4(OC31)CC4)=O)C=CN2)=O Chemical compound CN1C(C2=C(C(=C1)C1=CC=CC=3NC(C4(OC31)CC4)=O)C=CN2)=O WYJVNKCWTPZLLE-UHFFFAOYSA-N 0.000 claims 6
- SZLGPPBPAXZKQQ-UHFFFAOYSA-N CN1C(C2=C(C(=C1)C=1C=C(C=C3NC(C4(CCC4)NC13)=O)S(=O)(=O)C)C=CN2)=O Chemical compound CN1C(C2=C(C(=C1)C=1C=C(C=C3NC(C4(CCC4)NC13)=O)S(=O)(=O)C)C=CN2)=O SZLGPPBPAXZKQQ-UHFFFAOYSA-N 0.000 claims 6
- JSNIIGHYZBWOSP-UHFFFAOYSA-N CN1C(C2=C(C(=C1)C=1C=C(C=C3NC(C4(CCCC4)NC13)=O)S(=O)(=O)C)C=CN2)=O Chemical compound CN1C(C2=C(C(=C1)C=1C=C(C=C3NC(C4(CCCC4)NC13)=O)S(=O)(=O)C)C=CN2)=O JSNIIGHYZBWOSP-UHFFFAOYSA-N 0.000 claims 6
- OIDVRFDJFDTSDS-UHFFFAOYSA-N CN1C(C2=C(C(=C1)C=1C=C(C=C3NC(C4(CCCCC4)NC13)=O)S(=O)(=O)C)C=CN2)=O Chemical compound CN1C(C2=C(C(=C1)C=1C=C(C=C3NC(C4(CCCCC4)NC13)=O)S(=O)(=O)C)C=CN2)=O OIDVRFDJFDTSDS-UHFFFAOYSA-N 0.000 claims 6
- WUOBHXKRFOEWOR-UHFFFAOYSA-N COC=1C=C(C2=C(NC(C(O2)(C)C)=O)C1)C=1C2=C(C(N(C1)C)=O)NN=C2 Chemical compound COC=1C=C(C2=C(NC(C(O2)(C)C)=O)C1)C=1C2=C(C(N(C1)C)=O)NN=C2 WUOBHXKRFOEWOR-UHFFFAOYSA-N 0.000 claims 6
- ZEABVHUCUWANHU-UHFFFAOYSA-N COC=1C=C(C2=C(NC(C(O2)C2=CC=CC=C2)=O)C1)C=1C2=C(C(N(C1)C)=O)NC=C2 Chemical compound COC=1C=C(C2=C(NC(C(O2)C2=CC=CC=C2)=O)C1)C=1C2=C(C(N(C1)C)=O)NC=C2 ZEABVHUCUWANHU-UHFFFAOYSA-N 0.000 claims 6
- NNJNYMIRXGUCJK-UHFFFAOYSA-N ClC1=C(C=CC(=C1)F)C1OC2=C(NC1=O)C=C(C=C2C=2C1=C(C(N(C2)C)=O)NC=C1)OC Chemical compound ClC1=C(C=CC(=C1)F)C1OC2=C(NC1=O)C=C(C=C2C=2C1=C(C(N(C2)C)=O)NC=C1)OC NNJNYMIRXGUCJK-UHFFFAOYSA-N 0.000 claims 6
- AOJJSUZBOXZQNB-TZSSRYMLSA-N Doxorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-TZSSRYMLSA-N 0.000 claims 6
- SLFXKAJDMQVESP-UHFFFAOYSA-N FC(C(=O)O)(F)F.CN1C(C2=C(C(=C1)C1=CC=CC=3NC(C(OC31)C3=NC=CC=C3)=O)C=CN2)=O Chemical compound FC(C(=O)O)(F)F.CN1C(C2=C(C(=C1)C1=CC=CC=3NC(C(OC31)C3=NC=CC=C3)=O)C=CN2)=O SLFXKAJDMQVESP-UHFFFAOYSA-N 0.000 claims 6
- 229940122245 Janus kinase inhibitor Drugs 0.000 claims 6
- BKQWIHVVMWEYDH-UHFFFAOYSA-N NCC=1C=C(C2=C(NC(C(O2)C(C)C)=O)C1)C=1C2=C(C(N(C1)C)=O)NC=C2 Chemical compound NCC=1C=C(C2=C(NC(C(O2)C(C)C)=O)C1)C=1C2=C(C(N(C1)C)=O)NC=C2 BKQWIHVVMWEYDH-UHFFFAOYSA-N 0.000 claims 6
- 206010028980 Neoplasm Diseases 0.000 claims 6
- OKZRWDHEALFURO-UHFFFAOYSA-N O1C(=CC=C1)C=1C=C(C2=C(NC(C(O2)C(C)C)=O)C1)C=1C2=C(C(N(C1)C)=O)NC=C2 Chemical compound O1C(=CC=C1)C=1C=C(C2=C(NC(C(O2)C(C)C)=O)C1)C=1C2=C(C(N(C1)C)=O)NC=C2 OKZRWDHEALFURO-UHFFFAOYSA-N 0.000 claims 6
- AUHMZDOEKXETAW-UHFFFAOYSA-N OC(C)C=1C=C(C2=C(N(C(C(O2)(C)C)=O)C)C1)C=1C2=C(C(N(C1)C)=O)NC=C2 Chemical compound OC(C)C=1C=C(C2=C(N(C(C(O2)(C)C)=O)C)C1)C=1C2=C(C(N(C1)C)=O)NC=C2 AUHMZDOEKXETAW-UHFFFAOYSA-N 0.000 claims 6
- DXINHNGNHIKJDL-UHFFFAOYSA-N OC(C)C=1C=C(C2=C(NC(C(O2)(C)C)=O)C1)C=1C2=C(C(N(C1)C)=O)NC=C2 Chemical compound OC(C)C=1C=C(C2=C(NC(C(O2)(C)C)=O)C1)C=1C2=C(C(N(C1)C)=O)NC=C2 DXINHNGNHIKJDL-UHFFFAOYSA-N 0.000 claims 6
- NILVYPJGBOOINW-UHFFFAOYSA-N OC(C)C=1C=C(C2=C(NC(C(O2)C(C)C)=O)C1)C=1C2=C(C(N(C1)C)=O)NC=C2 Chemical compound OC(C)C=1C=C(C2=C(NC(C(O2)C(C)C)=O)C1)C=1C2=C(C(N(C1)C)=O)NC=C2 NILVYPJGBOOINW-UHFFFAOYSA-N 0.000 claims 6
- YNXBIVULWPMDOG-UHFFFAOYSA-N OCC=1C=C(C2=C(NC(C(O2)C(C)C)=O)C1)C=1C2=C(C(N(C1)C)=O)NC=C2 Chemical compound OCC=1C=C(C2=C(NC(C(O2)C(C)C)=O)C1)C=1C2=C(C(N(C1)C)=O)NC=C2 YNXBIVULWPMDOG-UHFFFAOYSA-N 0.000 claims 6
- AWKUZPDMHVLKQW-UHFFFAOYSA-N OCCC1OC2=C(NC1=O)C=C(C=C2C=2C1=C(C(N(C2)C)=O)NC=C1)S(=O)(=O)C Chemical compound OCCC1OC2=C(NC1=O)C=C(C=C2C=2C1=C(C(N(C2)C)=O)NC=C1)S(=O)(=O)C AWKUZPDMHVLKQW-UHFFFAOYSA-N 0.000 claims 6
- NKANXQFJJICGDU-QPLCGJKRSA-N Tamoxifen Chemical compound C=1C=CC=CC=1C(/CC)=C(C=1C=CC(OCCN(C)C)=CC=1)/C1=CC=CC=C1 NKANXQFJJICGDU-QPLCGJKRSA-N 0.000 claims 6
- RJURFGZVJUQBHK-UHFFFAOYSA-N actinomycin D Natural products CC1OC(=O)C(C(C)C)N(C)C(=O)CN(C)C(=O)C2CCCN2C(=O)C(C(C)C)NC(=O)C1NC(=O)C1=C(N)C(=O)C(C)=C2OC(C(C)=CC=C3C(=O)NC4C(=O)NC(C(N5CCCC5C(=O)N(C)CC(=O)N(C)C(C(C)C)C(=O)OC4C)=O)C(C)C)=C3N=C21 RJURFGZVJUQBHK-UHFFFAOYSA-N 0.000 claims 6
- GXJABQQUPOEUTA-RDJZCZTQSA-N bortezomib Chemical compound C([C@@H](C(=O)N[C@@H](CC(C)C)B(O)O)NC(=O)C=1N=CC=NC=1)C1=CC=CC=C1 GXJABQQUPOEUTA-RDJZCZTQSA-N 0.000 claims 6
- 229960001467 bortezomib Drugs 0.000 claims 6
- 229960002092 busulfan Drugs 0.000 claims 6
- 201000011510 cancer Diseases 0.000 claims 6
- YAGDWXZVBYSOAH-UHFFFAOYSA-N COC=1C=C(C2=C(NC(C(O2)(C)C)=O)C1)C=1C2=C(C(N(C1)C)=O)NC=C2 Chemical compound COC=1C=C(C2=C(NC(C(O2)(C)C)=O)C1)C=1C2=C(C(N(C1)C)=O)NC=C2 YAGDWXZVBYSOAH-UHFFFAOYSA-N 0.000 claims 5
- BMKDZUISNHGIBY-ZETCQYMHSA-N (+)-dexrazoxane Chemical compound C([C@H](C)N1CC(=O)NC(=O)C1)N1CC(=O)NC(=O)C1 BMKDZUISNHGIBY-ZETCQYMHSA-N 0.000 claims 3
- FPVKHBSQESCIEP-UHFFFAOYSA-N (8S)-3-(2-deoxy-beta-D-erythro-pentofuranosyl)-3,6,7,8-tetrahydroimidazo[4,5-d][1,3]diazepin-8-ol Natural products C1C(O)C(CO)OC1N1C(NC=NCC2O)=C2N=C1 FPVKHBSQESCIEP-UHFFFAOYSA-N 0.000 claims 3
- FDKXTQMXEQVLRF-ZHACJKMWSA-N (E)-dacarbazine Chemical compound CN(C)\N=N\c1[nH]cnc1C(N)=O FDKXTQMXEQVLRF-ZHACJKMWSA-N 0.000 claims 3
- XGQXULJHBWKUJY-LYIKAWCPSA-N (z)-but-2-enedioic acid;n-[2-(diethylamino)ethyl]-5-[(z)-(5-fluoro-2-oxo-1h-indol-3-ylidene)methyl]-2,4-dimethyl-1h-pyrrole-3-carboxamide Chemical compound OC(=O)\C=C/C(O)=O.CCN(CC)CCNC(=O)C1=C(C)NC(\C=C/2C3=CC(F)=CC=C3NC\2=O)=C1C XGQXULJHBWKUJY-LYIKAWCPSA-N 0.000 claims 3
- HJTAZXHBEBIQQX-UHFFFAOYSA-N 1,5-bis(chloromethyl)naphthalene Chemical compound C1=CC=C2C(CCl)=CC=CC2=C1CCl HJTAZXHBEBIQQX-UHFFFAOYSA-N 0.000 claims 3
- UEJJHQNACJXSKW-UHFFFAOYSA-N 2-(2,6-dioxopiperidin-3-yl)-1H-isoindole-1,3(2H)-dione Chemical compound O=C1C2=CC=CC=C2C(=O)N1C1CCC(=O)NC1=O UEJJHQNACJXSKW-UHFFFAOYSA-N 0.000 claims 3
- RTQWWZBSTRGEAV-PKHIMPSTSA-N 2-[[(2s)-2-[bis(carboxymethyl)amino]-3-[4-(methylcarbamoylamino)phenyl]propyl]-[2-[bis(carboxymethyl)amino]propyl]amino]acetic acid Chemical compound CNC(=O)NC1=CC=C(C[C@@H](CN(CC(C)N(CC(O)=O)CC(O)=O)CC(O)=O)N(CC(O)=O)CC(O)=O)C=C1 RTQWWZBSTRGEAV-PKHIMPSTSA-N 0.000 claims 3
- AOJJSUZBOXZQNB-VTZDEGQISA-N 4'-epidoxorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-VTZDEGQISA-N 0.000 claims 3
- IDPUKCWIGUEADI-UHFFFAOYSA-N 5-[bis(2-chloroethyl)amino]uracil Chemical compound ClCCN(CCCl)C1=CNC(=O)NC1=O IDPUKCWIGUEADI-UHFFFAOYSA-N 0.000 claims 3
- XAUDJQYHKZQPEU-KVQBGUIXSA-N 5-aza-2'-deoxycytidine Chemical compound O=C1N=C(N)N=CN1[C@@H]1O[C@H](CO)[C@@H](O)C1 XAUDJQYHKZQPEU-KVQBGUIXSA-N 0.000 claims 3
- NMUSYJAQQFHJEW-KVTDHHQDSA-N 5-azacytidine Chemical compound O=C1N=C(N)N=CN1[C@H]1[C@H](O)[C@H](O)[C@@H](CO)O1 NMUSYJAQQFHJEW-KVTDHHQDSA-N 0.000 claims 3
- WYWHKKSPHMUBEB-UHFFFAOYSA-N 6-Mercaptoguanine Natural products N1C(N)=NC(=S)C2=C1N=CN2 WYWHKKSPHMUBEB-UHFFFAOYSA-N 0.000 claims 3
- STQGQHZAVUOBTE-UHFFFAOYSA-N 7-Cyan-hept-2t-en-4,6-diinsaeure Natural products C1=2C(O)=C3C(=O)C=4C(OC)=CC=CC=4C(=O)C3=C(O)C=2CC(O)(C(C)=O)CC1OC1CC(N)C(O)C(C)O1 STQGQHZAVUOBTE-UHFFFAOYSA-N 0.000 claims 3
- SHGAZHPCJJPHSC-ZVCIMWCZSA-N 9-cis-retinoic acid Chemical compound OC(=O)/C=C(\C)/C=C/C=C(/C)\C=C\C1=C(C)CCCC1(C)C SHGAZHPCJJPHSC-ZVCIMWCZSA-N 0.000 claims 3
- BFYIZQONLCFLEV-DAELLWKTSA-N Aromasine Chemical compound O=C1C=C[C@]2(C)[C@H]3CC[C@](C)(C(CC4)=O)[C@@H]4[C@@H]3CC(=C)C2=C1 BFYIZQONLCFLEV-DAELLWKTSA-N 0.000 claims 3
- 102000015790 Asparaginase Human genes 0.000 claims 3
- 108010024976 Asparaginase Proteins 0.000 claims 3
- MLDQJTXFUGDVEO-UHFFFAOYSA-N BAY-43-9006 Chemical compound C1=NC(C(=O)NC)=CC(OC=2C=CC(NC(=O)NC=3C=C(C(Cl)=CC=3)C(F)(F)F)=CC=2)=C1 MLDQJTXFUGDVEO-UHFFFAOYSA-N 0.000 claims 3
- 108010006654 Bleomycin Proteins 0.000 claims 3
- 229940126074 CDK kinase inhibitor Drugs 0.000 claims 3
- GAGWJHPBXLXJQN-UORFTKCHSA-N Capecitabine Chemical compound C1=C(F)C(NC(=O)OCCCCC)=NC(=O)N1[C@H]1[C@H](O)[C@H](O)[C@@H](C)O1 GAGWJHPBXLXJQN-UORFTKCHSA-N 0.000 claims 3
- GAGWJHPBXLXJQN-UHFFFAOYSA-N Capecitabine Natural products C1=C(F)C(NC(=O)OCCCCC)=NC(=O)N1C1C(O)C(O)C(C)O1 GAGWJHPBXLXJQN-UHFFFAOYSA-N 0.000 claims 3
- DLGOEMSEDOSKAD-UHFFFAOYSA-N Carmustine Chemical compound ClCCNC(=O)N(N=O)CCCl DLGOEMSEDOSKAD-UHFFFAOYSA-N 0.000 claims 3
- PTOAARAWEBMLNO-KVQBGUIXSA-N Cladribine Chemical compound C1=NC=2C(N)=NC(Cl)=NC=2N1[C@H]1C[C@H](O)[C@@H](CO)O1 PTOAARAWEBMLNO-KVQBGUIXSA-N 0.000 claims 3
- 102100034770 Cyclin-dependent kinase inhibitor 3 Human genes 0.000 claims 3
- CMSMOCZEIVJLDB-UHFFFAOYSA-N Cyclophosphamide Chemical compound ClCCN(CCCl)P1(=O)NCCCO1 CMSMOCZEIVJLDB-UHFFFAOYSA-N 0.000 claims 3
- UHDGCWIWMRVCDJ-CCXZUQQUSA-N Cytarabine Chemical compound O=C1N=C(N)C=CN1[C@H]1[C@@H](O)[C@H](O)[C@@H](CO)O1 UHDGCWIWMRVCDJ-CCXZUQQUSA-N 0.000 claims 3
- 229940126190 DNA methyltransferase inhibitor Drugs 0.000 claims 3
- 108010092160 Dactinomycin Proteins 0.000 claims 3
- ZBNZXTGUTAYRHI-UHFFFAOYSA-N Dasatinib Chemical compound C=1C(N2CCN(CCO)CC2)=NC(C)=NC=1NC(S1)=NC=C1C(=O)NC1=C(C)C=CC=C1Cl ZBNZXTGUTAYRHI-UHFFFAOYSA-N 0.000 claims 3
- HTIJFSOGRVMCQR-UHFFFAOYSA-N Epirubicin Natural products COc1cccc2C(=O)c3c(O)c4CC(O)(CC(OC5CC(N)C(=O)C(C)O5)c4c(O)c3C(=O)c12)C(=O)CO HTIJFSOGRVMCQR-UHFFFAOYSA-N 0.000 claims 3
- 108010029961 Filgrastim Proteins 0.000 claims 3
- GHASVSINZRGABV-UHFFFAOYSA-N Fluorouracil Chemical compound FC1=CNC(=O)NC1=O GHASVSINZRGABV-UHFFFAOYSA-N 0.000 claims 3
- VWUXBMIQPBEWFH-WCCTWKNTSA-N Fulvestrant Chemical compound OC1=CC=C2[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3[C@H](CCCCCCCCCS(=O)CCCC(F)(F)C(F)(F)F)CC2=C1 VWUXBMIQPBEWFH-WCCTWKNTSA-N 0.000 claims 3
- 108010069236 Goserelin Proteins 0.000 claims 3
- 102100039619 Granulocyte colony-stimulating factor Human genes 0.000 claims 3
- 101000945639 Homo sapiens Cyclin-dependent kinase inhibitor 3 Proteins 0.000 claims 3
- 101000997835 Homo sapiens Tyrosine-protein kinase JAK1 Proteins 0.000 claims 3
- XDXDZDZNSLXDNA-TZNDIEGXSA-N Idarubicin Chemical compound C1[C@H](N)[C@H](O)[C@H](C)O[C@H]1O[C@@H]1C2=C(O)C(C(=O)C3=CC=CC=C3C3=O)=C3C(O)=C2C[C@@](O)(C(C)=O)C1 XDXDZDZNSLXDNA-TZNDIEGXSA-N 0.000 claims 3
- XDXDZDZNSLXDNA-UHFFFAOYSA-N Idarubicin Natural products C1C(N)C(O)C(C)OC1OC1C2=C(O)C(C(=O)C3=CC=CC=C3C3=O)=C3C(O)=C2CC(O)(C(C)=O)C1 XDXDZDZNSLXDNA-UHFFFAOYSA-N 0.000 claims 3
- 108010078049 Interferon alpha-2 Proteins 0.000 claims 3
- 239000005411 L01XE02 - Gefitinib Substances 0.000 claims 3
- 239000005551 L01XE03 - Erlotinib Substances 0.000 claims 3
- 239000002147 L01XE04 - Sunitinib Substances 0.000 claims 3
- 239000005511 L01XE05 - Sorafenib Substances 0.000 claims 3
- 239000002067 L01XE06 - Dasatinib Substances 0.000 claims 3
- UIARLYUEJFELEN-LROUJFHJSA-N LSM-1231 Chemical compound C12=C3N4C5=CC=CC=C5C3=C3C(=O)NCC3=C2C2=CC=CC=C2N1[C@]1(C)[C@](CO)(O)C[C@H]4O1 UIARLYUEJFELEN-LROUJFHJSA-N 0.000 claims 3
- 229940124647 MEK inhibitor Drugs 0.000 claims 3
- ZDZOTLJHXYCWBA-VCVYQWHSSA-N N-debenzoyl-N-(tert-butoxycarbonyl)-10-deacetyltaxol Chemical compound O([C@H]1[C@H]2[C@@](C([C@H](O)C3=C(C)[C@@H](OC(=O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)C=4C=CC=CC=4)C[C@]1(O)C3(C)C)=O)(C)[C@@H](O)C[C@H]1OC[C@]12OC(=O)C)C(=O)C1=CC=CC=C1 ZDZOTLJHXYCWBA-VCVYQWHSSA-N 0.000 claims 3
- JOOXLOJCABQBSG-UHFFFAOYSA-N N-tert-butyl-3-[[5-methyl-2-[4-[2-(1-pyrrolidinyl)ethoxy]anilino]-4-pyrimidinyl]amino]benzenesulfonamide Chemical compound N1=C(NC=2C=C(C=CC=2)S(=O)(=O)NC(C)(C)C)C(C)=CN=C1NC(C=C1)=CC=C1OCCN1CCCC1 JOOXLOJCABQBSG-UHFFFAOYSA-N 0.000 claims 3
- 229940116355 PI3 kinase inhibitor Drugs 0.000 claims 3
- 229940122016 Pim kinase inhibitor Drugs 0.000 claims 3
- 229940079156 Proteasome inhibitor Drugs 0.000 claims 3
- 229940124639 Selective inhibitor Drugs 0.000 claims 3
- NAVMQTYZDKMPEU-UHFFFAOYSA-N Targretin Chemical compound CC1=CC(C(CCC2(C)C)(C)C)=C2C=C1C(=C)C1=CC=C(C(O)=O)C=C1 NAVMQTYZDKMPEU-UHFFFAOYSA-N 0.000 claims 3
- BPEGJWRSRHCHSN-UHFFFAOYSA-N Temozolomide Chemical compound O=C1N(C)N=NC2=C(C(N)=O)N=CN21 BPEGJWRSRHCHSN-UHFFFAOYSA-N 0.000 claims 3
- FOCVUCIESVLUNU-UHFFFAOYSA-N Thiotepa Chemical compound C1CN1P(N1CC1)(=S)N1CC1 FOCVUCIESVLUNU-UHFFFAOYSA-N 0.000 claims 3
- 239000004012 Tofacitinib Substances 0.000 claims 3
- 102100033438 Tyrosine-protein kinase JAK1 Human genes 0.000 claims 3
- JXLYSJRDGCGARV-WWYNWVTFSA-N Vinblastine Natural products O=C(O[C@H]1[C@](O)(C(=O)OC)[C@@H]2N(C)c3c(cc(c(OC)c3)[C@]3(C(=O)OC)c4[nH]c5c(c4CCN4C[C@](O)(CC)C[C@H](C3)C4)cccc5)[C@@]32[C@H]2[C@@]1(CC)C=CCN2CC3)C JXLYSJRDGCGARV-WWYNWVTFSA-N 0.000 claims 3
- 229960002184 abarelix Drugs 0.000 claims 3
- AIWRTTMUVOZGPW-HSPKUQOVSA-N abarelix Chemical compound C([C@@H](C(=O)N[C@H](CC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCCNC(C)C)C(=O)N1[C@@H](CCC1)C(=O)N[C@H](C)C(N)=O)N(C)C(=O)[C@H](CO)NC(=O)[C@@H](CC=1C=NC=CC=1)NC(=O)[C@@H](CC=1C=CC(Cl)=CC=1)NC(=O)[C@@H](CC=1C=C2C=CC=CC2=CC=1)NC(C)=O)C1=CC=C(O)C=C1 AIWRTTMUVOZGPW-HSPKUQOVSA-N 0.000 claims 3
- 108010023617 abarelix Proteins 0.000 claims 3
- RJURFGZVJUQBHK-IIXSONLDSA-N actinomycin D Chemical compound C[C@H]1OC(=O)[C@H](C(C)C)N(C)C(=O)CN(C)C(=O)[C@@H]2CCCN2C(=O)[C@@H](C(C)C)NC(=O)[C@H]1NC(=O)C1=C(N)C(=O)C(C)=C2OC(C(C)=CC=C3C(=O)N[C@@H]4C(=O)N[C@@H](C(N5CCC[C@H]5C(=O)N(C)CC(=O)N(C)[C@@H](C(C)C)C(=O)O[C@@H]4C)=O)C(C)C)=C3N=C21 RJURFGZVJUQBHK-IIXSONLDSA-N 0.000 claims 3
- 229960005310 aldesleukin Drugs 0.000 claims 3
- 108700025316 aldesleukin Proteins 0.000 claims 3
- 229960000548 alemtuzumab Drugs 0.000 claims 3
- 229960001445 alitretinoin Drugs 0.000 claims 3
- SHGAZHPCJJPHSC-YCNIQYBTSA-N all-trans-retinoic acid Chemical compound OC(=O)\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C SHGAZHPCJJPHSC-YCNIQYBTSA-N 0.000 claims 3
- 229960003459 allopurinol Drugs 0.000 claims 3
- OFCNXPDARWKPPY-UHFFFAOYSA-N allopurinol Chemical compound OC1=NC=NC2=C1C=NN2 OFCNXPDARWKPPY-UHFFFAOYSA-N 0.000 claims 3
- 229960000473 altretamine Drugs 0.000 claims 3
- 229960002932 anastrozole Drugs 0.000 claims 3
- YBBLVLTVTVSKRW-UHFFFAOYSA-N anastrozole Chemical compound N#CC(C)(C)C1=CC(C(C)(C#N)C)=CC(CN2N=CN=C2)=C1 YBBLVLTVTVSKRW-UHFFFAOYSA-N 0.000 claims 3
- GOLCXWYRSKYTSP-UHFFFAOYSA-N arsenic trioxide Inorganic materials O1[As]2O[As]1O2 GOLCXWYRSKYTSP-UHFFFAOYSA-N 0.000 claims 3
- 229960002594 arsenic trioxide Drugs 0.000 claims 3
- 229960003272 asparaginase Drugs 0.000 claims 3
- DCXYFEDJOCDNAF-UHFFFAOYSA-M asparaginate Chemical compound [O-]C(=O)C(N)CC(N)=O DCXYFEDJOCDNAF-UHFFFAOYSA-M 0.000 claims 3
- 229960002756 azacitidine Drugs 0.000 claims 3
- VSRXQHXAPYXROS-UHFFFAOYSA-N azanide;cyclobutane-1,1-dicarboxylic acid;platinum(2+) Chemical compound [NH2-].[NH2-].[Pt+2].OC(=O)C1(C(O)=O)CCC1 VSRXQHXAPYXROS-UHFFFAOYSA-N 0.000 claims 3
- 229950000971 baricitinib Drugs 0.000 claims 3
- XUZMWHLSFXCVMG-UHFFFAOYSA-N baricitinib Chemical compound C1N(S(=O)(=O)CC)CC1(CC#N)N1N=CC(C=2C=3C=CNC=3N=CN=2)=C1 XUZMWHLSFXCVMG-UHFFFAOYSA-N 0.000 claims 3
- 229960000397 bevacizumab Drugs 0.000 claims 3
- 229960002938 bexarotene Drugs 0.000 claims 3
- 229960001561 bleomycin Drugs 0.000 claims 3
- OYVAGSVQBOHSSS-UAPAGMARSA-O bleomycin A2 Chemical compound N([C@H](C(=O)N[C@H](C)[C@@H](O)[C@H](C)C(=O)N[C@@H]([C@H](O)C)C(=O)NCCC=1SC=C(N=1)C=1SC=C(N=1)C(=O)NCCC[S+](C)C)[C@@H](O[C@H]1[C@H]([C@@H](O)[C@H](O)[C@H](CO)O1)O[C@@H]1[C@H]([C@@H](OC(N)=O)[C@H](O)[C@@H](CO)O1)O)C=1N=CNC=1)C(=O)C1=NC([C@H](CC(N)=O)NC[C@H](N)C(N)=O)=NC(N)=C1C OYVAGSVQBOHSSS-UAPAGMARSA-O 0.000 claims 3
- 229950009823 calusterone Drugs 0.000 claims 3
- IVFYLRMMHVYGJH-PVPPCFLZSA-N calusterone Chemical compound C1C[C@]2(C)[C@](O)(C)CC[C@H]2[C@@H]2[C@@H](C)CC3=CC(=O)CC[C@]3(C)[C@H]21 IVFYLRMMHVYGJH-PVPPCFLZSA-N 0.000 claims 3
- 229960004117 capecitabine Drugs 0.000 claims 3
- 229960004562 carboplatin Drugs 0.000 claims 3
- 229960005243 carmustine Drugs 0.000 claims 3
- 229960005395 cetuximab Drugs 0.000 claims 3
- JCKYGMPEJWAADB-UHFFFAOYSA-N chlorambucil Chemical compound OC(=O)CCCC1=CC=C(N(CCCl)CCCl)C=C1 JCKYGMPEJWAADB-UHFFFAOYSA-N 0.000 claims 3
- 229960004630 chlorambucil Drugs 0.000 claims 3
- DQLATGHUWYMOKM-UHFFFAOYSA-L cisplatin Chemical compound N[Pt](N)(Cl)Cl DQLATGHUWYMOKM-UHFFFAOYSA-L 0.000 claims 3
- 229960004316 cisplatin Drugs 0.000 claims 3
- 229960002436 cladribine Drugs 0.000 claims 3
- WDDPHFBMKLOVOX-AYQXTPAHSA-N clofarabine Chemical compound C1=NC=2C(N)=NC(Cl)=NC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@@H]1F WDDPHFBMKLOVOX-AYQXTPAHSA-N 0.000 claims 3
- 229960000928 clofarabine Drugs 0.000 claims 3
- 239000002875 cyclin dependent kinase inhibitor Substances 0.000 claims 3
- 229940043378 cyclin-dependent kinase inhibitor Drugs 0.000 claims 3
- 229960004397 cyclophosphamide Drugs 0.000 claims 3
- 229960000684 cytarabine Drugs 0.000 claims 3
- 229960003901 dacarbazine Drugs 0.000 claims 3
- 229960000640 dactinomycin Drugs 0.000 claims 3
- 229940018872 dalteparin sodium Drugs 0.000 claims 3
- 229960002448 dasatinib Drugs 0.000 claims 3
- 229960000975 daunorubicin Drugs 0.000 claims 3
- STQGQHZAVUOBTE-VGBVRHCVSA-N daunorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(C)=O)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 STQGQHZAVUOBTE-VGBVRHCVSA-N 0.000 claims 3
- 229960003603 decitabine Drugs 0.000 claims 3
- 229960002923 denileukin diftitox Drugs 0.000 claims 3
- 108010017271 denileukin diftitox Proteins 0.000 claims 3
- 229960003957 dexamethasone Drugs 0.000 claims 3
- UREBDLICKHMUKA-CXSFZGCWSA-N dexamethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O UREBDLICKHMUKA-CXSFZGCWSA-N 0.000 claims 3
- 229960000605 dexrazoxane Drugs 0.000 claims 3
- 201000010099 disease Diseases 0.000 claims 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 3
- NYDXNILOWQXUOF-UHFFFAOYSA-L disodium;2-[[4-[2-(2-amino-4-oxo-1,7-dihydropyrrolo[2,3-d]pyrimidin-5-yl)ethyl]benzoyl]amino]pentanedioate Chemical compound [Na+].[Na+].C=1NC=2NC(N)=NC(=O)C=2C=1CCC1=CC=C(C(=O)NC(CCC([O-])=O)C([O-])=O)C=C1 NYDXNILOWQXUOF-UHFFFAOYSA-L 0.000 claims 3
- 239000003968 dna methyltransferase inhibitor Substances 0.000 claims 3
- 229960003668 docetaxel Drugs 0.000 claims 3
- 229960004679 doxorubicin Drugs 0.000 claims 3
- NOTIQUSPUUHHEH-UXOVVSIBSA-N dromostanolone propionate Chemical compound C([C@@H]1CC2)C(=O)[C@H](C)C[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H](OC(=O)CC)[C@@]2(C)CC1 NOTIQUSPUUHHEH-UXOVVSIBSA-N 0.000 claims 3
- 229950004683 drostanolone propionate Drugs 0.000 claims 3
- 229960002224 eculizumab Drugs 0.000 claims 3
- 229960001904 epirubicin Drugs 0.000 claims 3
- AAKJLRGGTJKAMG-UHFFFAOYSA-N erlotinib Chemical compound C=12C=C(OCCOC)C(OCCOC)=CC2=NC=NC=1NC1=CC=CC(C#C)=C1 AAKJLRGGTJKAMG-UHFFFAOYSA-N 0.000 claims 3
- 229960001433 erlotinib Drugs 0.000 claims 3
- 229960001842 estramustine Drugs 0.000 claims 3
- FRPJXPJMRWBBIH-RBRWEJTLSA-N estramustine Chemical compound ClCCN(CCCl)C(=O)OC1=CC=C2[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1 FRPJXPJMRWBBIH-RBRWEJTLSA-N 0.000 claims 3
- 229960005420 etoposide Drugs 0.000 claims 3
- VJJPUSNTGOMMGY-MRVIYFEKSA-N etoposide Chemical compound COC1=C(O)C(OC)=CC([C@@H]2C3=CC=4OCOC=4C=C3[C@@H](O[C@H]3[C@@H]([C@@H](O)[C@@H]4O[C@H](C)OC[C@H]4O3)O)[C@@H]3[C@@H]2C(OC3)=O)=C1 VJJPUSNTGOMMGY-MRVIYFEKSA-N 0.000 claims 3
- LIQODXNTTZAGID-OCBXBXKTSA-N etoposide phosphate Chemical compound COC1=C(OP(O)(O)=O)C(OC)=CC([C@@H]2C3=CC=4OCOC=4C=C3[C@@H](O[C@H]3[C@@H]([C@@H](O)[C@@H]4O[C@H](C)OC[C@H]4O3)O)[C@@H]3[C@@H]2C(OC3)=O)=C1 LIQODXNTTZAGID-OCBXBXKTSA-N 0.000 claims 3
- 229960000752 etoposide phosphate Drugs 0.000 claims 3
- 229960000255 exemestane Drugs 0.000 claims 3
- IVLVTNPOHDFFCJ-UHFFFAOYSA-N fentanyl citrate Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O.C=1C=CC=CC=1N(C(=O)CC)C(CC1)CCN1CCC1=CC=CC=C1 IVLVTNPOHDFFCJ-UHFFFAOYSA-N 0.000 claims 3
- 229960004207 fentanyl citrate Drugs 0.000 claims 3
- 229960004177 filgrastim Drugs 0.000 claims 3
- 229960000961 floxuridine Drugs 0.000 claims 3
- ODKNJVUHOIMIIZ-RRKCRQDMSA-N floxuridine Chemical compound C1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C(F)=C1 ODKNJVUHOIMIIZ-RRKCRQDMSA-N 0.000 claims 3
- 229960000390 fludarabine Drugs 0.000 claims 3
- GIUYCYHIANZCFB-FJFJXFQQSA-N fludarabine phosphate Chemical compound C1=NC=2C(N)=NC(F)=NC=2N1[C@@H]1O[C@H](COP(O)(O)=O)[C@@H](O)[C@@H]1O GIUYCYHIANZCFB-FJFJXFQQSA-N 0.000 claims 3
- 229960002949 fluorouracil Drugs 0.000 claims 3
- 229960002258 fulvestrant Drugs 0.000 claims 3
- 229960002584 gefitinib Drugs 0.000 claims 3
- XGALLCVXEZPNRQ-UHFFFAOYSA-N gefitinib Chemical compound C=12C=C(OCCCN3CCOCC3)C(OC)=CC2=NC=NC=1NC1=CC=C(F)C(Cl)=C1 XGALLCVXEZPNRQ-UHFFFAOYSA-N 0.000 claims 3
- 229960005277 gemcitabine Drugs 0.000 claims 3
- SDUQYLNIPVEERB-QPPQHZFASA-N gemcitabine Chemical compound O=C1N=C(N)C=CN1[C@H]1C(F)(F)[C@H](O)[C@@H](CO)O1 SDUQYLNIPVEERB-QPPQHZFASA-N 0.000 claims 3
- 229960003297 gemtuzumab ozogamicin Drugs 0.000 claims 3
- 229960003690 goserelin acetate Drugs 0.000 claims 3
- UUVWYPNAQBNQJQ-UHFFFAOYSA-N hexamethylmelamine Chemical compound CN(C)C1=NC(N(C)C)=NC(N(C)C)=N1 UUVWYPNAQBNQJQ-UHFFFAOYSA-N 0.000 claims 3
- 229940121372 histone deacetylase inhibitor Drugs 0.000 claims 3
- 239000003276 histone deacetylase inhibitor Substances 0.000 claims 3
- 229960003911 histrelin acetate Drugs 0.000 claims 3
- BKEMVGVBBDMHKL-VYFXDUNUSA-N histrelin acetate Chemical compound CC(O)=O.CC(O)=O.CCNC(=O)[C@@H]1CCCN1C(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@H]1NC(=O)CC1)CC(N=C1)=CN1CC1=CC=CC=C1 BKEMVGVBBDMHKL-VYFXDUNUSA-N 0.000 claims 3
- 229960001001 ibritumomab tiuxetan Drugs 0.000 claims 3
- 229960000908 idarubicin Drugs 0.000 claims 3
- 229960001101 ifosfamide Drugs 0.000 claims 3
- HOMGKSMUEGBAAB-UHFFFAOYSA-N ifosfamide Chemical compound ClCCNP1(=O)OCCCN1CCCl HOMGKSMUEGBAAB-UHFFFAOYSA-N 0.000 claims 3
- 229960003685 imatinib mesylate Drugs 0.000 claims 3
- YLMAHDNUQAMNNX-UHFFFAOYSA-N imatinib methanesulfonate Chemical compound CS(O)(=O)=O.C1CN(C)CCN1CC1=CC=C(C(=O)NC=2C=C(NC=3N=C(C=CN=3)C=3C=NC=CC=3)C(C)=CC=2)C=C1 YLMAHDNUQAMNNX-UHFFFAOYSA-N 0.000 claims 3
- 239000002955 immunomodulating agent Substances 0.000 claims 3
- 229940121354 immunomodulator Drugs 0.000 claims 3
- 230000002584 immunomodulator Effects 0.000 claims 3
- 229960003521 interferon alfa-2a Drugs 0.000 claims 3
- 238000001990 intravenous administration Methods 0.000 claims 3
- 229950001845 lestaurtinib Drugs 0.000 claims 3
- 229940124302 mTOR inhibitor Drugs 0.000 claims 3
- 239000003628 mammalian target of rapamycin inhibitor Substances 0.000 claims 3
- 229960001924 melphalan Drugs 0.000 claims 3
- SGDBTWWWUNNDEQ-LBPRGKRZSA-N melphalan Chemical compound OC(=O)[C@@H](N)CC1=CC=C(N(CCCl)CCCl)C=C1 SGDBTWWWUNNDEQ-LBPRGKRZSA-N 0.000 claims 3
- 229960000901 mepacrine Drugs 0.000 claims 3
- CFCUWKMKBJTWLW-BKHRDMLASA-N mithramycin Chemical compound O([C@@H]1C[C@@H](O[C@H](C)[C@H]1O)OC=1C=C2C=C3C[C@H]([C@@H](C(=O)C3=C(O)C2=C(O)C=1C)O[C@@H]1O[C@H](C)[C@@H](O)[C@H](O[C@@H]2O[C@H](C)[C@H](O)[C@H](O[C@@H]3O[C@H](C)[C@@H](O)[C@@](C)(O)C3)C2)C1)[C@H](OC)C(=O)[C@@H](O)[C@@H](C)O)[C@H]1C[C@@H](O)[C@H](O)[C@@H](C)O1 CFCUWKMKBJTWLW-BKHRDMLASA-N 0.000 claims 3
- 239000002829 mitogen activated protein kinase inhibitor Substances 0.000 claims 3
- 229950008814 momelotinib Drugs 0.000 claims 3
- ZVHNDZWQTBEVRY-UHFFFAOYSA-N momelotinib Chemical compound C1=CC(C(NCC#N)=O)=CC=C1C1=CC=NC(NC=2C=CC(=CC=2)N2CCOCC2)=N1 ZVHNDZWQTBEVRY-UHFFFAOYSA-N 0.000 claims 3
- BLCLNMBMMGCOAS-UHFFFAOYSA-N n-[1-[[1-[[1-[[1-[[1-[[1-[[1-[2-[(carbamoylamino)carbamoyl]pyrrolidin-1-yl]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-3-[(2-methylpropan-2-yl)oxy]-1-oxopropan-2-yl]amino]-3-(4-hydroxyphenyl)-1-oxopropan-2-yl]amin Chemical compound C1CCC(C(=O)NNC(N)=O)N1C(=O)C(CCCN=C(N)N)NC(=O)C(CC(C)C)NC(=O)C(COC(C)(C)C)NC(=O)C(NC(=O)C(CO)NC(=O)C(CC=1C2=CC=CC=C2NC=1)NC(=O)C(CC=1NC=NC=1)NC(=O)C1NC(=O)CC1)CC1=CC=C(O)C=C1 BLCLNMBMMGCOAS-UHFFFAOYSA-N 0.000 claims 3
- RIJLVEAXPNLDTC-UHFFFAOYSA-N n-[5-[4-[(1,1-dioxo-1,4-thiazinan-4-yl)methyl]phenyl]-[1,2,4]triazolo[1,5-a]pyridin-2-yl]cyclopropanecarboxamide Chemical compound C1CC1C(=O)NC(=NN12)N=C1C=CC=C2C(C=C1)=CC=C1CN1CCS(=O)(=O)CC1 RIJLVEAXPNLDTC-UHFFFAOYSA-N 0.000 claims 3
- 229950011410 pacritinib Drugs 0.000 claims 3
- HWXVIOGONBBTBY-ONEGZZNKSA-N pacritinib Chemical compound C=1C=C(C=2)NC(N=3)=NC=CC=3C(C=3)=CC=CC=3COC\C=C\COCC=2C=1OCCN1CCCC1 HWXVIOGONBBTBY-ONEGZZNKSA-N 0.000 claims 3
- 229940046231 pamidronate Drugs 0.000 claims 3
- WRUUGTRCQOWXEG-UHFFFAOYSA-N pamidronate Chemical compound NCCC(O)(P(O)(O)=O)P(O)(O)=O WRUUGTRCQOWXEG-UHFFFAOYSA-N 0.000 claims 3
- 229960001972 panitumumab Drugs 0.000 claims 3
- HQQSBEDKMRHYME-UHFFFAOYSA-N pefloxacin mesylate Chemical compound [H+].CS([O-])(=O)=O.C1=C2N(CC)C=C(C(O)=O)C(=O)C2=CC(F)=C1N1CCN(C)CC1 HQQSBEDKMRHYME-UHFFFAOYSA-N 0.000 claims 3
- 229960001373 pegfilgrastim Drugs 0.000 claims 3
- 108010044644 pegfilgrastim Proteins 0.000 claims 3
- 229960003349 pemetrexed disodium Drugs 0.000 claims 3
- 229960002340 pentostatin Drugs 0.000 claims 3
- FPVKHBSQESCIEP-JQCXWYLXSA-N pentostatin Chemical compound C1[C@H](O)[C@@H](CO)O[C@H]1N1C(N=CNC[C@H]2O)=C2N=C1 FPVKHBSQESCIEP-JQCXWYLXSA-N 0.000 claims 3
- 239000002935 phosphatidylinositol 3 kinase inhibitor Substances 0.000 claims 3
- NJBFOOCLYDNZJN-UHFFFAOYSA-N pipobroman Chemical compound BrCCC(=O)N1CCN(C(=O)CCBr)CC1 NJBFOOCLYDNZJN-UHFFFAOYSA-N 0.000 claims 3
- 229960000952 pipobroman Drugs 0.000 claims 3
- 229960003171 plicamycin Drugs 0.000 claims 3
- CPTBDICYNRMXFX-UHFFFAOYSA-N procarbazine Chemical compound CNNCC1=CC=C(C(=O)NC(C)C)C=C1 CPTBDICYNRMXFX-UHFFFAOYSA-N 0.000 claims 3
- 229960000624 procarbazine Drugs 0.000 claims 3
- 230000002062 proliferating effect Effects 0.000 claims 3
- 239000003207 proteasome inhibitor Substances 0.000 claims 3
- GPKJTRJOBQGKQK-UHFFFAOYSA-N quinacrine Chemical compound C1=C(OC)C=C2C(NC(C)CCCN(CC)CC)=C(C=CC(Cl)=C3)C3=NC2=C1 GPKJTRJOBQGKQK-UHFFFAOYSA-N 0.000 claims 3
- 229960000424 rasburicase Drugs 0.000 claims 3
- 108010084837 rasburicase Proteins 0.000 claims 3
- 229960004641 rituximab Drugs 0.000 claims 3
- 229960003787 sorafenib Drugs 0.000 claims 3
- 229960001052 streptozocin Drugs 0.000 claims 3
- ZSJLQEPLLKMAKR-GKHCUFPYSA-N streptozocin Chemical compound O=NN(C)C(=O)N[C@H]1[C@@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O ZSJLQEPLLKMAKR-GKHCUFPYSA-N 0.000 claims 3
- WINHZLLDWRZWRT-ATVHPVEESA-N sunitinib Chemical compound CCN(CC)CCNC(=O)C1=C(C)NC(\C=C/2C3=CC(F)=CC=C3NC\2=O)=C1C WINHZLLDWRZWRT-ATVHPVEESA-N 0.000 claims 3
- 229960001796 sunitinib Drugs 0.000 claims 3
- 229960001603 tamoxifen Drugs 0.000 claims 3
- 229960004964 temozolomide Drugs 0.000 claims 3
- 229960001278 teniposide Drugs 0.000 claims 3
- NRUKOCRGYNPUPR-QBPJDGROSA-N teniposide Chemical compound COC1=C(O)C(OC)=CC([C@@H]2C3=CC=4OCOC=4C=C3[C@@H](O[C@H]3[C@@H]([C@@H](O)[C@@H]4O[C@@H](OC[C@H]4O3)C=3SC=CC=3)O)[C@@H]3[C@@H]2C(OC3)=O)=C1 NRUKOCRGYNPUPR-QBPJDGROSA-N 0.000 claims 3
- 229960005353 testolactone Drugs 0.000 claims 3
- BPEWUONYVDABNZ-DZBHQSCQSA-N testolactone Chemical compound O=C1C=C[C@]2(C)[C@H]3CC[C@](C)(OC(=O)CC4)[C@@H]4[C@@H]3CCC2=C1 BPEWUONYVDABNZ-DZBHQSCQSA-N 0.000 claims 3
- 229960003433 thalidomide Drugs 0.000 claims 3
- 229960001196 thiotepa Drugs 0.000 claims 3
- 229960003087 tioguanine Drugs 0.000 claims 3
- MNRILEROXIRVNJ-UHFFFAOYSA-N tioguanine Chemical compound N1C(N)=NC(=S)C2=NC=N[C]21 MNRILEROXIRVNJ-UHFFFAOYSA-N 0.000 claims 3
- 229960001350 tofacitinib Drugs 0.000 claims 3
- UJLAWZDWDVHWOW-YPMHNXCESA-N tofacitinib Chemical compound C[C@@H]1CCN(C(=O)CC#N)C[C@@H]1N(C)C1=NC=NC2=C1C=CN2 UJLAWZDWDVHWOW-YPMHNXCESA-N 0.000 claims 3
- 229960000303 topotecan Drugs 0.000 claims 3
- UCFGDBYHRUNTLO-QHCPKHFHSA-N topotecan Chemical compound C1=C(O)C(CN(C)C)=C2C=C(CN3C4=CC5=C(C3=O)COC(=O)[C@]5(O)CC)C4=NC2=C1 UCFGDBYHRUNTLO-QHCPKHFHSA-N 0.000 claims 3
- XFCLJVABOIYOMF-QPLCGJKRSA-N toremifene Chemical compound C1=CC(OCCN(C)C)=CC=C1C(\C=1C=CC=CC=1)=C(\CCCl)C1=CC=CC=C1 XFCLJVABOIYOMF-QPLCGJKRSA-N 0.000 claims 3
- 229960005026 toremifene Drugs 0.000 claims 3
- 229960005267 tositumomab Drugs 0.000 claims 3
- 229960000575 trastuzumab Drugs 0.000 claims 3
- 229960001727 tretinoin Drugs 0.000 claims 3
- 229960001055 uracil mustard Drugs 0.000 claims 3
- 229960000653 valrubicin Drugs 0.000 claims 3
- ZOCKGBMQLCSHFP-KQRAQHLDSA-N valrubicin Chemical compound O([C@H]1C[C@](CC2=C(O)C=3C(=O)C4=CC=CC(OC)=C4C(=O)C=3C(O)=C21)(O)C(=O)COC(=O)CCCC)[C@H]1C[C@H](NC(=O)C(F)(F)F)[C@H](O)[C@H](C)O1 ZOCKGBMQLCSHFP-KQRAQHLDSA-N 0.000 claims 3
- 229960003048 vinblastine Drugs 0.000 claims 3
- JXLYSJRDGCGARV-XQKSVPLYSA-N vincaleukoblastine Chemical compound C([C@@H](C[C@]1(C(=O)OC)C=2C(=CC3=C([C@]45[C@H]([C@@]([C@H](OC(C)=O)[C@]6(CC)C=CCN([C@H]56)CC4)(O)C(=O)OC)N3C)C=2)OC)C[C@@](C2)(O)CC)N2CCC2=C1NC1=CC=CC=C21 JXLYSJRDGCGARV-XQKSVPLYSA-N 0.000 claims 3
- 229960004528 vincristine Drugs 0.000 claims 3
- OGWKCGZFUXNPDA-XQKSVPLYSA-N vincristine Chemical compound C([N@]1C[C@@H](C[C@]2(C(=O)OC)C=3C(=CC4=C([C@]56[C@H]([C@@]([C@H](OC(C)=O)[C@]7(CC)C=CCN([C@H]67)CC5)(O)C(=O)OC)N4C=O)C=3)OC)C[C@@](C1)(O)CC)CC1=C2NC2=CC=CC=C12 OGWKCGZFUXNPDA-XQKSVPLYSA-N 0.000 claims 3
- OGWKCGZFUXNPDA-UHFFFAOYSA-N vincristine Natural products C1C(CC)(O)CC(CC2(C(=O)OC)C=3C(=CC4=C(C56C(C(C(OC(C)=O)C7(CC)C=CCN(C67)CC5)(O)C(=O)OC)N4C=O)C=3)OC)CN1CCC1=C2NC2=CC=CC=C12 OGWKCGZFUXNPDA-UHFFFAOYSA-N 0.000 claims 3
- GBABOYUKABKIAF-GHYRFKGUSA-N vinorelbine Chemical compound C1N(CC=2C3=CC=CC=C3NC=22)CC(CC)=C[C@H]1C[C@]2(C(=O)OC)C1=CC([C@]23[C@H]([C@]([C@H](OC(C)=O)[C@]4(CC)C=CCN([C@H]34)CC2)(O)C(=O)OC)N2C)=C2C=C1OC GBABOYUKABKIAF-GHYRFKGUSA-N 0.000 claims 3
- 229960002066 vinorelbine Drugs 0.000 claims 3
- WAEXFXRVDQXREF-UHFFFAOYSA-N vorinostat Chemical compound ONC(=O)CCCCCCC(=O)NC1=CC=CC=C1 WAEXFXRVDQXREF-UHFFFAOYSA-N 0.000 claims 3
- 229960000237 vorinostat Drugs 0.000 claims 3
- XRASPMIURGNCCH-UHFFFAOYSA-N zoledronic acid Chemical compound OP(=O)(O)C(P(O)(O)=O)(O)CN1C=CN=C1 XRASPMIURGNCCH-UHFFFAOYSA-N 0.000 claims 3
- 229960004276 zoledronic acid Drugs 0.000 claims 3
- HQQTZCPKNZVLFF-UHFFFAOYSA-N 4h-1,2-benzoxazin-3-one Chemical compound C1=CC=C2ONC(=O)CC2=C1 HQQTZCPKNZVLFF-UHFFFAOYSA-N 0.000 claims 1
- 208000031261 Acute myeloid leukaemia Diseases 0.000 claims 1
- 208000031671 Large B-Cell Diffuse Lymphoma Diseases 0.000 claims 1
- 208000033776 Myeloid Acute Leukemia Diseases 0.000 claims 1
- 206010012818 diffuse large B-cell lymphoma Diseases 0.000 claims 1
- 230000002489 hematologic effect Effects 0.000 claims 1
- 229940121649 protein inhibitor Drugs 0.000 claims 1
- 239000012268 protein inhibitor Substances 0.000 claims 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00ย -ย C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00ย -ย C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/538—1,4-Oxazines, e.g. morpholine ortho- or peri-condensed with carbocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
- A61K31/542—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with heterocyclic ring systems
- A61K31/545—Compounds containing 5-thia-1-azabicyclo [4.2.0] octane ring systems, i.e. compounds containing a ring system of the formula:, e.g. cephalosporins, cefaclor, or cephalexine
- A61K31/546—Compounds containing 5-thia-1-azabicyclo [4.2.0] octane ring systems, i.e. compounds containing a ring system of the formula:, e.g. cephalosporins, cefaclor, or cephalexine containing further heterocyclic rings, e.g. cephalothin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00ย -ย A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/02—Nasal agents, e.g. decongestants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
- A61P31/22—Antivirals for DNA viruses for herpes viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00ย -ย A61K41/00
Claims (14)
1. Inhibitor BET proteina, naznaฤen time, da je za uporabu u lijeฤenju proliferativne bolesti, pri ฤemu se inhibitor BET proteina daje u kombinaciji s jednim ili viลกe dodatnih terapijskih sredstava, gdje:
(a) inhibitor BET proteina se bira od sljedeฤih:
8-(6-metil-7-okso-6,7-dihidro-1H-pirolo[2,3-c]piridin-4-il)-2-fenil-1H-1,4-benzoksazin-3(4H)-on;
2-izopropil-8-(6-metil-7-okso-6,7-dihidro-1H-pirolo[2,3-c]piridin-4-il)-2H-1,4-benzoksazin-3(4H)-on;
2-metil-8-(6-metil-7-okso-6,7-dihidro-1H-pirolo[2,3-c]piridin-4-il)-2H-1,4-benzoksazin-3(4H)-on;
2-etil-8-(6-metil-7-okso-6,7-dihidro-1H-pirolo[2,3-c]piridin-4-il)-2H-1,4-benzoksazin-3(4H)-on;
8-(6-metil-7-okso-6,7-dihidro-1H-pirolo[2,3-c]piridin-4-il)-2-piridin-2-il-2H-1,4-benzoksazin-3(4H)-on 2,2,2-trifluoroacetat;
2-ciklopropil-8-(6-metil-7-okso-6,7-dihidro-1H-pirolo[2,3-c]piridin-4-il)-2H-1,4-benzoksazin-3(4H)-on;
8-(6-metil-7-okso-6,7-dihidro-1H-pirolo[2,3-c]piridin-4-il)-2-(tetrahidro-2H-piran-4-il)-2H-1,4-benzoksazin-3(4H)-on;
2-etil-4-metil-8-(6-metil-7-okso-6,7-dihidro-1H-pirolo[2,3-c]piridin-4-il)-2H-1,4-benzoksazin-3(4H)-on;
2-izopropil-6-metoksi-8-(6-metil-7-okso-6,7-dihidro-1H-pirolo[2,3-c]piridin-4-il)-2H-1,4-benzoksazin-3(4H)-on;
2-izopropil-6-metoksi-4-metil-8-(6-metil-7-okso-6,7-dihidro-1H-pirolo[2,3-c]piridin-4-il)-2H-1,4-benzoksazin-3(4H)-on;
[2-izopropil-6-metoksi-8-(6-metil-7-okso-6,7-dihidro-1H-pirolo[2,3-c]piridin-4-il)-3-okso-2,3-dihidro-4H-1,4-benzoksazin-4-il]octena kiselina;
2-[2-izopropil-6-metoksi-8-(6-metil-7-okso-6,7-dihidro-1H-pirolo[2,3-c]piridin-4-il)-3-okso-2,3-dihidro-4H-1,4-benzoksazin-4-il]-N-metilacetamid;
2-[2-izopropil-6-metoksi-8-(6-metil-7-okso-6,7-dihidro-1H-pirolo[2,3-c]piridin-4-il)-3-okso-2,3-dihidro-4H-1,4-benzoksazin-4-il]acetamid;
2-izopropil-6-metoksi-8-(6-metil-7-okso-6,7-dihidro-1H-pirolo[2,3-c]piridin-4-il)-4-[2-(4-metilpiperazin-1-il)-2-oksoetil]-2H-1,4-benzoksazin-3(4H)-on;
2-izopropil-6-metoksi-8-(6-metil-7-okso-6,7-dihidro-1H-pirolo[2,3-c]piridin-4- il)-4-(piridin-4-ilmetil)-2H-1,4-benzoksazin-3(4H)-on;
2,4-diizopropil-6-metoksi-8-(6-metil-7-okso-6,7-dihidro-1H-pirolo[2,3-c]piridin- 4-il)-2H-1,4-benzoksazin-3(4H)-on;
2-izopropil-8-(6-metil-7-okso-6,7-dihidro-1H-pirolo[2,3-c]piridin-4-il)-3-okso-3,4-dihidro-2H-1,4-benzoksazin-6-karbonitril;
2-izopropil-4-metil-8-(6-metil-7-okso-6, 7-dihidro-1H-pirolo[2,3-c]piridin-4-il)- 3-okso-3,4-dihidro-2H-1,4-benzoksazin-6-karbonitril;
2-izopropil-4-metil-8-(6-metil-7-okso-6,7-dihidro-1H-pirolo[2,3-c]piridin-4-il)-3-okso-3,4-dihidro-2H-1,4-benzoksazin-6-karboksamid;
2-izopropil-N-metil-8-(6-metil-7-okso-6,7-dihidro-1H-pirolo[2,3-c]piridin-4-il)-3-okso-3,4-dihidro-2H-1,4-benzoksazin-6 -karboksamid;
2-izopropil-8-(6-metil-7-okso-6,7-dihidro-1H-pirolo[2,3-c]piridin-4-il)-6-nitro- 2H-1,4-benzoksazin-3(4H)-on;
4-(2-izopropil-6-metoksi-4-metil-3,4-dihidro-2H-1,4-benzoksazin-8-il)-6-metil- 1,6-dihidro-7H-pirolo[2,3-c]piridin-7-on;
2-ciklopropil-6-metoksi-8-(6-metil-7-okso-6,7-dihidro-1H-pirolo[2,3-c]piridin-4-il)-2H-1,4-benzoksazin-3(4H)-on;
6-metoksi-8-(6-metil-7-okso-6,7-dihidro-1H-pirolo[2,3-c]piridin-4-il)-2-fenil-2H-1,4-benzoksazin-3(4H)-on;
2-(2-kloro-4-fluorofenil)-6-metoksi-8-(6-metil-7-okso-6,7-dihidro-1H-pirolo[2,3-c]piridin-4-il)-2H-1,4-benzoksazin-3(4H)-on;
2-izopropil-6-metoksi-8-(6-metil-7-okso-6,7-dihidro-1H-pirazolo[3,4-c]piridin-4- il)-2H-1,4-benzoksazin-3(4H)-on;
6-metoksi-2,2-dimetil-8-(6-metil-7-okso-6,7-dihidro-1H-pirolo[2,3-c]piridin-4- il)-2H-1,4-benzoksazin-3(4H)-on;
2-izopropil-8-(6-metil-7-okso-6,7-dihidro-1H-pirolo[2,3-c]piridin-4-il)-6-(1-metil-1H-pirazol-4-il)-2H-1,4-benzoksazin-3(4H)-on;
6-metoksi-2,2-dimetil-8-(6-metil-7-okso-6,7-dihidro-1H-pirazolo[3,4-c]piridin-4-il)-2H-1,4-benzoksazin-3(4H)-on;
8-(6-metil-7-okso-6,7-dihidro-1H-pirolo[2,3-c]piridin-4-il)spiro[1,4-benzoksazin- 2,1'-ciklopropan]-3(4H)-on;
2,2-dimetil-8-(6-metil-7-okso-6,7-dihidro-1H-pirolo[2,3-c]piridin-4-il)-2H-1,4- benzoksazin-3(4H)-on;
3,3-dimetil-5-(6-metil-7-okso-6,7-dihidro-1H-pirolo[2,3-c]piridin-4-il)-3,4- dihidrokinoksalin-2(1H)-on;
2-izopropil-8-(6-metil-7-okso-6,7-dihidro-1H-pirolo[2,3-c]piridin-4-il)-6- (morfolin-4-ilkarbonil)-2H-1,4-benzoksazin-3(4H)-on;
2-izopropil-N,N-dimetil-8-(6-metil-7-okso-6,7-dihidro-1H-pirolo[2,3-c]piridin-4-il)-3-okso-3,4-dihidro-2H-1,4-benzoksazin-6-karboksamid;
2-ciklopentil-6-metoksi-8-(6-metil-7-okso-6,7-dihidro-1H-pirolo[2,3-c]piridin-4-il)-2H-1,4-benzoksazin-3(4H)-on;
6-(hidroksimetil)-2-izopropil-8-(6-metil-7-okso-6,7-dihidro-1H-pirolo[2,3-c]piridin-4 -il)-2H-1,4-benzoksazin-3( 4H)-on;
2-izopropil-6-(metoksimetil)-8-(6-metil-7-okso-6,7-dihidro-1H-pirolo[2,3-c]piridin-4-il)-2H-1,4-benzoksazin-3(4H)-on;
6-(aminometil)-2-izopropil-8-(6-metiI-7-okso-6,7-dihidro-1H-pirolo[2,3-c]piridin-4-il)-2H-1,4-benzoksazin-3(4H)-on;
N-{[2-izopropil-8-(6-metil-7-okso-6,7-dihidro-1H-pirolo[2,3-c]piridin-4-il)-3- okso-3,4-dihidro-2H-1,4-benzoksazin-6-il]metil} etansulfonamid;
N-{[2-izopropil-8-(6-metil-7-okso-6,7-dihidro-1H-pirolo[2,3-c]piridin-4-il)-3-okso-3,4-dihidro-2H-1,4-benzoksazin-6-il]metil}acetamid;
2-izopropil-8-(6-metil-7-okso-6,7-dihidro-1H-pirolo[2,3-c]piridin-4-il)-3-okso- 3,4-dihidro-2H-1,4-benzoksazin-6-karboksamid;
2-ciklopentil-6-metoksi-8-(6-metil-7-okso-6,7-dihidro-1H-pirazolo[3,4-c]piridin-4-il)-2H-1,4-benzoksazin-3 (4H)-on;
6-(2-furil)-2-izopropil-8-(6-metil-7-okso-6,7-dihidro-1H-pirolo[2,3-c]piridin-4- il)-2H-1,4-benzoksazin-3(4H)-on;
2-izopropil-8-(6-metil-7-okso-6,7-dihidro-1H-pirolo[2,3-c]piridin-4-il)-6- (metilsulfonil)-2H-1,4-benzoksazin-3(4H)-on;
2,2-dimetil-8-(6-metil-7-okso-6,7-dihidro-1H-pirolo[2,3-c]piridin-4-il)-6- (metilsulfonil)-2H-1,4-benzoksazin-3(4H)-on;
8-(6-metil-7-okso-6,7-dihidro-1H-pirolo[2,3-c]piridin-4-il)-6-(metilsulfonil)-2-fenil-2H-1,4-benzoksazin-3(4H)-on;
2-izopropil-4-metil-8-(6-metil-7-okso-6,7-dihidro-1H-pirolo[2,3-c]piridin-4-il)- 6-(metilsulfonil)-2H-1,4-benzoksazin-3(4H)-on;
2-(2-hidroksietil)-8-(6-metil-7-okso-6,7-dihidro-1H-pirolo[2,3-c]piridin-4-il)-6- (metilsulfonil)-2H-1,4-benzoksazin-3(4H)-on;
6-acetil-2-izopropil-8-(6-metil-7-okso-6,7-dihidro-1H-pirolo[2,3-c]piridin-4-il)- 2H-1,4-benzoksazin-3(4H)-on;
6-(1-hidroksietil)-2-izopropil-8-(6-metil-7-okso-6,7-dihidro-1H-pirolo[2,3-c]piridin-4-il)-2H-1,4-benzoksazin-3(4H)-on;
6-(etilsulfonil)-2-izopropil-8 -(6-metil- 7-okso-6,7-dihidro-1H-pirolo[2,3-c]piridin-4-il)-2H-1,4-benzoksazin-3(4H)-on;
2-izopropil-6-(izopropilsulfonil)-8-(6-metil-7-okso-6,7-dihidro-1H-pirolo[2,3-c]piridin-4-il)-2H-1,4-benzoksazin-3(4H)-on;
4-(ciklopropilmetil)-2-izopropil-8-(6-metil-7-okso-6,7-dihidro-1H-pirolo[2,3-c]piridin-4-il)-6-(metilsulfonil)-2H-1,4-benzoksazin-3(4H)-on;
4-etil-2-izopropil-8-(6-metil-7-okso-6,7-dihidro-1H-pirolo[2,3-c]piridin-4-il)-6- (metilsulfonil)-2H-1,4-benzoksazin-3(4H)-on;
6-(etilsulfonil)-2-izopropil-4-metil-8-(6-metil-7-okso-6,7-dihidro-1H-pirolo[2,3-c]piridin-4-il)-2H-1,4-benzoksazin-3(4H)-on;
2-izopropil-6-(izopropilsulfonil)-4-metil-8-(6-metil-7-okso-6,7-dihidro-1H- pirolo[2,3-c]piridin-4-il)-2H-1,4-benzoksazin-3(4H)-on;
8-(6-metil-7-okso-6,7-dihidro-1H-pirolo[2,3-c]piridin-4-il)-6-(metilsulfonil)spiro[1,4-benzoksazin-2,1'-ciklopropan]-3(4H)-on;
3,3-dimetil-5-(6-metil-7-okso-6,7-dihidro-1H-pirolo[2,3-c]piridin-4-il)-7- (metilsulfonil)-3,4-dihidrokinoksalin-2(1H)-on;
8'-(6-metil-7-okso-6,7-dihidro-1H-pirolo[2,3-c]piridin-4-il)-6'-(metilsulfonil)-1',4'-dihidro-3'H-spiro[ciklopentan-1,2'-kinoksalin]-3'-on;
(3S)-3-izopropil-5-(6-metil-7-okso-6,7-dihidro-1H-pirolo[2,3-c]piridin-4-il)-7- (metilsulfonil)-3,4-dihidrokinoksalin-2(1H)-on;
(3R)-3-izopropil-5-(6-metil-7-okso-6,7-dihidro-1H-pirolo[2,3-c]piridin-4-il)-7- (metilsulfonil)-3,4-dihidrokinoksalin-2(1H)-on;
8'-(6-metil-7-okso-6,7-dihidro-1H-pirolo[2,3-c]piridin-4-il)-6'-(metilsulfonil)-1',4'-dihidro-3'H-spiro[ciklobutan-1,2'-kinoksalin]-3'-on;
4-metil-8-(6-metil-7-okso-6,7-dihidro-1H-pirolo[2,3-c]piridin-4-il)-6- (metilsulfonil)spiro[1,4-benzoksazin-2,1'-ciklopropan]-3(4H)-on;
8'-(6-metil-7-okso-6,7-dihidro-1H-pirolo[2,3-c]piridin-4-il)-6'-(metilsulfonil)-1',4'-dihidro-3'H-spiro[cikloheksan-1,2'-kinoksalin]-3'-on;
8-(6-metil-7-okso-6,7-dihidro-1H-pirazolo[3,4-c]piridin-4-il)-6- (metilsulfonil)spiro[1,4-benzoksazin-2,1'-ciklopropan]-3(4H)-on;
4-metil-8-(6-metil-7-okso-6,7-dihidro-1H-pirazolo[3,4-c]piridin-4-il)-6- (metilsulfonil)spiro[1,4-benzoksazin-2,1'-ciklopropan]-3(4H)-on;
2-izopropil-N,N-dimetil-8-(6-metil-7-okso-6,7-dihidro-1H-pirolo[2,3-c]piridin-4-il)-3-okso-3,4-dihidro-2H-1,4-benzoksazin-6-sulfonamid;
2-izopropil-N-metil-8-(6-metil-7-okso-6,7-dihidro-1H-pirolo[2,3-c]piridin-4-il)- 3-okso-3,4-dihidro-2H-1,4-benzoksazin-6-sulfonamid;
N,N,2,2,4-pentametil-8-(6-metil-7-okso-6,7-dihidro-1H-pirolo[2,3-c]piridin-4- il)-3-okso-3,4-dihidro-2H-1,4-benzoksazin-6-sulfonamid;
N,N,2,2-tetrametil-8-(6-metil-7-okso-6,7-dihidro-1H-pirolo[2,3-c]piridin-4-il)- 3-okso-3,4-dihidro-2H-1,4-benzoksazin-6-sulfonamid;
2-izopropil-N,N,4-trimetil-8-(6-metil-7-okso-6,7-dihidro-1H-pirolo[2,3-c]piridin-4-il)-3-okso-3,4-dihidro-2H-1,4-benzoksazin-6-sulfonamid;
2,2-dimetil-8-(6-metil-7-okso-6,7-dihidro-1H-pirolo[2,3-c]piridin-4-il)-6- (piperidin-1-ilsulfonil)-2H-1,4-benzoksazin-3(4H)-on;
2,2,4-trimetil-8-(6-metil-7-okso-6,7-dihidro-1H-pirolo[2,3-c]piridin-4-il)-6- (piperidin-1-ilsulfonil)-2H-1,4-benzoksazin-3(4H)-on;
N-izopropil-2,2-dimetil-8-(6-metil-7-okso-6,7-dihidro-1H-pirolo[2,3-c]piridin-4-il)-3-okso-3,4-dihidro-2H-1,4-benzoksazin-6-sulfonamid;
2,2,4-trimetil-8-(6-metil-7-okso-6,7-dihidro-1H-pirolo[2,3-c]piridin-4-il)-6- (metilsulfonil)-2H-1,4-benzoksazin-3(4H)-on;
6-(etilsulfonil)-2,2,4-trimetil-8-(6-metil-7-okso-6,7-dihidro-1H-pirolo[2,3-c)piridin-4-il)-2H-1,4-benzoksazin-3(4H)-on;
6-(izopropilsulfonil)-2,2,4-trimetil-8-(6-metil-7-okso-6,7-dihidro-1H-pirolo[2,3-c]piridin-4-il)-2H-1,4-benzoksazin-3(4H)-on;
6-(etilsulfonil)-2,2-dimetil-8-(6-metil-7-okso-6,7-dihidro-1H-pirolo[2,3-c]piridin-4-il)-2H-1,4-benzoksazin-3(4H)-on;
6-(izopropilsulfonil)-2,2-dimetil-8-(6-metil-7-okso-6,7-dihidro-1H-pirolo[2,3-c]piridin-4-il)-2H-1,4-benzoksazin-3(4H)-on;
6-acetil-2,2-dimetil-8-(6-metil-7-okso-6,7-dihidro-1H-pirolo[2,3-c]piridin-4-il)-2H-1,4-benzoksazin-3(4H)-on;
6-(1-hidroksietil)-2,2-dimetil-8-(6-metil-7-okso-6,7-dihidro-1H-pirolo[2,3-c]piridin-4-il)-2H-1,4-benzoksazin-3(4H)-on;
6-acetil-2,2,4-trimetil-8-(6-metil-7-okso-6,7-dihidro-1H-pirolo[2,3-c]piridin-4-il)-2H-1,4-benzoksazin-3(4H)-on;
6-(1-hidroksietil)-2,2,4-trimetil-8-(6-metil-7-okso-6,7-dihidro-1H-pirolo[2,3-c]piridin-4-il)-2H-1,4-benzoksazin-3(4H)-on; i
2-izopropil-8-(6-metil-7-okso-6,7-dihidro-1H-pirazolo[3,4-c]piridin-4-il)-6- (metilsulfonil)-2H-1,4-benzoksazin-3(4H)-on;
ili farmaceutski prihvatljiva sol od bilo kojega od predstojeฤih; i
(b) jedan ili viลกe dodatnih terapijskih sredstava su JAK inhibitor, inhibitor Pim kinaze, inhibitor PI3 kinaze, MEK inhibitor, inhibitor o ciklinu ovisne kinaze, b-RAF inhibitor, mTOR inhibitor, inhibitor proteazoma, HDAC inhibitor, inhibitor metil transferaze DNA, deksametazon, melfalan, ili imunomodulator, pri ฤemu navedeni JAK inhibitor je tofacitinib, baricitinib, CYT387, GLPG0634, lestaurtinib, pakritinib, TG101348, ili JAK1-selektivni inhibitor.
2. Kombinacija inhibitora BET proteina i jednog ili viลกe dodatnih terapijskih sredstava, naznaฤena time, da je za uporabu u lijeฤenju proliferativne bolesti, pri ฤemu:
a) inhibitor BET proteina se bira od sljedeฤih:
8-(6-metil-7-okso-6,7-dihidro-1H-pirolo[2,3-c]piridin-4-il)-2-fenil-1H-1,4-benzoksazin-3(4H)-on;
2-izopropil-8-(6-metil-7-okso-6,7-dihidro-1H-pirolo[2,3-c]piridin-4-il)-2H-1,4-benzoksazin-3(4H)-on;
2-metil-8-(6-metil-7-okso-6,7-dihidro-1H-pirolo[2,3-c]piridin-4-il)-2H-1,4-benzoksazin-3(4H)-on;
2-etil-8-(6-metil-7-okso-6,7-dihidro-1H-pirolo[2,3-c]piridin-4-il)-2H-1,4-benzoksazin-3(4H)-on;
8-(6-metil-7-okso-6,7-dihidro-1H-pirolo[2,3-c]piridin-4-il)-2-piridin-2-il-2H-1,4-benzoksazin-3(4H)-on 2,2,2-trifluoroacetat;
2-ciklopropil-8-(6-metil-7-okso-6,7-dihidro-1H-pirolo[2,3-c]piridin-4-il)-2H-1,4-benzoksazin-3(4H)-on;
8-(6-metil-7-okso-6,7-dihidro-1H-pirolo[2,3-c]piridin-4-il)-2-(tetrahidro-2H-piran-4-il)-2H-1,4-benzoksazin-3(4H)-on;
2-etil-4-metil-8-(6-metil-7-okso-6,7-dihidro-1H-pirolo[2,3-c]piridin-4-il)-2H-1,4-benzoksazin-3(4H)-on;
2-izopropil-6-metoksi-8-(6-metil-7-okso-6,7-dihidro-1H-pirolo[2,3-c]piridin-4-il)-2H-1,4-benzoksazin-3(4H)-on;
2-izopropil-6-metoksi-4-metil-8-(6-metil-7-okso-6,7-dihidro-1H-pirolo[2,3-c]piridin-4-il)-2H-1,4-benzoksazin-3(4H)-on;
[2-izopropil-6-metoksi-8-(6-metil-7-okso-6,7-dihidro-1H-pirolo[2,3-c]piridin-4-il)-3-okso-2,3-dihidro-4H-1,4-benzoksazin-4-il]octena kiselina;
2-[2-izopropil-6-metoksi-8-(6-metil-7-okso-6,7-dihidro-1H-pirolo[2,3-c]piridin-4-il)-3-okso-2,3-dihidro-4H-1,4-benzoksazin-4-il]-N-metilacetamid;
2-[2-izopropil-6-metoksi-8-(6-metil-7-okso-6,7-dihidro-1H-pirolo[2,3-c]piridin-4-il)-3-okso-2,3-dihidro-4H-1,4-benzoksazin-4-il]acetamid;
2-izopropil-6-metoksi-8-(6-metil-7-okso-6,7-dihidro-1H-pirolo[2,3-c]piridin-4-il)-4-[2-(4-metilpiperazin-1-il)-2-oksoetil]-2H-1,4-benzoksazin-3(4H)-on;
2-izopropil-6-metoksi-8-(6-metil-7-okso-6,7-dihidro-1H-pirolo[2,3-c]piridin-4- il)-4-(piridin-4-ilmetil)-2H-1,4-benzoksazin-3(4H)-on;
2,4-diizopropil-6-metoksi-8-(6-metil-7-okso-6,7-dihidro-1H-pirolo[2,3-c]piridin- 4-il)-2H-1,4-benzoksazin-3(4H)-on;
2-izopropil-8-(6-metil-7-okso-6,7-dihidro-1H-pirolo[2,3-c]piridin-4-il)-3-okso-3,4-dihidro-2H-1,4-benzoksazin-6-karbonitril;
2-izopropil-4-metil-8-(6-metil-7-okso-6, 7-dihidro-1H-pirolo[2,3-c]piridin-4-il)- 3-okso-3,4-dihidro-2H-1,4-benzoksazin-6-karbonitril;
2-izopropil-4-metil-8-(6-metil-7-okso-6,7-dihidro-1H-pirolo[2,3-c]piridin-4-il)-3-okso-3,4-dihidro-2H-1,4-benzoksazin-6-karboksamid;
2-izopropil-N-metil-8-(6-metil-7-okso-6,7-dihidro-1H-pirolo[2,3-c]piridin-4-il)-3-okso-3,4-dihidro-2H-1,4-benzoksazin-6 -karboksamid;
2-izopropil-8-(6-metil-7-okso-6,7-dihidro-1H-pirolo[2,3-c]piridin-4-il)-6-nitro- 2H-1,4-benzoksazin-3(4H)-on;
4-(2-izopropil-6-metoksi-4-metil-3,4-dihidro-2H-1,4-benzoksazin-8-il)-6-metil- 1,6-dihidro-7H-pirolo[2,3-c]piridin-7-on;
2-ciklopropil-6-metoksi-8-(6-metil-7-okso-6,7-dihidro-1H-pirolo[2,3-c]piridin-4-il)-2H-1,4-benzoksazin-3(4H)-on;
6-metoksi-8-(6-metil-7-okso-6,7-dihidro-1H-pirolo[2,3-c]piridin-4-il)-2-fenil-2H-1,4-benzoksazin-3(4H)-on;
2-(2-kloro-4-fluorofenil)-6-metoksi-8-(6-metil-7-okso-6,7-dihidro-1H-pirolo[2,3-c]piridin-4-il)-2H-1,4-benzoksazin-3(4H)-on;
2-izopropil-6-metoksi-8-(6-metil-7-okso-6,7-dihidro-1H-pirazolo[3,4-c]piridin-4- il)-2H-1,4-benzoksazin-3(4H)-on;
6-metoksi-2,2-dimetil-8-(6-metil-7-okso-6,7-dihidro-1H-pirolo[2,3-c]piridin-4- il)-2H-1,4-benzoksazin-3(4H)-on;
2-izopropil-8-(6-metil-7-okso-6,7-dihidro-1H-pirolo[2,3-c]piridin-4-il)-6-(1-metil-1H-pirazol-4-il)-2H-1,4-benzoksazin-3(4H)-on;
6-metoksi-2,2-dimetil-8-(6-metil-7-okso-6,7-dihidro-1H-pirazolo[3,4-c]piridin-4-il)-2H-1,4-benzoksazin-3(4H)-on;
8-(6-metil-7-okso-6,7-dihidro-1H-pirolo[2,3-c]piridin-4-il)spiro[1,4-benzoksazin- 2,1'-ciklopropan]-3(4H)-on;
2,2-dimetil-8-(6-metil-7-okso-6,7-dihidro-1H-pirolo[2,3-c]piridin-4-il)-2H-1,4- benzoksazin-3(4H)-on;
3,3-dimetil-5-(6-metil-7-okso-6,7-dihidro-1H-pirolo[2,3-c]piridin-4-il)-3,4- dihidrokinoksalin-2(1H)-on;
2-izopropil-8-(6-metil-7-okso-6,7-dihidro-1H-pirolo[2,3-c]piridin-4-il)-6- (morfolin-4-ilkarbonil)-2H-1,4-benzoksazin-3(4H)-on;
2-izopropil-N,N-dimetil-8-(6-metil-7-okso-6,7-dihidro-1H-pirolo[2,3-c]piridin-4-il)-3-okso-3,4-dihidro-2H-1,4-benzoksazin-6-karboksamid;
2-ciklopentil-6-metoksi-8-(6-metil-7-okso-6,7-dihidro-1H-pirolo[2,3-c]piridin-4-il)-2H-1,4-benzoksazin-3(4H)-on;
6-(hidroksimetil)-2-izopropil-8-(6-metil-7-okso-6,7-dihidro-1H-pirolo[2,3-c]piridin-4 -il)-2H-1,4-benzoksazin-3( 4H)-on;
2-izopropil-6-(metoksimetil)-8-(6-metil-7-okso-6,7-dihidro-1H-pirolo[2,3-c]piridin-4-il)-2H-1,4-benzoksazin-3(4H)-on;
6-(aminometil)-2-izopropil-8-(6-metiI-7-okso-6,7-dihidro-1H-pirolo[2,3-c]piridin-4-il)-2H-1,4-benzoksazin-3(4H)-on;
N-{[2-izopropil-8-(6-metil-7-okso-6,7-dihidro-1H-pirolo[2,3-c]piridin-4-il)-3- okso-3,4-dihidro-2H-1,4-benzoksazin-6-il]metil} etansulfonamid;
N-{[2-izopropil-8-(6-metil-7-okso-6,7-dihidro-1H-pirolo[2,3-c]piridin-4-il)-3-okso-3,4-dihidro-2H-1,4-benzoksazin-6-il]metil}acetamid;
2-izopropil-8-(6-metil-7-okso-6,7-dihidro-1H-pirolo[2,3-c]piridin-4-il)-3-okso- 3,4-dihidro-2H-1,4-benzoksazin-6-karboksamid;
2-ciklopentil-6-metoksi-8-(6-metil-7-okso-6,7-dihidro-1H-pirazolo[3,4-c]piridin-4-il)-2H-1,4-benzoksazin-3 (4H)-on;
6-(2-furil)-2-izopropil-8-(6-metil-7-okso-6,7-dihidro-1H-pirolo[2,3-c]piridin-4- il)-2H-1,4-benzoksazin-3(4H)-on;
2-izopropil-8-(6-metil-7-okso-6,7-dihidro-1H-pirolo[2,3-c]piridin-4-il)-6- (metilsulfonil)-2H-1,4-benzoksazin-3(4H)-on;
2,2-dimetil-8-(6-metil-7-okso-6,7-dihidro-1H-pirolo[2,3-c]piridin-4-il)-6- (metilsulfonil)-2H-1,4-benzoksazin-3(4H)-on;
8-(6-metil-7-okso-6,7-dihidro-1H-pirolo[2,3-c]piridin-4-il)-6-(metilsulfonil)-2-fenil-2H-1,4-benzoksazin-3(4H)-on;
2-izopropil-4-metil-8-(6-metil-7-okso-6,7-dihidro-1H-pirolo[2,3-c]piridin-4-il)- 6-(metilsulfonil)-2H-1,4-benzoksazin-3(4H)-on;
2-(2-hidroksietil)-8-(6-metil-7-okso-6,7-dihidro-1H-pirolo[2,3-c]piridin-4-il)-6- (metilsulfonil)-2H-1,4-benzoksazin-3(4H)-on;
6-acetil-2-izopropil-8-(6-metil-7-okso-6,7-dihidro-1H-pirolo[2,3-c]piridin-4-il)- 2H-1,4-benzoksazin-3(4H)-on;
6-(1-hidroksietil)-2-izopropil-8-(6-metil-7-okso-6,7-dihidro-1H-pirolo[2,3-c]piridin-4-il)-2H-1,4-benzoksazin-3(4H)-on;
6-(etilsulfonil)-2-izopropil-8 -(6-metil- 7-okso-6,7-dihidro-1H-pirolo[2,3-c]piridin-4-il)-2H-1,4-benzoksazin-3(4H)-on;
2-izopropil-6-(izopropilsulfonil)-8-(6-metil-7-okso-6,7-dihidro-1H-pirolo[2,3-c]piridin-4-il)-2H-1,4-benzoksazin-3(4H)-on;
4-(ciklopropilmetil)-2-izopropil-8-(6-metil-7-okso-6,7-dihidro-1H-pirolo[2,3-c]piridin-4-il)-6-(metilsulfonil)-2H-1,4-benzoksazin-3(4H)-on;
4-etil-2-izopropil-8-(6-metil-7-okso-6,7-dihidro-1H-pirolo[2,3-c]piridin-4-il)-6- (metilsulfonil)-2H-1,4-benzoksazin-3(4H)-on;
6-(etilsulfonil)-2-izopropil-4-metil-8-(6-metil-7-okso-6,7-dihidro-1H-pirolo[2,3-c]piridin-4-il)-2H-1,4-benzoksazin-3(4H)-on;
2-izopropil-6-(izopropilsulfonil)-4-metil-8-(6-metil-7-okso-6,7-dihidro-1H- pirolo[2,3-c]piridin-4-il)-2H-1,4-benzoksazin-3(4H)-on;
8-(6-metil-7-okso-6,7-dihidro-1H-pirolo[2,3-c]piridin-4-il)-6-(metilsulfonil)spiro[1,4-benzoksazin-2,1'-ciklopropan]-3(4H)-on;
3,3-dimetil-5-(6-metil-7-okso-6,7-dihidro-1H-pirolo[2,3-c]piridin-4-il)-7- (metilsulfonil)-3,4-dihidrokinoksalin-2(1H)-on;
8'-(6-metil-7-okso-6,7-dihidro-1H-pirolo[2,3-c]piridin-4-il)-6'-(metilsulfonil)-1',4'-dihidro-3'H-spiro[ciklopentan-1,2'-kinoksalin]-3'-on;
(3S)-3-izopropil-5-(6-metil-7-okso-6,7-dihidro-1H-pirolo[2,3-c]piridin-4-il)-7- (metilsulfonil)-3,4-dihidrokinoksalin-2(1H)-on;
(3R)-3-izopropil-5-(6-metil-7-okso-6,7-dihidro-1H-pirolo[2,3-c]piridin-4-il)-7- (metilsulfonil)-3,4-dihidrokinoksalin-2(1H)-on;
8'-(6-metil-7-okso-6,7-dihidro-1H-pirolo[2,3-c]piridin-4-il)-6'-(metilsulfonil)-1',4'-dihidro-3'H-spiro[ciklobutan-1,2'-kinoksalin]-3'-on;
4-metil-8-(6-metil-7-okso-6,7-dihidro-1H-pirolo[2,3-c]piridin-4-il)-6- (metilsulfonil)spiro[1,4-benzoksazin-2,1'-ciklopropan]-3(4H)-on;
8'-(6-metil-7-okso-6,7-dihidro-1H-pirolo[2,3-c]piridin-4-il)-6'-(metilsulfonil)-1',4'-dihidro-3'H-spiro[cikloheksan-1,2'-kinoksalin]-3'-on;
8-(6-metil-7-okso-6,7-dihidro-1H-pirazolo[3,4-c]piridin-4-il)-6- (metilsulfonil)spiro[1,4-benzoksazin-2,1'-ciklopropan]-3(4H)-on;
4-metil-8-(6-metil-7-okso-6,7-dihidro-1H-pirazolo[3,4-c]piridin-4-il)-6- (metilsulfonil)spiro[1,4-benzoksazin-2,1'-ciklopropan]-3(4H)-on;
2-izopropil-N,N-dimetil-8-(6-metil-7-okso-6,7-dihidro-1H-pirolo[2,3-c]piridin-4-il)-3-okso-3,4-dihidro-2H-1,4-benzoksazin-6-sulfonamid;
2-izopropil-N-metil-8-(6-metil-7-okso-6,7-dihidro-1H-pirolo[2,3-c]piridin-4-il)- 3-okso-3,4-dihidro-2H-1,4-benzoksazin-6-sulfonamid;
N,N,2,2,4-pentametil-8-(6-metil-7-okso-6,7-dihidro-1H-pirolo[2,3-c]piridin-4- il)-3-okso-3,4-dihidro-2H-1,4-benzoksazin-6-sulfonamid;
N,N,2,2-tetrametil-8-(6-metil-7-okso-6,7-dihidro-1H-pirolo[2,3-c]piridin-4-il)- 3-okso-3,4-dihidro-2H-1,4-benzoksazin-6-sulfonamid;
2-izopropil-N,N,4-trimetil-8-(6-metil-7-okso-6,7-dihidro-1H-pirolo[2,3-c]piridin-4-il)-3-okso-3,4-dihidro-2H-1,4-benzoksazin-6-sulfonamid;
2,2-dimetil-8-(6-metil-7-okso-6,7-dihidro-1H-pirolo[2,3-c]piridin-4-il)-6- (piperidin-1-ilsulfonil)-2H-1,4-benzoksazin-3(4H)-on;
2,2,4-trimetil-8-(6-metil-7-okso-6,7-dihidro-1H-pirolo[2,3-c]piridin-4-il)-6- (piperidin-1-ilsulfonil)-2H-1,4-benzoksazin-3(4H)-on;
N-izopropil-2,2-dimetil-8-(6-metil-7-okso-6,7-dihidro-1H-pirolo[2,3-c]piridin-4-il)-3-okso-3,4-dihidro-2H-1,4-benzoksazin-6-sulfonamid;
2,2,4-trimetil-8-(6-metil-7-okso-6,7-dihidro-1H-pirolo[2,3-c]piridin-4-il)-6- (metilsulfonil)-2H-1,4-benzoksazin-3(4H)-on;
6-(etilsulfonil)-2,2,4-trimetil-8-(6-metil-7-okso-6,7-dihidro-1H-pirolo[2,3-c)piridin-4-il)-2H-1,4-benzoksazin-3(4H)-on;
6-(izopropilsulfonil)-2,2,4-trimetil-8-(6-metil-7-okso-6,7-dihidro-1H-pirolo[2,3-c]piridin-4-il)-2H-1,4-benzoksazin-3(4H)-on;
6-(etilsulfonil)-2,2-dimetil-8-(6-metil-7-okso-6,7-dihidro-1H-pirolo[2,3-c]piridin-4-il)-2H-1,4-benzoksazin-3(4H)-on;
6-(izopropilsulfonil)-2,2-dimetil-8-(6-metil-7-okso-6,7-dihidro-1H-pirolo[2,3-c]piridin-4-il)-2H-1,4-benzoksazin-3(4H)-on;
6-acetil-2,2-dimetil-8-(6-metil-7-okso-6,7-dihidro-1H-pirolo[2,3-c]piridin-4-il)-2H-1,4-benzoksazin-3(4H)-on;
6-(1-hidroksietil)-2,2-dimetil-8-(6-metil-7-okso-6,7-dihidro-1H-pirolo[2,3-c]piridin-4-il)-2H-1,4-benzoksazin-3(4H)-on;
6-acetil-2,2,4-trimetil-8-(6-metil-7-okso-6,7-dihidro-1H-pirolo[2,3-c]piridin-4-il)-2H-1,4-benzoksazin-3(4H)-on;
6-(1-hidroksietil)-2,2,4-trimetil-8-(6-metil-7-okso-6,7-dihidro-1H-pirolo[2,3-c]piridin-4-il)-2H-1,4-benzoksazin-3(4H)-on; i
2-izopropil-8-(6-metil-7-okso-6,7-dihidro-1H-pirazolo[3,4-c]piridin-4-il)-6- (metilsulfonil)-2H-1,4-benzoksazin-3(4H)-on;
ili farmaceutski prihvatljiva sol od bilo kojega od predstojeฤih; i
b) jedan ili viลกe dodatnih terapijskih sredstava su JAK inhibitor, inhibitor Pim kinaze, inhibitor PI3 kinaze, MEK inhibitor, inhibitor o ciklinu ovisne kinaze, b-RAF inhibitor, mTOR inhibitor, inhibitor proteazoma, HDAC inhibitor, inhibitor metil transferaze DNA, deksametazon, melfalan, ili imunomodulator, pri ฤemu navedeni JAK inhibitor je tofacitinib, baricitinib, CYT387, GLPG0634, lestaurtinib, pakritinib, TG101348, ili JAK1-selektivni inhibitor.
3. Terapijsko sredstvo, naznaฤeno time, da je za uporabu u lijeฤenju proliferativne bolesti, pri ฤemu se terapijsko sredstvo daje u kombinaciji s inhibitorom BET proteina, gdje:
a) inhibitor BET proteina se bira od sljedeฤih:
8-(6-metil-7-okso-6,7-dihidro-1H-pirolo[2,3-c]piridin-4-il)-2-fenil-1H-1,4-benzoksazin-3(4H)-on;
2-izopropil-8-(6-metil-7-okso-6,7-dihidro-1H-pirolo[2,3-c]piridin-4-il)-2H-1,4-benzoksazin-3(4H)-on;
2-metil-8-(6-metil-7-okso-6,7-dihidro-1H-pirolo[2,3-c]piridin-4-il)-2H-1,4-benzoksazin-3(4H)-on;
2-etil-8-(6-metil-7-okso-6,7-dihidro-1H-pirolo[2,3-c]piridin-4-il)-2H-1,4-benzoksazin-3(4H)-on;
8-(6-metil-7-okso-6,7-dihidro-1H-pirolo[2,3-c]piridin-4-il)-2-piridin-2-il-2H-1,4-benzoksazin-3(4H)-on 2,2,2-trifluoroacetat;
2-ciklopropil-8-(6-metil-7-okso-6,7-dihidro-1H-pirolo[2,3-c]piridin-4-il)-2H-1,4-benzoksazin-3(4H)-on;
8-(6-metil-7-okso-6,7-dihidro-1H-pirolo[2,3-c]piridin-4-il)-2-(tetrahidro-2H-piran-4-il)-2H-1,4-benzoksazin-3(4H)-on;
2-etil-4-metil-8-(6-metil-7-okso-6,7-dihidro-1H-pirolo[2,3-c]piridin-4-il)-2H-1,4-benzoksazin-3(4H)-on;
2-izopropil-6-metoksi-8-(6-metil-7-okso-6,7-dihidro-1H-pirolo[2,3-c]piridin-4-il)-2H-1,4-benzoksazin-3(4H)-on;
2-izopropil-6-metoksi-4-metil-8-(6-metil-7-okso-6,7-dihidro-1H-pirolo[2,3-c]piridin-4-il)-2H-1,4-benzoksazin-3(4H)-on;
[2-izopropil-6-metoksi-8-(6-metil-7-okso-6,7-dihidro-1H-pirolo[2,3-c]piridin-4-il)-3-okso-2,3-dihidro-4H-1,4-benzoksazin-4-il]octena kiselina;
2-[2-izopropil-6-metoksi-8-(6-metil-7-okso-6,7-dihidro-1H-pirolo[2,3-c]piridin-4-il)-3-okso-2,3-dihidro-4H-1,4-benzoksazin-4-il]-N-metilacetamid;
2-[2-izopropil-6-metoksi-8-(6-metil-7-okso-6,7-dihidro-1H-pirolo[2,3-c]piridin-4-il)-3-okso-2,3-dihidro-4H-1,4-benzoksazin-4-il]acetamid;
2-izopropil-6-metoksi-8-(6-metil-7-okso-6,7-dihidro-1H-pirolo[2,3-c]piridin-4-il)-4-[2-(4-metilpiperazin-1-il)-2-oksoetil]-2H-1,4-benzoksazin-3(4H)-on;
2-izopropil-6-metoksi-8-(6-metil-7-okso-6,7-dihidro-1H-pirolo[2,3-c]piridin-4- il)-4-(piridin-4-ilmetil)-2H-1,4-benzoksazin-3(4H)-on;
2,4-diizopropil-6-metoksi-8-(6-metil-7-okso-6,7-dihidro-1H-pirolo[2,3-c]piridin- 4-il)-2H-1,4-benzoksazin-3(4H)-on;
2-izopropil-8-(6-metil-7-okso-6,7-dihidro-1H-pirolo[2,3-c]piridin-4-il)-3-okso-3,4-dihidro-2H-1,4-benzoksazin-6-karbonitril;
2-izopropil-4-metil-8-(6-metil-7-okso-6, 7-dihidro-1H-pirolo[2,3-c]piridin-4-il)- 3-okso-3,4-dihidro-2H-1,4-benzoksazin-6-karbonitril;
2-izopropil-4-metil-8-(6-metil-7-okso-6,7-dihidro-1H-pirolo[2,3-c]piridin-4-il)-3-okso-3,4-dihidro-2H-1,4-benzoksazin-6-karboksamid;
2-izopropil-N-metil-8-(6-metil-7-okso-6,7-dihidro-1H-pirolo[2,3-c]piridin-4-il)-3-okso-3,4-dihidro-2H-1,4-benzoksazin-6 -karboksamid;
2-izopropil-8-(6-metil-7-okso-6,7-dihidro-1H-pirolo[2,3-c]piridin-4-il)-6-nitro- 2H-1,4-benzoksazin-3(4H)-on;
4-(2-izopropil-6-metoksi-4-metil-3,4-dihidro-2H-1,4-benzoksazin-8-il)-6-metil- 1,6-dihidro-7H-pirolo[2,3-c]piridin-7-on;
2-ciklopropil-6-metoksi-8-(6-metil-7-okso-6,7-dihidro-1H-pirolo[2,3-c]piridin-4-il)-2H-1,4-benzoksazin-3(4H)-on;
6-metoksi-8-(6-metil-7-okso-6,7-dihidro-1H-pirolo[2,3-c]piridin-4-il)-2-fenil-2H-1,4-benzoksazin-3(4H)-on;
2-(2-kloro-4-fluorofenil)-6-metoksi-8-(6-metil-7-okso-6,7-dihidro-1H-pirolo[2,3-c]piridin-4-il)-2H-1,4-benzoksazin-3(4H)-on;
2-izopropil-6-metoksi-8-(6-metil-7-okso-6,7-dihidro-1H-pirazolo[3,4-c]piridin-4- il)-2H-1,4-benzoksazin-3(4H)-on;
6-metoksi-2,2-dimetil-8-(6-metil-7-okso-6,7-dihidro-1H-pirolo[2,3-c]piridin-4- il)-2H-1,4-benzoksazin-3(4H)-on;
2-izopropil-8-(6-metil-7-okso-6,7-dihidro-1H-pirolo[2,3-c]piridin-4-il)-6-(1-metil-1H-pirazol-4-il)-2H-1,4-benzoksazin-3(4H)-on;
6-metoksi-2,2-dimetil-8-(6-metil-7-okso-6,7-dihidro-1H-pirazolo[3,4-c]piridin-4-il)-2H-1,4-benzoksazin-3(4H)-on;
8-(6-metil-7-okso-6,7-dihidro-1H-pirolo[2,3-c]piridin-4-il)spiro[1,4-benzoksazin- 2,1'-ciklopropan]-3(4H)-on;
2,2-dimetil-8-(6-metil-7-okso-6,7-dihidro-1H-pirolo[2,3-c]piridin-4-il)-2H-1,4- benzoksazin-3(4H)-on;
3,3-dimetil-5-(6-metil-7-okso-6,7-dihidro-1H-pirolo[2,3-c]piridin-4-il)-3,4- dihidrokinoksalin-2(1H)-on;
2-izopropil-8-(6-metil-7-okso-6,7-dihidro-1H-pirolo[2,3-c]piridin-4-il)-6- (morfolin-4-ilkarbonil)-2H-1,4-benzoksazin-3(4H)-on;
2-izopropil-N,N-dimetil-8-(6-metil-7-okso-6,7-dihidro-1H-pirolo[2,3-c]piridin-4-il)-3-okso-3,4-dihidro-2H-1,4-benzoksazin-6-karboksamid;
2-ciklopentil-6-metoksi-8-(6-metil-7-okso-6,7-dihidro-1H-pirolo[2,3-c]piridin-4-il)-2H-1,4-benzoksazin-3(4H)-on;
6-(hidroksimetil)-2-izopropil-8-(6-metil-7-okso-6,7-dihidro-1H-pirolo[2,3-c]piridin-4 -il)-2H-1,4-benzoksazin-3( 4H)-on;
2-izopropil-6-(metoksimetil)-8-(6-metil-7-okso-6,7-dihidro-1H-pirolo[2,3-c]piridin-4-il)-2H-1,4-benzoksazin-3(4H)-on;
6-(aminometil)-2-izopropil-8-(6-metiI-7-okso-6,7-dihidro-1H-pirolo[2,3-c]piridin-4-il)-2H-1,4-benzoksazin-3(4H)-on;
N-{[2-izopropil-8-(6-metil-7-okso-6,7-dihidro-1H-pirolo[2,3-c]piridin-4-il)-3- okso-3,4-dihidro-2H-1,4-benzoksazin-6-il]metil} etansulfonamid;
N-{[2-izopropil-8-(6-metil-7-okso-6,7-dihidro-1H-pirolo[2,3-c]piridin-4-il)-3-okso-3,4-dihidro-2H-1,4-benzoksazin-6-il]metil}acetamid;
2-izopropil-8-(6-metil-7-okso-6,7-dihidro-1H-pirolo[2,3-c]piridin-4-il)-3-okso- 3,4-dihidro-2H-1,4-benzoksazin-6-karboksamid;
2-ciklopentil-6-metoksi-8-(6-metil-7-okso-6,7-dihidro-1H-pirazolo[3,4-c]piridin-4-il)-2H-1,4-benzoksazin-3 (4H)-on;
6-(2-furil)-2-izopropil-8-(6-metil-7-okso-6,7-dihidro-1H-pirolo[2,3-c]piridin-4- il)-2H-1,4-benzoksazin-3(4H)-on;
2-izopropil-8-(6-metil-7-okso-6,7-dihidro-1H-pirolo[2,3-c]piridin-4-il)-6- (metilsulfonil)-2H-1,4-benzoksazin-3(4H)-on;
2,2-dimetil-8-(6-metil-7-okso-6,7-dihidro-1H-pirolo[2,3-c]piridin-4-il)-6- (metilsulfonil)-2H-1,4-benzoksazin-3(4H)-on;
8-(6-metil-7-okso-6,7-dihidro-1H-pirolo[2,3-c]piridin-4-il)-6-(metilsulfonil)-2-fenil-2H-1,4-benzoksazin-3(4H)-on;
2-izopropil-4-metil-8-(6-metil-7-okso-6,7-dihidro-1H-pirolo[2,3-c]piridin-4-il)- 6-(metilsulfonil)-2H-1,4-benzoksazin-3(4H)-on;
2-(2-hidroksietil)-8-(6-metil-7-okso-6,7-dihidro-1H-pirolo[2,3-c]piridin-4-il)-6- (metilsulfonil)-2H-1,4-benzoksazin-3(4H)-on;
6-acetil-2-izopropil-8-(6-metil-7-okso-6,7-dihidro-1H-pirolo[2,3-c]piridin-4-il)- 2H-1,4-benzoksazin-3(4H)-on;
6-(1-hidroksietil)-2-izopropil-8-(6-metil-7-okso-6,7-dihidro-1H-pirolo[2,3-c]piridin-4-il)-2H-1,4-benzoksazin-3(4H)-on;
6-(etilsulfonil)-2-izopropil-8 -(6-metil- 7-okso-6,7-dihidro-1H-pirolo[2,3-c]piridin-4-il)-2H-1,4-benzoksazin-3(4H)-on;
2-izopropil-6-(izopropilsulfonil)-8-(6-metil-7-okso-6,7-dihidro-1H-pirolo[2,3-c]piridin-4-il)-2H-1,4-benzoksazin-3(4H)-on;
4-(ciklopropilmetil)-2-izopropil-8-(6-metil-7-okso-6,7-dihidro-1H-pirolo[2,3-c]piridin-4-il)-6-(metilsulfonil)-2H-1,4-benzoksazin-3(4H)-on;
4-etil-2-izopropil-8-(6-metil-7-okso-6,7-dihidro-1H-pirolo[2,3-c]piridin-4-il)-6- (metilsulfonil)-2H-1,4-benzoksazin-3(4H)-on;
6-(etilsulfonil)-2-izopropil-4-metil-8-(6-metil-7-okso-6,7-dihidro-1H-pirolo[2,3-c]piridin-4-il)-2H-1,4-benzoksazin-3(4H)-on;
2-izopropil-6-(izopropilsulfonil)-4-metil-8-(6-metil-7-okso-6,7-dihidro-1H- pirolo[2,3-c]piridin-4-il)-2H-1,4-benzoksazin-3(4H)-on;
8-(6-metil-7-okso-6,7-dihidro-1H-pirolo[2,3-c]piridin-4-il)-6-(metilsulfonil)spiro[1,4-benzoksazin-2,1'-ciklopropan]-3(4H)-on;
3,3-dimetil-5-(6-metil-7-okso-6,7-dihidro-1H-pirolo[2,3-c]piridin-4-il)-7- (metilsulfonil)-3,4-dihidrokinoksalin-2(1H)-on;
8'-(6-metil-7-okso-6,7-dihidro-1H-pirolo[2,3-c]piridin-4-il)-6'-(metilsulfonil)-1',4'-dihidro-3'H-spiro[ciklopentan-1,2'-kinoksalin]-3'-on;
(3S)-3-izopropil-5-(6-metil-7-okso-6,7-dihidro-1H-pirolo[2,3-c]piridin-4-il)-7- (metilsulfonil)-3,4-dihidrokinoksalin-2(1H)-on;
(3R)-3-izopropil-5-(6-metil-7-okso-6,7-dihidro-1H-pirolo[2,3-c]piridin-4-il)-7- (metilsulfonil)-3,4-dihidrokinoksalin-2(1H)-on;
8'-(6-metil-7-okso-6,7-dihidro-1H-pirolo[2,3-c]piridin-4-il)-6'-(metilsulfonil)-1',4'-dihidro-3'H-spiro[ciklobutan-1,2'-kinoksalin]-3'-on;
4-metil-8-(6-metil-7-okso-6,7-dihidro-1H-pirolo[2,3-c]piridin-4-il)-6- (metilsulfonil)spiro[1,4-benzoksazin-2,1'-ciklopropan]-3(4H)-on;
8'-(6-metil-7-okso-6,7-dihidro-1H-pirolo[2,3-c]piridin-4-il)-6'-(metilsulfonil)-1',4'-dihidro-3'H-spiro[cikloheksan-1,2'-kinoksalin]-3'-on;
8-(6-metil-7-okso-6,7-dihidro-1H-pirazolo[3,4-c]piridin-4-il)-6- (metilsulfonil)spiro[1,4-benzoksazin-2,1'-ciklopropan]-3(4H)-on;
4-metil-8-(6-metil-7-okso-6,7-dihidro-1H-pirazolo[3,4-c]piridin-4-il)-6- (metilsulfonil)spiro[1,4-benzoksazin-2,1'-ciklopropan]-3(4H)-on;
2-izopropil-N,N-dimetil-8-(6-metil-7-okso-6,7-dihidro-1H-pirolo[2,3-c]piridin-4-il)-3-okso-3,4-dihidro-2H-1,4-benzoksazin-6-sulfonamid;
2-izopropil-N-metil-8-(6-metil-7-okso-6,7-dihidro-1H-pirolo[2,3-c]piridin-4-il)- 3-okso-3,4-dihidro-2H-1,4-benzoksazin-6-sulfonamid;
N,N,2,2,4-pentametil-8-(6-metil-7-okso-6,7-dihidro-1H-pirolo[2,3-c]piridin-4- il)-3-okso-3,4-dihidro-2H-1,4-benzoksazin-6-sulfonamid;
N,N,2,2-tetrametil-8-(6-metil-7-okso-6,7-dihidro-1H-pirolo[2,3-c]piridin-4-il)- 3-okso-3,4-dihidro-2H-1,4-benzoksazin-6-sulfonamid;
2-izopropil-N,N,4-trimetil-8-(6-metil-7-okso-6,7-dihidro-1H-pirolo[2,3-c]piridin-4-il)-3-okso-3,4-dihidro-2H-1,4-benzoksazin-6-sulfonamid;
2,2-dimetil-8-(6-metil-7-okso-6,7-dihidro-1H-pirolo[2,3-c]piridin-4-il)-6- (piperidin-1-ilsulfonil)-2H-1,4-benzoksazin-3(4H)-on;
2,2,4-trimetil-8-(6-metil-7-okso-6,7-dihidro-1H-pirolo[2,3-c]piridin-4-il)-6- (piperidin-1-ilsulfonil)-2H-1,4-benzoksazin-3(4H)-on;
N-izopropil-2,2-dimetil-8-(6-metil-7-okso-6,7-dihidro-1H-pirolo[2,3-c]piridin-4-il)-3-okso-3,4-dihidro-2H-1,4-benzoksazin-6-sulfonamid;
2,2,4-trimetil-8-(6-metil-7-okso-6,7-dihidro-1H-pirolo[2,3-c]piridin-4-il)-6- (metilsulfonil)-2H-1,4-benzoksazin-3(4H)-on;
6-(etilsulfonil)-2,2,4-trimetil-8-(6-metil-7-okso-6,7-dihidro-1H-pirolo[2,3-c)piridin-4-il)-2H-1,4-benzoksazin-3(4H)-on;
6-(izopropilsulfonil)-2,2,4-trimetil-8-(6-metil-7-okso-6,7-dihidro-1H-pirolo[2,3-c]piridin-4-il)-2H-1,4-benzoksazin-3(4H)-on;
6-(etilsulfonil)-2,2-dimetil-8-(6-metil-7-okso-6,7-dihidro-1H-pirolo[2,3-c]piridin-4-il)-2H-1,4-benzoksazin-3(4H)-on;
6-(izopropilsulfonil)-2,2-dimetil-8-(6-metil-7-okso-6,7-dihidro-1H-pirolo[2,3-c]piridin-4-il)-2H-1,4-benzoksazin-3(4H)-on;
6-acetil-2,2-dimetil-8-(6-metil-7-okso-6,7-dihidro-1H-pirolo[2,3-c]piridin-4-il)-2H-1,4-benzoksazin-3(4H)-on;
6-(1-hidroksietil)-2,2-dimetil-8-(6-metil-7-okso-6,7-dihidro-1H-pirolo[2,3-c]piridin-4-il)-2H-1,4-benzoksazin-3(4H)-on;
6-acetil-2,2,4-trimetil-8-(6-metil-7-okso-6,7-dihidro-1H-pirolo[2,3-c]piridin-4-il)-2H-1,4-benzoksazin-3(4H)-on;
6-(1-hidroksietil)-2,2,4-trimetil-8-(6-metil-7-okso-6,7-dihidro-1H-pirolo[2,3-c]piridin-4-il)-2H-1,4-benzoksazin-3(4H)-on; i
2-izopropil-8-(6-metil-7-okso-6,7-dihidro-1H-pirazolo[3,4-c]piridin-4-il)-6- (metilsulfonil)-2H-1,4-benzoksazin-3(4H)-on;
ili farmaceutski prihvatljiva sol od bilo kojega od predstojeฤih; i
b) jedan ili viลกe dodatnih terapijskih sredstava su JAK inhibitor, inhibitor Pim kinaze, inhibitor PI3 kinaze, MEK inhibitor, inhibitor o ciklinu ovisne kinaze, b-RAF inhibitor, mTOR inhibitor, inhibitor proteazoma, HDAC inhibitor, inhibitor metil transferaze DNA, deksametazon, melfalan, ili imunomodulator, pri ฤemu navedeni JAK inhibitor je tofacitinib, baricitinib, CYT387, GLPG0634, lestaurtinib, pakritinib, TG101348, ili JAK1-selektivni inhibitor.
4. Inhibitor BET proteina prema patentnom zahtjevu 1, ili kombinacija inhibitora BET protein i dodatnog terapijskog sredstva prema patentnom zahtjevu 2, ili terapijsko sredstvo prema patentnom zahtjevu 3, naznaฤeni time, da navedeni inhibitor BET proteina je 2,2,4-trimetil-8-(6-metil-7-okso-6,7-dihidro-1H-pirolo[2,3-c]piridin-4-il)-6-(metilsulfonil)-2H-1,4-benzoksazin-3(4H)-on, i njegove farmaceutski prihvatljive soli.
5. Inhibitor BET proteina prema bilo kojem od patentnih zahtjeva 1 i 4, ili kombinacija inhibitora BET proteina i dodatnog terapijskog sredstva prema bilo kojem od patentnih zahtjeva 2 i 4, ili terapijsko sredstvo prema bilo kojem od patentnih zahtjeva 3 i 4, naznaฤeni time, da se navedeno terapijsko sredstvo i navedeni inhibitor BET proteina daju istovremeno.
6. Inhibitor BET proteina prema bilo kojem od patentnih zahtjeva 1 i 4, ili kombinacija inhibitora BET proteina i dodatnog terapijskog sredstva prema bilo kojem od patentnih zahtjeva 2 i 4, ili terapijsko sredstvo prema bilo kojem od patentnih zahtjeva 3 i 4, naznaฤeni time, da se navedeno terapijsko sredstvo i navedeni inhibitor BET proteina daju uzastopno.
7. Inhibitor BET proteina, naznaฤen time, da je za uporabu u lijeฤenju raka, pri ฤemu se inhibitor BET proteina daje u kombinaciji s kemoterapeutskim sredstvom, gdje se navedeni inhibitor BET proteina bira od sljedeฤih:
8-(6-metil-7-okso-6,7-dihidro-1H-pirolo[2,3-c]piridin-4-il)-2-fenil-1H-1,4-benzoksazin-3(4H)-on;
2-izopropil-8-(6-metil-7-okso-6,7-dihidro-1H-pirolo[2,3-c]piridin-4-il)-2H-1,4-benzoksazin-3(4H)-on;
2-metil-8-(6-metil-7-okso-6,7-dihidro-1H-pirolo[2,3-c]piridin-4-il)-2H-1,4-benzoksazin-3(4H)-on;
2-etil-8-(6-metil-7-okso-6,7-dihidro-1H-pirolo[2,3-c]piridin-4-il)-2H-1,4-benzoksazin-3(4H)-on;
8-(6-metil-7-okso-6,7-dihidro-1H-pirolo[2,3-c]piridin-4-il)-2-piridin-2-il-2H-1,4-benzoksazin-3(4H)-on 2,2,2-trifluoroacetat;
2-ciklopropil-8-(6-metil-7-okso-6,7-dihidro-1H-pirolo[2,3-c]piridin-4-il)-2H-1,4-benzoksazin-3(4H)-on;
8-(6-metil-7-okso-6,7-dihidro-1H-pirolo[2,3-c]piridin-4-il)-2-(tetrahidro-2H-piran-4-il)-2H-1,4-benzoksazin-3(4H)-on;
2-etil-4-metil-8-(6-metil-7-okso-6,7-dihidro-1H-pirolo[2,3-c]piridin-4-il)-2H-1,4-benzoksazin-3(4H)-on;
2-izopropil-6-metoksi-8-(6-metil-7-okso-6,7-dihidro-1H-pirolo[2,3-c]piridin-4-il)-2H-1,4-benzoksazin-3(4H)-on;
2-izopropil-6-metoksi-4-metil-8-(6-metil-7-okso-6,7-dihidro-1H-pirolo[2,3-c]piridin-4-il)-2H-1,4-benzoksazin-3(4H)-on;
[2-izopropil-6-metoksi-8-(6-metil-7-okso-6,7-dihidro-1H-pirolo[2,3-c]piridin-4-il)-3-okso-2,3-dihidro-4H-1,4-benzoksazin-4-il]octena kiselina;
2-[2-izopropil-6-metoksi-8-(6-metil-7-okso-6,7-dihidro-1H-pirolo[2,3-c]piridin-4-il)-3-okso-2,3-dihidro-4H-1,4-benzoksazin-4-il]-N-metilacetamid;
2-[2-izopropil-6-metoksi-8-(6-metil-7-okso-6,7-dihidro-1H-pirolo[2,3-c]piridin-4-il)-3-okso-2,3-dihidro-4H-1,4-benzoksazin-4-il]acetamid;
2-izopropil-6-metoksi-8-(6-metil-7-okso-6,7-dihidro-1H-pirolo[2,3-c]piridin-4-il)-4-[2-(4-metilpiperazin-1-il)-2-oksoetil]-2H-1,4-benzoksazin-3(4H)-on;
2-izopropil-6-metoksi-8-(6-metil-7-okso-6,7-dihidro-1H-pirolo[2,3-c]piridin-4- il)-4-(piridin-4-ilmetil)-2H-1,4-benzoksazin-3(4H)-on;
2,4-diizopropil-6-metoksi-8-(6-metil-7-okso-6,7-dihidro-1H-pirolo[2,3-c]piridin- 4-il)-2H-1,4-benzoksazin-3(4H)-on;
2-izopropil-8-(6-metil-7-okso-6,7-dihidro-1H-pirolo[2,3-c]piridin-4-il)-3-okso-3,4-dihidro-2H-1,4-benzoksazin-6-karbonitril;
2-izopropil-4-metil-8-(6-metil-7-okso-6, 7-dihidro-1H-pirolo[2,3-c]piridin-4-il)- 3-okso-3,4-dihidro-2H-1,4-benzoksazin-6-karbonitril;
2-izopropil-4-metil-8-(6-metil-7-okso-6,7-dihidro-1H-pirolo[2,3-c]piridin-4-il)-3-okso-3,4-dihidro-2H-1,4-benzoksazin-6-karboksamid;
2-izopropil-N-metil-8-(6-metil-7-okso-6,7-dihidro-1H-pirolo[2,3-c]piridin-4-il)-3-okso-3,4-dihidro-2H-1,4-benzoksazin-6 -karboksamid;
2-izopropil-8-(6-metil-7-okso-6,7-dihidro-1H-pirolo[2,3-c]piridin-4-il)-6-nitro- 2H-1,4-benzoksazin-3(4H)-on;
4-(2-izopropil-6-metoksi-4-metil-3,4-dihidro-2H-1,4-benzoksazin-8-il)-6-metil- 1,6-dihidro-7H-pirolo[2,3-c]piridin-7-on;
2-ciklopropil-6-metoksi-8-(6-metil-7-okso-6,7-dihidro-1H-pirolo[2,3-c]piridin-4-il)-2H-1,4-benzoksazin-3(4H)-on;
6-metoksi-8-(6-metil-7-okso-6,7-dihidro-1H-pirolo[2,3-c]piridin-4-il)-2-fenil-2H-1,4-benzoksazin-3(4H)-on;
2-(2-kloro-4-fluorofenil)-6-metoksi-8-(6-metil-7-okso-6,7-dihidro-1H-pirolo[2,3-c]piridin-4-il)-2H-1,4-benzoksazin-3(4H)-on;
2-izopropil-6-metoksi-8-(6-metil-7-okso-6,7-dihidro-1H-pirazolo[3,4-c]piridin-4- il)-2H-1,4-benzoksazin-3(4H)-on;
6-metoksi-2,2-dimetil-8-(6-metil-7-okso-6,7-dihidro-1H-pirolo[2,3-c]piridin-4- il)-2H-1,4-benzoksazin-3(4H)-on;
2-izopropil-8-(6-metil-7-okso-6,7-dihidro-1H-pirolo[2,3-c]piridin-4-il)-6-(1-metil-1H-pirazol-4-il)-2H-1,4-benzoksazin-3(4H)-on;
6-metoksi-2,2-dimetil-8-(6-metil-7-okso-6,7-dihidro-1H-pirazolo[3,4-c]piridin-4-il)-2H-1,4-benzoksazin-3(4H)-on;
8-(6-metil-7-okso-6,7-dihidro-1H-pirolo[2,3-c]piridin-4-il)spiro[1,4-benzoksazin- 2,1'-ciklopropan]-3(4H)-on;
2,2-dimetil-8-(6-metil-7-okso-6,7-dihidro-1H-pirolo[2,3-c]piridin-4-il)-2H-1,4- benzoksazin-3(4H)-on;
3,3-dimetil-5-(6-metil-7-okso-6,7-dihidro-1H-pirolo[2,3-c]piridin-4-il)-3,4- dihidrokinoksalin-2(1H)-on;
2-izopropil-8-(6-metil-7-okso-6,7-dihidro-1H-pirolo[2,3-c]piridin-4-il)-6- (morfolin-4-ilkarbonil)-2H-1,4-benzoksazin-3(4H)-on;
2-izopropil-N,N-dimetil-8-(6-metil-7-okso-6,7-dihidro-1H-pirolo[2,3-c]piridin-4-il)-3-okso-3,4-dihidro-2H-1,4-benzoksazin-6-karboksamid;
2-ciklopentil-6-metoksi-8-(6-metil-7-okso-6,7-dihidro-1H-pirolo[2,3-c]piridin-4-il)-2H-1,4-benzoksazin-3(4H)-on;
6-(hidroksimetil)-2-izopropil-8-(6-metil-7-okso-6,7-dihidro-1H-pirolo[2,3-c]piridin-4 -il)-2H-1,4-benzoksazin-3( 4H)-on;
2-izopropil-6-(metoksimetil)-8-(6-metil-7-okso-6,7-dihidro-1H-pirolo[2,3-c]piridin-4-il)-2H-1,4-benzoksazin-3(4H)-on;
6-(aminometil)-2-izopropil-8-(6-metiI-7-okso-6,7-dihidro-1H-pirolo[2,3-c]piridin-4-il)-2H-1,4-benzoksazin-3(4H)-on;
N-{[2-izopropil-8-(6-metil-7-okso-6,7-dihidro-1H-pirolo[2,3-c]piridin-4-il)-3- okso-3,4-dihidro-2H-1,4-benzoksazin-6-il]metil} etansulfonamid;
N-{[2-izopropil-8-(6-metil-7-okso-6,7-dihidro-1H-pirolo[2,3-c]piridin-4-il)-3-okso-3,4-dihidro-2H-1,4-benzoksazin-6-il]metil}acetamid;
2-izopropil-8-(6-metil-7-okso-6,7-dihidro-1H-pirolo[2,3-c]piridin-4-il)-3-okso- 3,4-dihidro-2H-1,4-benzoksazin-6-karboksamid;
2-ciklopentil-6-metoksi-8-(6-metil-7-okso-6,7-dihidro-1H-pirazolo[3,4-c]piridin-4-il)-2H-1,4-benzoksazin-3 (4H)-on;
6-(2-furil)-2-izopropil-8-(6-metil-7-okso-6,7-dihidro-1H-pirolo[2,3-c]piridin-4- il)-2H-1,4-benzoksazin-3(4H)-on;
2-izopropil-8-(6-metil-7-okso-6,7-dihidro-1H-pirolo[2,3-c]piridin-4-il)-6- (metilsulfonil)-2H-1,4-benzoksazin-3(4H)-on;
2,2-dimetil-8-(6-metil-7-okso-6,7-dihidro-1H-pirolo[2,3-c]piridin-4-il)-6- (metilsulfonil)-2H-1,4-benzoksazin-3(4H)-on;
8-(6-metil-7-okso-6,7-dihidro-1H-pirolo[2,3-c]piridin-4-il)-6-(metilsulfonil)-2-fenil-2H-1,4-benzoksazin-3(4H)-on;
2-izopropil-4-metil-8-(6-metil-7-okso-6,7-dihidro-1H-pirolo[2,3-c]piridin-4-il)- 6-(metilsulfonil)-2H-1,4-benzoksazin-3(4H)-on;
2-(2-hidroksietil)-8-(6-metil-7-okso-6,7-dihidro-1H-pirolo[2,3-c]piridin-4-il)-6- (metilsulfonil)-2H-1,4-benzoksazin-3(4H)-on;
6-acetil-2-izopropil-8-(6-metil-7-okso-6,7-dihidro-1H-pirolo[2,3-c]piridin-4-il)- 2H-1,4-benzoksazin-3(4H)-on;
6-(1-hidroksietil)-2-izopropil-8-(6-metil-7-okso-6,7-dihidro-1H-pirolo[2,3-c]piridin-4-il)-2H-1,4-benzoksazin-3(4H)-on;
6-(etilsulfonil)-2-izopropil-8 -(6-metil- 7-okso-6,7-dihidro-1H-pirolo[2,3-c]piridin-4-il)-2H-1,4-benzoksazin-3(4H)-on;
2-izopropil-6-(izopropilsulfonil)-8-(6-metil-7-okso-6,7-dihidro-1H-pirolo[2,3-c]piridin-4-il)-2H-1,4-benzoksazin-3(4H)-on;
4-(ciklopropilmetil)-2-izopropil-8-(6-metil-7-okso-6,7-dihidro-1H-pirolo[2,3-c]piridin-4-il)-6-(metilsulfonil)-2H-1,4-benzoksazin-3(4H)-on;
4-etil-2-izopropil-8-(6-metil-7-okso-6,7-dihidro-1H-pirolo[2,3-c]piridin-4-il)-6- (metilsulfonil)-2H-1,4-benzoksazin-3(4H)-on;
6-(etilsulfonil)-2-izopropil-4-metil-8-(6-metil-7-okso-6,7-dihidro-1H-pirolo[2,3-c]piridin-4-il)-2H-1,4-benzoksazin-3(4H)-on;
2-izopropil-6-(izopropilsulfonil)-4-metil-8-(6-metil-7-okso-6,7-dihidro-1H- pirolo[2,3-c]piridin-4-il)-2H-1,4-benzoksazin-3(4H)-on;
8-(6-metil-7-okso-6,7-dihidro-1H-pirolo[2,3-c]piridin-4-il)-6-(metilsulfonil)spiro[1,4-benzoksazin-2,1'-ciklopropan]-3(4H)-on;
3,3-dimetil-5-(6-metil-7-okso-6,7-dihidro-1H-pirolo[2,3-c]piridin-4-il)-7- (metilsulfonil)-3,4-dihidrokinoksalin-2(1H)-on;
8'-(6-metil-7-okso-6,7-dihidro-1H-pirolo[2,3-c]piridin-4-il)-6'-(metilsulfonil)-1',4'-dihidro-3'H-spiro[ciklopentan-1,2'-kinoksalin]-3'-on;
(3S)-3-izopropil-5-(6-metil-7-okso-6,7-dihidro-1H-pirolo[2,3-c]piridin-4-il)-7- (metilsulfonil)-3,4-dihidrokinoksalin-2(1H)-on;
(3R)-3-izopropil-5-(6-metil-7-okso-6,7-dihidro-1H-pirolo[2,3-c]piridin-4-il)-7- (metilsulfonil)-3,4-dihidrokinoksalin-2(1H)-on;
8'-(6-metil-7-okso-6,7-dihidro-1H-pirolo[2,3-c]piridin-4-il)-6'-(metilsulfonil)-1',4'-dihidro-3'H-spiro[ciklobutan-1,2'-kinoksalin]-3'-on;
4-metil-8-(6-metil-7-okso-6,7-dihidro-1H-pirolo[2,3-c]piridin-4-il)-6- (metilsulfonil)spiro[1,4-benzoksazin-2,1'-ciklopropan]-3(4H)-on;
8'-(6-metil-7-okso-6,7-dihidro-1H-pirolo[2,3-c]piridin-4-il)-6'-(metilsulfonil)-1',4'-dihidro-3'H-spiro[cikloheksan-1,2'-kinoksalin]-3'-on;
8-(6-metil-7-okso-6,7-dihidro-1H-pirazolo[3,4-c]piridin-4-il)-6- (metilsulfonil)spiro[1,4-benzoksazin-2,1'-ciklopropan]-3(4H)-on;
4-metil-8-(6-metil-7-okso-6,7-dihidro-1H-pirazolo[3,4-c]piridin-4-il)-6- (metilsulfonil)spiro[1,4-benzoksazin-2,1'-ciklopropan]-3(4H)-on;
2-izopropil-N,N-dimetil-8-(6-metil-7-okso-6,7-dihidro-1H-pirolo[2,3-c]piridin-4-il)-3-okso-3,4-dihidro-2H-1,4-benzoksazin-6-sulfonamid;
2-izopropil-N-metil-8-(6-metil-7-okso-6,7-dihidro-1H-pirolo[2,3-c]piridin-4-il)- 3-okso-3,4-dihidro-2H-1,4-benzoksazin-6-sulfonamid;
N,N,2,2,4-pentametil-8-(6-metil-7-okso-6,7-dihidro-1H-pirolo[2,3-c]piridin-4- il)-3-okso-3,4-dihidro-2H-1,4-benzoksazin-6-sulfonamid;
N,N,2,2-tetrametil-8-(6-metil-7-okso-6,7-dihidro-1H-pirolo[2,3-c]piridin-4-il)- 3-okso-3,4-dihidro-2H-1,4-benzoksazin-6-sulfonamid;
2-izopropil-N,N,4-trimetil-8-(6-metil-7-okso-6,7-dihidro-1H-pirolo[2,3-c]piridin-4-il)-3-okso-3,4-dihidro-2H-1,4-benzoksazin-6-sulfonamid;
2,2-dimetil-8-(6-metil-7-okso-6,7-dihidro-1H-pirolo[2,3-c]piridin-4-il)-6- (piperidin-1-ilsulfonil)-2H-1,4-benzoksazin-3(4H)-on;
2,2,4-trimetil-8-(6-metil-7-okso-6,7-dihidro-1H-pirolo[2,3-c]piridin-4-il)-6- (piperidin-1-ilsulfonil)-2H-1,4-benzoksazin-3(4H)-on;
N-izopropil-2,2-dimetil-8-(6-metil-7-okso-6,7-dihidro-1H-pirolo[2,3-c]piridin-4-il)-3-okso-3,4-dihidro-2H-1,4-benzoksazin-6-sulfonamid;
2,2,4-trimetil-8-(6-metil-7-okso-6,7-dihidro-1H-pirolo[2,3-c]piridin-4-il)-6- (metilsulfonil)-2H-1,4-benzoksazin-3(4H)-on;
6-(etilsulfonil)-2,2,4-trimetil-8-(6-metil-7-okso-6,7-dihidro-1H-pirolo[2,3-c)piridin-4-il)-2H-1,4-benzoksazin-3(4H)-on;
6-(izopropilsulfonil)-2,2,4-trimetil-8-(6-metil-7-okso-6,7-dihidro-1H-pirolo[2,3-c]piridin-4-il)-2H-1,4-benzoksazin-3(4H)-on;
6-(etilsulfonil)-2,2-dimetil-8-(6-metil-7-okso-6,7-dihidro-1H-pirolo[2,3-c]piridin-4-il)-2H-1,4-benzoksazin-3(4H)-on;
6-(izopropilsulfonil)-2,2-dimetil-8-(6-metil-7-okso-6,7-dihidro-1H-pirolo[2,3-c]piridin-4-il)-2H-1,4-benzoksazin-3(4H)-on;
6-acetil-2,2-dimetil-8-(6-metil-7-okso-6,7-dihidro-1H-pirolo[2,3-c]piridin-4-il)-2H-1,4-benzoksazin-3(4H)-on;
6-(1-hidroksietil)-2,2-dimetil-8-(6-metil-7-okso-6,7-dihidro-1H-pirolo[2,3-c]piridin-4-il)-2H-1,4-benzoksazin-3(4H)-on;
6-acetil-2,2,4-trimetil-8-(6-metil-7-okso-6,7-dihidro-1H-pirolo[2,3-c]piridin-4-il)-2H-1,4-benzoksazin-3(4H)-on;
6-(1-hidroksietil)-2,2,4-trimetil-8-(6-metil-7-okso-6,7-dihidro-1H-pirolo[2,3-c]piridin-4-il)-2H-1,4-benzoksazin-3(4H)-on; i
2-izopropil-8-(6-metil-7-okso-6,7-dihidro-1H-pirazolo[3,4-c]piridin-4-il)-6- (metilsulfonil)-2H-1,4-benzoksazin-3(4H)-on;
ili farmaceutski prihvatljiva sol od bilo kojega od predstojeฤih;
pri ฤemu se navedeno kemoterapeutsko sredstvo bira od sljedeฤih: abareliks, aldesleukin, alemtuzumab, alitretinoin, alopurinol, altretamin, anastrozol, arsenski trioksid, asparaginaza, azacitidin, bevacizumab, beksaroten, bleomicin, bortezombi, bortezomib, intravenozni busulfan, oralni busulfan, kalusteron, kapecitabin, karboplatin, karmustin, cetuksimab, klorambucil, cisplatin, kladribin, klofarabin, ciklofosfamid, citarabin, dakarbazin, daktinomicin, dalteparin natrij, dasatinib, daunorubicin, decitabin, denileukin, denileukin diftitoks, deksrazoksan, docetaksel, doksorubicin, dromostanolon propionat, ekulizumab, epirubicin, erlotinib, estramustin, etopozid fosfat, etopozid, eksemestan, fentanil citrat, filgrastim, floksuridin, fludarabin, fluorouracil, fulvestrant, gefitinib, gemcitabin, gemtuzumab ozogamicin, goserelin acetat, histrelin acetat, ibritumomab tiuksetan, idarubicin, ifosfamid, imatinib mesilat, interferon alfa 2a, irinotekan, lapatinib ditosilat, lenalidomid, letrozol, leukovorin, leuprolid acetat, levamisol, lomustin, mekloretamin, megestrol acetat, melfalan, merkaptopurin, metotreksat, metoksalen, mitomicin C, mitotan, mitoksantron, nandrolon fenpropionat, nelarabin, nofetumomab, oksaliplatin, paklitaksel, pamidronat, panitumumab, pegaspargas, pegfilgrastim, pemetreksed dinatrij, pentostatin, pipobroman, plikamicin, prokarbazin, kvinakrin, rasburikaza, rituksimab, sorafenib, streptozocin, sunitinib, sunitinib maleat, tamoksifen, temozolomid, tenipozid, testolakton, talidomid, tiogvanin, tiotepa, topotekan, toremifen, tositumomab, trastuzumab, tretinoin, uracil mustard, valrubicin, vinblastin, vinkristin, vinorelbin, vorinostat, i zoledronat.
8. Kombinacija inhibitora BET proteina i kemoterapeutskog sredstva, naznaฤena time, da je za uporabu u lijeฤenju raka, pri ฤemu se navedeni inhibitor BET proteina bira od sljedeฤih:
8-(6-metil-7-okso-6,7-dihidro-1H-pirolo[2,3-c]piridin-4-il)-2-fenil-1H-1,4-benzoksazin-3(4H)-on;
2-izopropil-8-(6-metil-7-okso-6,7-dihidro-1H-pirolo[2,3-c]piridin-4-il)-2H-1,4-benzoksazin-3(4H)-on;
2-metil-8-(6-metil-7-okso-6,7-dihidro-1H-pirolo[2,3-c]piridin-4-il)-2H-1,4-benzoksazin-3(4H)-on;
2-etil-8-(6-metil-7-okso-6,7-dihidro-1H-pirolo[2,3-c]piridin-4-il)-2H-1,4-benzoksazin-3(4H)-on;
8-(6-metil-7-okso-6,7-dihidro-1H-pirolo[2,3-c]piridin-4-il)-2-piridin-2-il-2H-1,4-benzoksazin-3(4H)-on 2,2,2-trifluoroacetat;
2-ciklopropil-8-(6-metil-7-okso-6,7-dihidro-1H-pirolo[2,3-c]piridin-4-il)-2H-1,4-benzoksazin-3(4H)-on;
8-(6-metil-7-okso-6,7-dihidro-1H-pirolo[2,3-c]piridin-4-il)-2-(tetrahidro-2H-piran-4-il)-2H-1,4-benzoksazin-3(4H)-on;
2-etil-4-metil-8-(6-metil-7-okso-6,7-dihidro-1H-pirolo[2,3-c]piridin-4-il)-2H-1,4-benzoksazin-3(4H)-on;
2-izopropil-6-metoksi-8-(6-metil-7-okso-6,7-dihidro-1H-pirolo[2,3-c]piridin-4-il)-2H-1,4-benzoksazin-3(4H)-on;
2-izopropil-6-metoksi-4-metil-8-(6-metil-7-okso-6,7-dihidro-1H-pirolo[2,3-c]piridin-4-il)-2H-1,4-benzoksazin-3(4H)-on;
[2-izopropil-6-metoksi-8-(6-metil-7-okso-6,7-dihidro-1H-pirolo[2,3-c]piridin-4-il)-3-okso-2,3-dihidro-4H-1,4-benzoksazin-4-il]octena kiselina;
2-[2-izopropil-6-metoksi-8-(6-metil-7-okso-6,7-dihidro-1H-pirolo[2,3-c]piridin-4-il)-3-okso-2,3-dihidro-4H-1,4-benzoksazin-4-il]-N-metilacetamid;
2-[2-izopropil-6-metoksi-8-(6-metil-7-okso-6,7-dihidro-1H-pirolo[2,3-c]piridin-4-il)-3-okso-2,3-dihidro-4H-1,4-benzoksazin-4-il]acetamid;
2-izopropil-6-metoksi-8-(6-metil-7-okso-6,7-dihidro-1H-pirolo[2,3-c]piridin-4-il)-4-[2-(4-metilpiperazin-1-il)-2-oksoetil]-2H-1,4-benzoksazin-3(4H)-on;
2-izopropil-6-metoksi-8-(6-metil-7-okso-6,7-dihidro-1H-pirolo[2,3-c]piridin-4- il)-4-(piridin-4-ilmetil)-2H-1,4-benzoksazin-3(4H)-on;
2,4-diizopropil-6-metoksi-8-(6-metil-7-okso-6,7-dihidro-1H-pirolo[2,3-c]piridin- 4-il)-2H-1,4-benzoksazin-3(4H)-on;
2-izopropil-8-(6-metil-7-okso-6,7-dihidro-1H-pirolo[2,3-c]piridin-4-il)-3-okso-3,4-dihidro-2H-1,4-benzoksazin-6-karbonitril;
2-izopropil-4-metil-8-(6-metil-7-okso-6, 7-dihidro-1H-pirolo[2,3-c]piridin-4-il)- 3-okso-3,4-dihidro-2H-1,4-benzoksazin-6-karbonitril;
2-izopropil-4-metil-8-(6-metil-7-okso-6,7-dihidro-1H-pirolo[2,3-c]piridin-4-il)-3-okso-3,4-dihidro-2H-1,4-benzoksazin-6-karboksamid;
2-izopropil-N-metil-8-(6-metil-7-okso-6,7-dihidro-1H-pirolo[2,3-c]piridin-4-il)-3-okso-3,4-dihidro-2H-1,4-benzoksazin-6 -karboksamid;
2-izopropil-8-(6-metil-7-okso-6,7-dihidro-1H-pirolo[2,3-c]piridin-4-il)-6-nitro- 2H-1,4-benzoksazin-3(4H)-on;
4-(2-izopropil-6-metoksi-4-metil-3,4-dihidro-2H-1,4-benzoksazin-8-il)-6-metil- 1,6-dihidro-7H-pirolo[2,3-c]piridin-7-on;
2-ciklopropil-6-metoksi-8-(6-metil-7-okso-6,7-dihidro-1H-pirolo[2,3-c]piridin-4-il)-2H-1,4-benzoksazin-3(4H)-on;
6-metoksi-8-(6-metil-7-okso-6,7-dihidro-1H-pirolo[2,3-c]piridin-4-il)-2-fenil-2H-1,4-benzoksazin-3(4H)-on;
2-(2-kloro-4-fluorofenil)-6-metoksi-8-(6-metil-7-okso-6,7-dihidro-1H-pirolo[2,3-c]piridin-4-il)-2H-1,4-benzoksazin-3(4H)-on;
2-izopropil-6-metoksi-8-(6-metil-7-okso-6,7-dihidro-1H-pirazolo[3,4-c]piridin-4- il)-2H-1,4-benzoksazin-3(4H)-on;
6-metoksi-2,2-dimetil-8-(6-metil-7-okso-6,7-dihidro-1H-pirolo[2,3-c]piridin-4- il)-2H-1,4-benzoksazin-3(4H)-on;
2-izopropil-8-(6-metil-7-okso-6,7-dihidro-1H-pirolo[2,3-c]piridin-4-il)-6-(1-metil-1H-pirazol-4-il)-2H-1,4-benzoksazin-3(4H)-on;
6-metoksi-2,2-dimetil-8-(6-metil-7-okso-6,7-dihidro-1H-pirazolo[3,4-c]piridin-4-il)-2H-1,4-benzoksazin-3(4H)-on;
8-(6-metil-7-okso-6,7-dihidro-1H-pirolo[2,3-c]piridin-4-il)spiro[1,4-benzoksazin- 2,1'-ciklopropan]-3(4H)-on;
2,2-dimetil-8-(6-metil-7-okso-6,7-dihidro-1H-pirolo[2,3-c]piridin-4-il)-2H-1,4- benzoksazin-3(4H)-on;
3,3-dimetil-5-(6-metil-7-okso-6,7-dihidro-1H-pirolo[2,3-c]piridin-4-il)-3,4- dihidrokinoksalin-2(1H)-on;
2-izopropil-8-(6-metil-7-okso-6,7-dihidro-1H-pirolo[2,3-c]piridin-4-il)-6- (morfolin-4-ilkarbonil)-2H-1,4-benzoksazin-3(4H)-on;
2-izopropil-N,N-dimetil-8-(6-metil-7-okso-6,7-dihidro-1H-pirolo[2,3-c]piridin-4-il)-3-okso-3,4-dihidro-2H-1,4-benzoksazin-6-karboksamid;
2-ciklopentil-6-metoksi-8-(6-metil-7-okso-6,7-dihidro-1H-pirolo[2,3-c]piridin-4-il)-2H-1,4-benzoksazin-3(4H)-on;
6-(hidroksimetil)-2-izopropil-8-(6-metil-7-okso-6,7-dihidro-1H-pirolo[2,3-c]piridin-4 -il)-2H-1,4-benzoksazin-3( 4H)-on;
2-izopropil-6-(metoksimetil)-8-(6-metil-7-okso-6,7-dihidro-1H-pirolo[2,3-c]piridin-4-il)-2H-1,4-benzoksazin-3(4H)-on;
6-(aminometil)-2-izopropil-8-(6-metiI-7-okso-6,7-dihidro-1H-pirolo[2,3-c]piridin-4-il)-2H-1,4-benzoksazin-3(4H)-on;
N-{[2-izopropil-8-(6-metil-7-okso-6,7-dihidro-1H-pirolo[2,3-c]piridin-4-il)-3- okso-3,4-dihidro-2H-1,4-benzoksazin-6-il]metil} etansulfonamid;
N-{[2-izopropil-8-(6-metil-7-okso-6,7-dihidro-1H-pirolo[2,3-c]piridin-4-il)-3-okso-3,4-dihidro-2H-1,4-benzoksazin-6-il]metil}acetamid;
2-izopropil-8-(6-metil-7-okso-6,7-dihidro-1H-pirolo[2,3-c]piridin-4-il)-3-okso- 3,4-dihidro-2H-1,4-benzoksazin-6-karboksamid;
2-ciklopentil-6-metoksi-8-(6-metil-7-okso-6,7-dihidro-1H-pirazolo[3,4-c]piridin-4-il)-2H-1,4-benzoksazin-3 (4H)-on;
6-(2-furil)-2-izopropil-8-(6-metil-7-okso-6,7-dihidro-1H-pirolo[2,3-c]piridin-4- il)-2H-1,4-benzoksazin-3(4H)-on;
2-izopropil-8-(6-metil-7-okso-6,7-dihidro-1H-pirolo[2,3-c]piridin-4-il)-6- (metilsulfonil)-2H-1,4-benzoksazin-3(4H)-on;
2,2-dimetil-8-(6-metil-7-okso-6,7-dihidro-1H-pirolo[2,3-c]piridin-4-il)-6- (metilsulfonil)-2H-1,4-benzoksazin-3(4H)-on;
8-(6-metil-7-okso-6,7-dihidro-1H-pirolo[2,3-c]piridin-4-il)-6-(metilsulfonil)-2-fenil-2H-1,4-benzoksazin-3(4H)-on;
2-izopropil-4-metil-8-(6-metil-7-okso-6,7-dihidro-1H-pirolo[2,3-c]piridin-4-il)- 6-(metilsulfonil)-2H-1,4-benzoksazin-3(4H)-on;
2-(2-hidroksietil)-8-(6-metil-7-okso-6,7-dihidro-1H-pirolo[2,3-c]piridin-4-il)-6- (metilsulfonil)-2H-1,4-benzoksazin-3(4H)-on;
6-acetil-2-izopropil-8-(6-metil-7-okso-6,7-dihidro-1H-pirolo[2,3-c]piridin-4-il)- 2H-1,4-benzoksazin-3(4H)-on;
6-(1-hidroksietil)-2-izopropil-8-(6-metil-7-okso-6,7-dihidro-1H-pirolo[2,3-c]piridin-4-il)-2H-1,4-benzoksazin-3(4H)-on;
6-(etilsulfonil)-2-izopropil-8 -(6-metil- 7-okso-6,7-dihidro-1H-pirolo[2,3-c]piridin-4-il)-2H-1,4-benzoksazin-3(4H)-on;
2-izopropil-6-(izopropilsulfonil)-8-(6-metil-7-okso-6,7-dihidro-1H-pirolo[2,3-c]piridin-4-il)-2H-1,4-benzoksazin-3(4H)-on;
4-(ciklopropilmetil)-2-izopropil-8-(6-metil-7-okso-6,7-dihidro-1H-pirolo[2,3-c]piridin-4-il)-6-(metilsulfonil)-2H-1,4-benzoksazin-3(4H)-on;
4-etil-2-izopropil-8-(6-metil-7-okso-6,7-dihidro-1H-pirolo[2,3-c]piridin-4-il)-6- (metilsulfonil)-2H-1,4-benzoksazin-3(4H)-on;
6-(etilsulfonil)-2-izopropil-4-metil-8-(6-metil-7-okso-6,7-dihidro-1H-pirolo[2,3-c]piridin-4-il)-2H-1,4-benzoksazin-3(4H)-on;
2-izopropil-6-(izopropilsulfonil)-4-metil-8-(6-metil-7-okso-6,7-dihidro-1H- pirolo[2,3-c]piridin-4-il)-2H-1,4-benzoksazin-3(4H)-on;
8-(6-metil-7-okso-6,7-dihidro-1H-pirolo[2,3-c]piridin-4-il)-6-(metilsulfonil)spiro[1,4-benzoksazin-2,1'-ciklopropan]-3(4H)-on;
3,3-dimetil-5-(6-metil-7-okso-6,7-dihidro-1H-pirolo[2,3-c]piridin-4-il)-7- (metilsulfonil)-3,4-dihidrokinoksalin-2(1H)-on;
8'-(6-metil-7-okso-6,7-dihidro-1H-pirolo[2,3-c]piridin-4-il)-6'-(metilsulfonil)-1',4'-dihidro-3'H-spiro[ciklopentan-1,2'-kinoksalin]-3'-on;
(3S)-3-izopropil-5-(6-metil-7-okso-6,7-dihidro-1H-pirolo[2,3-c]piridin-4-il)-7- (metilsulfonil)-3,4-dihidrokinoksalin-2(1H)-on;
(3R)-3-izopropil-5-(6-metil-7-okso-6,7-dihidro-1H-pirolo[2,3-c]piridin-4-il)-7- (metilsulfonil)-3,4-dihidrokinoksalin-2(1H)-on;
8'-(6-metil-7-okso-6,7-dihidro-1H-pirolo[2,3-c]piridin-4-il)-6'-(metilsulfonil)-1',4'-dihidro-3'H-spiro[ciklobutan-1,2'-kinoksalin]-3'-on;
4-metil-8-(6-metil-7-okso-6,7-dihidro-1H-pirolo[2,3-c]piridin-4-il)-6- (metilsulfonil)spiro[1,4-benzoksazin-2,1'-ciklopropan]-3(4H)-on;
8'-(6-metil-7-okso-6,7-dihidro-1H-pirolo[2,3-c]piridin-4-il)-6'-(metilsulfonil)-1',4'-dihidro-3'H-spiro[cikloheksan-1,2'-kinoksalin]-3'-on;
8-(6-metil-7-okso-6,7-dihidro-1H-pirazolo[3,4-c]piridin-4-il)-6- (metilsulfonil)spiro[1,4-benzoksazin-2,1'-ciklopropan]-3(4H)-on;
4-metil-8-(6-metil-7-okso-6,7-dihidro-1H-pirazolo[3,4-c]piridin-4-il)-6- (metilsulfonil)spiro[1,4-benzoksazin-2,1'-ciklopropan]-3(4H)-on;
2-izopropil-N,N-dimetil-8-(6-metil-7-okso-6,7-dihidro-1H-pirolo[2,3-c]piridin-4-il)-3-okso-3,4-dihidro-2H-1,4-benzoksazin-6-sulfonamid;
2-izopropil-N-metil-8-(6-metil-7-okso-6,7-dihidro-1H-pirolo[2,3-c]piridin-4-il)- 3-okso-3,4-dihidro-2H-1,4-benzoksazin-6-sulfonamid;
N,N,2,2,4-pentametil-8-(6-metil-7-okso-6,7-dihidro-1H-pirolo[2,3-c]piridin-4- il)-3-okso-3,4-dihidro-2H-1,4-benzoksazin-6-sulfonamid;
N,N,2,2-tetrametil-8-(6-metil-7-okso-6,7-dihidro-1H-pirolo[2,3-c]piridin-4-il)- 3-okso-3,4-dihidro-2H-1,4-benzoksazin-6-sulfonamid;
2-izopropil-N,N,4-trimetil-8-(6-metil-7-okso-6,7-dihidro-1H-pirolo[2,3-c]piridin-4-il)-3-okso-3,4-dihidro-2H-1,4-benzoksazin-6-sulfonamid;
2,2-dimetil-8-(6-metil-7-okso-6,7-dihidro-1H-pirolo[2,3-c]piridin-4-il)-6- (piperidin-1-ilsulfonil)-2H-1,4-benzoksazin-3(4H)-on;
2,2,4-trimetil-8-(6-metil-7-okso-6,7-dihidro-1H-pirolo[2,3-c]piridin-4-il)-6- (piperidin-1-ilsulfonil)-2H-1,4-benzoksazin-3(4H)-on;
N-izopropil-2,2-dimetil-8-(6-metil-7-okso-6,7-dihidro-1H-pirolo[2,3-c]piridin-4-il)-3-okso-3,4-dihidro-2H-1,4-benzoksazin-6-sulfonamid;
2,2,4-trimetil-8-(6-metil-7-okso-6,7-dihidro-1H-pirolo[2,3-c]piridin-4-il)-6- (metilsulfonil)-2H-1,4-benzoksazin-3(4H)-on;
6-(etilsulfonil)-2,2,4-trimetil-8-(6-metil-7-okso-6,7-dihidro-1H-pirolo[2,3-c)piridin-4-il)-2H-1,4-benzoksazin-3(4H)-on;
6-(izopropilsulfonil)-2,2,4-trimetil-8-(6-metil-7-okso-6,7-dihidro-1H-pirolo[2,3-c]piridin-4-il)-2H-1,4-benzoksazin-3(4H)-on;
6-(etilsulfonil)-2,2-dimetil-8-(6-metil-7-okso-6,7-dihidro-1H-pirolo[2,3-c]piridin-4-il)-2H-1,4-benzoksazin-3(4H)-on;
6-(izopropilsulfonil)-2,2-dimetil-8-(6-metil-7-okso-6,7-dihidro-1H-pirolo[2,3-c]piridin-4-il)-2H-1,4-benzoksazin-3(4H)-on;
6-acetil-2,2-dimetil-8-(6-metil-7-okso-6,7-dihidro-1H-pirolo[2,3-c]piridin-4-il)-2H-1,4-benzoksazin-3(4H)-on;
6-(1-hidroksietil)-2,2-dimetil-8-(6-metil-7-okso-6,7-dihidro-1H-pirolo[2,3-c]piridin-4-il)-2H-1,4-benzoksazin-3(4H)-on;
6-acetil-2,2,4-trimetil-8-(6-metil-7-okso-6,7-dihidro-1H-pirolo[2,3-c]piridin-4-il)-2H-1,4-benzoksazin-3(4H)-on;
6-(1-hidroksietil)-2,2,4-trimetil-8-(6-metil-7-okso-6,7-dihidro-1H-pirolo[2,3-c]piridin-4-il)-2H-1,4-benzoksazin-3(4H)-on; i
2-izopropil-8-(6-metil-7-okso-6,7-dihidro-1H-pirazolo[3,4-c]piridin-4-il)-6- (metilsulfonil)-2H-1,4-benzoksazin-3(4H)-on;
ili farmaceutski prihvatljiva sol od bilo kojega od predstojeฤih;
pri ฤemu se navedeno kemoterapeutsko sredstvo bira od sljedeฤih: abareliks, aldesleukin, alemtuzumab, alitretinoin, alopurinol, altretamin, anastrozol, arsenski trioksid, asparaginaza, azacitidin, bevacizumab, beksaroten, bleomicin, bortezombi, bortezomib, intravenozni busulfan, oralni busulfan, kalusteron, kapecitabin, karboplatin, karmustin, cetuksimab, klorambucil, cisplatin, kladribin, klofarabin, ciklofosfamid, citarabin, dakarbazin, daktinomicin, dalteparin natrij, dasatinib, daunorubicin, decitabin, denileukin, denileukin diftitoks, deksrazoksan, docetaksel, doksorubicin, dromostanolon propionat, ekulizumab, epirubicin, erlotinib, estramustin, etopozid fosfat, etopozid, eksemestan, fentanil citrat, filgrastim, floksuridin, fludarabin, fluorouracil, fulvestrant, gefitinib, gemcitabin, gemtuzumab ozogamicin, goserelin acetat, histrelin acetat, ibritumomab tiuksetan, idarubicin, ifosfamid, imatinib mesilat, interferon alfa 2a, irinotekan, lapatinib ditosilat, lenalidomid, letrozol, leukovorin, leuprolid acetat, levamisol, lomustin, mekloretamin, megestrol acetat, melfalan, merkaptopurin, metotreksat, metoksalen, mitomicin C, mitotan, mitoksantron, nandrolon fenpropionat, nelarabin, nofetumomab, oksaliplatin, paklitaksel, pamidronat, panitumumab, pegaspargas, pegfilgrastim, pemetreksed dinatrij, pentostatin, pipobroman, plikamicin, prokarbazin, kvinakrin, rasburikaza, rituksimab, sorafenib, streptozocin, sunitinib, sunitinib maleat, tamoksifen, temozolomid, tenipozid, testolakton, talidomid, tiogvanin, tiotepa, topotekan, toremifen, tositumomab, trastuzumab, tretinoin, uracil mustard, valrubicin, vinblastin, vinkristin, vinorelbin, vorinostat, i zoledronat.
9. Kemoterapeutsko sredstvo, naznaฤeno time, da je za uporabu u lijeฤenju raka, pri ฤemu se navedeno kemoterapeutsko sredstvo daje u kombinaciji s inhibitorom BET proteina, gdje se navedeni inhibitor BET proteina bira od sljedeฤih:
8-(6-metil-7-okso-6,7-dihidro-1H-pirolo[2,3-c]piridin-4-il)-2-fenil-1H-1,4-benzoksazin-3(4H)-on;
2-izopropil-8-(6-metil-7-okso-6,7-dihidro-1H-pirolo[2,3-c]piridin-4-il)-2H-1,4-benzoksazin-3(4H)-on;
2-metil-8-(6-metil-7-okso-6,7-dihidro-1H-pirolo[2,3-c]piridin-4-il)-2H-1,4-benzoksazin-3(4H)-on;
2-etil-8-(6-metil-7-okso-6,7-dihidro-1H-pirolo[2,3-c]piridin-4-il)-2H-1,4-benzoksazin-3(4H)-on;
8-(6-metil-7-okso-6,7-dihidro-1H-pirolo[2,3-c]piridin-4-il)-2-piridin-2-il-2H-1,4-benzoksazin-3(4H)-on 2,2,2-trifluoroacetat;
2-ciklopropil-8-(6-metil-7-okso-6,7-dihidro-1H-pirolo[2,3-c]piridin-4-il)-2H-1,4-benzoksazin-3(4H)-on;
8-(6-metil-7-okso-6,7-dihidro-1H-pirolo[2,3-c]piridin-4-il)-2-(tetrahidro-2H-piran-4-il)-2H-1,4-benzoksazin-3(4H)-on;
2-etil-4-metil-8-(6-metil-7-okso-6,7-dihidro-1H-pirolo[2,3-c]piridin-4-il)-2H-1,4-benzoksazin-3(4H)-on;
2-izopropil-6-metoksi-8-(6-metil-7-okso-6,7-dihidro-1H-pirolo[2,3-c]piridin-4-il)-2H-1,4-benzoksazin-3(4H)-on;
2-izopropil-6-metoksi-4-metil-8-(6-metil-7-okso-6,7-dihidro-1H-pirolo[2,3-c]piridin-4-il)-2H-1,4-benzoksazin-3(4H)-on;
[2-izopropil-6-metoksi-8-(6-metil-7-okso-6,7-dihidro-1H-pirolo[2,3-c]piridin-4-il)-3-okso-2,3-dihidro-4H-1,4-benzoksazin-4-il]octena kiselina;
2-[2-izopropil-6-metoksi-8-(6-metil-7-okso-6,7-dihidro-1H-pirolo[2,3-c]piridin-4-il)-3-okso-2,3-dihidro-4H-1,4-benzoksazin-4-il]-N-metilacetamid;
2-[2-izopropil-6-metoksi-8-(6-metil-7-okso-6,7-dihidro-1H-pirolo[2,3-c]piridin-4-il)-3-okso-2,3-dihidro-4H-1,4-benzoksazin-4-il]acetamid;
2-izopropil-6-metoksi-8-(6-metil-7-okso-6,7-dihidro-1H-pirolo[2,3-c]piridin-4-il)-4-[2-(4-metilpiperazin-1-il)-2-oksoetil]-2H-1,4-benzoksazin-3(4H)-on;
2-izopropil-6-metoksi-8-(6-metil-7-okso-6,7-dihidro-1H-pirolo[2,3-c]piridin-4- il)-4-(piridin-4-ilmetil)-2H-1,4-benzoksazin-3(4H)-on;
2,4-diizopropil-6-metoksi-8-(6-metil-7-okso-6,7-dihidro-1H-pirolo[2,3-c]piridin- 4-il)-2H-1,4-benzoksazin-3(4H)-on;
2-izopropil-8-(6-metil-7-okso-6,7-dihidro-1H-pirolo[2,3-c]piridin-4-il)-3-okso-3,4-dihidro-2H-1,4-benzoksazin-6-karbonitril;
2-izopropil-4-metil-8-(6-metil-7-okso-6, 7-dihidro-1H-pirolo[2,3-c]piridin-4-il)- 3-okso-3,4-dihidro-2H-1,4-benzoksazin-6-karbonitril;
2-izopropil-4-metil-8-(6-metil-7-okso-6,7-dihidro-1H-pirolo[2,3-c]piridin-4-il)-3-okso-3,4-dihidro-2H-1,4-benzoksazin-6-karboksamid;
2-izopropil-N-metil-8-(6-metil-7-okso-6,7-dihidro-1H-pirolo[2,3-c]piridin-4-il)-3-okso-3,4-dihidro-2H-1,4-benzoksazin-6 -karboksamid;
2-izopropil-8-(6-metil-7-okso-6,7-dihidro-1H-pirolo[2,3-c]piridin-4-il)-6-nitro- 2H-1,4-benzoksazin-3(4H)-on;
4-(2-izopropil-6-metoksi-4-metil-3,4-dihidro-2H-1,4-benzoksazin-8-il)-6-metil- 1,6-dihidro-7H-pirolo[2,3-c]piridin-7-on;
2-ciklopropil-6-metoksi-8-(6-metil-7-okso-6,7-dihidro-1H-pirolo[2,3-c]piridin-4-il)-2H-1,4-benzoksazin-3(4H)-on;
6-metoksi-8-(6-metil-7-okso-6,7-dihidro-1H-pirolo[2,3-c]piridin-4-il)-2-fenil-2H-1,4-benzoksazin-3(4H)-on;
2-(2-kloro-4-fluorofenil)-6-metoksi-8-(6-metil-7-okso-6,7-dihidro-1H-pirolo[2,3-c]piridin-4-il)-2H-1,4-benzoksazin-3(4H)-on;
2-izopropil-6-metoksi-8-(6-metil-7-okso-6,7-dihidro-1H-pirazolo[3,4-c]piridin-4- il)-2H-1,4-benzoksazin-3(4H)-on;
6-metoksi-2,2-dimetil-8-(6-metil-7-okso-6,7-dihidro-1H-pirolo[2,3-c]piridin-4- il)-2H-1,4-benzoksazin-3(4H)-on;
2-izopropil-8-(6-metil-7-okso-6,7-dihidro-1H-pirolo[2,3-c]piridin-4-il)-6-(1-metil-1H-pirazol-4-il)-2H-1,4-benzoksazin-3(4H)-on;
6-metoksi-2,2-dimetil-8-(6-metil-7-okso-6,7-dihidro-1H-pirazolo[3,4-c]piridin-4-il)-2H-1,4-benzoksazin-3(4H)-on;
8-(6-metil-7-okso-6,7-dihidro-1H-pirolo[2,3-c]piridin-4-il)spiro[1,4-benzoksazin- 2,1'-ciklopropan]-3(4H)-on;
2,2-dimetil-8-(6-metil-7-okso-6,7-dihidro-1H-pirolo[2,3-c]piridin-4-il)-2H-1,4- benzoksazin-3(4H)-on;
3,3-dimetil-5-(6-metil-7-okso-6,7-dihidro-1H-pirolo[2,3-c]piridin-4-il)-3,4- dihidrokinoksalin-2(1H)-on;
2-izopropil-8-(6-metil-7-okso-6,7-dihidro-1H-pirolo[2,3-c]piridin-4-il)-6- (morfolin-4-ilkarbonil)-2H-1,4-benzoksazin-3(4H)-on;
2-izopropil-N,N-dimetil-8-(6-metil-7-okso-6,7-dihidro-1H-pirolo[2,3-c]piridin-4-il)-3-okso-3,4-dihidro-2H-1,4-benzoksazin-6-karboksamid;
2-ciklopentil-6-metoksi-8-(6-metil-7-okso-6,7-dihidro-1H-pirolo[2,3-c]piridin-4-il)-2H-1,4-benzoksazin-3(4H)-on;
6-(hidroksimetil)-2-izopropil-8-(6-metil-7-okso-6,7-dihidro-1H-pirolo[2,3-c]piridin-4 -il)-2H-1,4-benzoksazin-3( 4H)-on;
2-izopropil-6-(metoksimetil)-8-(6-metil-7-okso-6,7-dihidro-1H-pirolo[2,3-c]piridin-4-il)-2H-1,4-benzoksazin-3(4H)-on;
6-(aminometil)-2-izopropil-8-(6-metiI-7-okso-6,7-dihidro-1H-pirolo[2,3-c]piridin-4-il)-2H-1,4-benzoksazin-3(4H)-on;
N-{[2-izopropil-8-(6-metil-7-okso-6,7-dihidro-1H-pirolo[2,3-c]piridin-4-il)-3- okso-3,4-dihidro-2H-1,4-benzoksazin-6-il]metil} etansulfonamid;
N-{[2-izopropil-8-(6-metil-7-okso-6,7-dihidro-1H-pirolo[2,3-c]piridin-4-il)-3-okso-3,4-dihidro-2H-1,4-benzoksazin-6-il]metil}acetamid;
2-izopropil-8-(6-metil-7-okso-6,7-dihidro-1H-pirolo[2,3-c]piridin-4-il)-3-okso- 3,4-dihidro-2H-1,4-benzoksazin-6-karboksamid;
2-ciklopentil-6-metoksi-8-(6-metil-7-okso-6,7-dihidro-1H-pirazolo[3,4-c]piridin-4-il)-2H-1,4-benzoksazin-3 (4H)-on;
6-(2-furil)-2-izopropil-8-(6-metil-7-okso-6,7-dihidro-1H-pirolo[2,3-c]piridin-4- il)-2H-1,4-benzoksazin-3(4H)-on;
2-izopropil-8-(6-metil-7-okso-6,7-dihidro-1H-pirolo[2,3-c]piridin-4-il)-6- (metilsulfonil)-2H-1,4-benzoksazin-3(4H)-on;
2,2-dimetil-8-(6-metil-7-okso-6,7-dihidro-1H-pirolo[2,3-c]piridin-4-il)-6- (metilsulfonil)-2H-1,4-benzoksazin-3(4H)-on;
8-(6-metil-7-okso-6,7-dihidro-1H-pirolo[2,3-c]piridin-4-il)-6-(metilsulfonil)-2-fenil-2H-1,4-benzoksazin-3(4H)-on;
2-izopropil-4-metil-8-(6-metil-7-okso-6,7-dihidro-1H-pirolo[2,3-c]piridin-4-il)- 6-(metilsulfonil)-2H-1,4-benzoksazin-3(4H)-on;
2-(2-hidroksietil)-8-(6-metil-7-okso-6,7-dihidro-1H-pirolo[2,3-c]piridin-4-il)-6- (metilsulfonil)-2H-1,4-benzoksazin-3(4H)-on;
6-acetil-2-izopropil-8-(6-metil-7-okso-6,7-dihidro-1H-pirolo[2,3-c]piridin-4-il)- 2H-1,4-benzoksazin-3(4H)-on;
6-(1-hidroksietil)-2-izopropil-8-(6-metil-7-okso-6,7-dihidro-1H-pirolo[2,3-c]piridin-4-il)-2H-1,4-benzoksazin-3(4H)-on;
6-(etilsulfonil)-2-izopropil-8 -(6-metil- 7-okso-6,7-dihidro-1H-pirolo[2,3-c]piridin-4-il)-2H-1,4-benzoksazin-3(4H)-on;
2-izopropil-6-(izopropilsulfonil)-8-(6-metil-7-okso-6,7-dihidro-1H-pirolo[2,3-c]piridin-4-il)-2H-1,4-benzoksazin-3(4H)-on;
4-(ciklopropilmetil)-2-izopropil-8-(6-metil-7-okso-6,7-dihidro-1H-pirolo[2,3-c]piridin-4-il)-6-(metilsulfonil)-2H-1,4-benzoksazin-3(4H)-on;
4-etil-2-izopropil-8-(6-metil-7-okso-6,7-dihidro-1H-pirolo[2,3-c]piridin-4-il)-6- (metilsulfonil)-2H-1,4-benzoksazin-3(4H)-on;
6-(etilsulfonil)-2-izopropil-4-metil-8-(6-metil-7-okso-6,7-dihidro-1H-pirolo[2,3-c]piridin-4-il)-2H-1,4-benzoksazin-3(4H)-on;
2-izopropil-6-(izopropilsulfonil)-4-metil-8-(6-metil-7-okso-6,7-dihidro-1H- pirolo[2,3-c]piridin-4-il)-2H-1,4-benzoksazin-3(4H)-on;
8-(6-metil-7-okso-6,7-dihidro-1H-pirolo[2,3-c]piridin-4-il)-6-(metilsulfonil)spiro[1,4-benzoksazin-2,1'-ciklopropan]-3(4H)-on;
3,3-dimetil-5-(6-metil-7-okso-6,7-dihidro-1H-pirolo[2,3-c]piridin-4-il)-7- (metilsulfonil)-3,4-dihidrokinoksalin-2(1H)-on;
8'-(6-metil-7-okso-6,7-dihidro-1H-pirolo[2,3-c]piridin-4-il)-6'-(metilsulfonil)-1',4'-dihidro-3'H-spiro[ciklopentan-1,2'-kinoksalin]-3'-on;
(3S)-3-izopropil-5-(6-metil-7-okso-6,7-dihidro-1H-pirolo[2,3-c]piridin-4-il)-7- (metilsulfonil)-3,4-dihidrokinoksalin-2(1H)-on;
(3R)-3-izopropil-5-(6-metil-7-okso-6,7-dihidro-1H-pirolo[2,3-c]piridin-4-il)-7- (metilsulfonil)-3,4-dihidrokinoksalin-2(1H)-on;
8'-(6-metil-7-okso-6,7-dihidro-1H-pirolo[2,3-c]piridin-4-il)-6'-(metilsulfonil)-1',4'-dihidro-3'H-spiro[ciklobutan-1,2'-kinoksalin]-3'-on;
4-metil-8-(6-metil-7-okso-6,7-dihidro-1H-pirolo[2,3-c]piridin-4-il)-6- (metilsulfonil)spiro[1,4-benzoksazin-2,1'-ciklopropan]-3(4H)-on;
8'-(6-metil-7-okso-6,7-dihidro-1H-pirolo[2,3-c]piridin-4-il)-6'-(metilsulfonil)-1',4'-dihidro-3'H-spiro[cikloheksan-1,2'-kinoksalin]-3'-on;
8-(6-metil-7-okso-6,7-dihidro-1H-pirazolo[3,4-c]piridin-4-il)-6- (metilsulfonil)spiro[1,4-benzoksazin-2,1'-ciklopropan]-3(4H)-on;
4-metil-8-(6-metil-7-okso-6,7-dihidro-1H-pirazolo[3,4-c]piridin-4-il)-6- (metilsulfonil)spiro[1,4-benzoksazin-2,1'-ciklopropan]-3(4H)-on;
2-izopropil-N,N-dimetil-8-(6-metil-7-okso-6,7-dihidro-1H-pirolo[2,3-c]piridin-4-il)-3-okso-3,4-dihidro-2H-1,4-benzoksazin-6-sulfonamid;
2-izopropil-N-metil-8-(6-metil-7-okso-6,7-dihidro-1H-pirolo[2,3-c]piridin-4-il)- 3-okso-3,4-dihidro-2H-1,4-benzoksazin-6-sulfonamid;
N,N,2,2,4-pentametil-8-(6-metil-7-okso-6,7-dihidro-1H-pirolo[2,3-c]piridin-4- il)-3-okso-3,4-dihidro-2H-1,4-benzoksazin-6-sulfonamid;
N,N,2,2-tetrametil-8-(6-metil-7-okso-6,7-dihidro-1H-pirolo[2,3-c]piridin-4-il)- 3-okso-3,4-dihidro-2H-1,4-benzoksazin-6-sulfonamid;
2-izopropil-N,N,4-trimetil-8-(6-metil-7-okso-6,7-dihidro-1H-pirolo[2,3-c]piridin-4-il)-3-okso-3,4-dihidro-2H-1,4-benzoksazin-6-sulfonamid;
2,2-dimetil-8-(6-metil-7-okso-6,7-dihidro-1H-pirolo[2,3-c]piridin-4-il)-6- (piperidin-1-ilsulfonil)-2H-1,4-benzoksazin-3(4H)-on;
2,2,4-trimetil-8-(6-metil-7-okso-6,7-dihidro-1H-pirolo[2,3-c]piridin-4-il)-6- (piperidin-1-ilsulfonil)-2H-1,4-benzoksazin-3(4H)-on;
N-izopropil-2,2-dimetil-8-(6-metil-7-okso-6,7-dihidro-1H-pirolo[2,3-c]piridin-4-il)-3-okso-3,4-dihidro-2H-1,4-benzoksazin-6-sulfonamid;
2,2,4-trimetil-8-(6-metil-7-okso-6,7-dihidro-1H-pirolo[2,3-c]piridin-4-il)-6- (metilsulfonil)-2H-1,4-benzoksazin-3(4H)-on;
6-(etilsulfonil)-2,2,4-trimetil-8-(6-metil-7-okso-6,7-dihidro-1H-pirolo[2,3-c)piridin-4-il)-2H-1,4-benzoksazin-3(4H)-on;
6-(izopropilsulfonil)-2,2,4-trimetil-8-(6-metil-7-okso-6,7-dihidro-1H-pirolo[2,3-c]piridin-4-il)-2H-1,4-benzoksazin-3(4H)-on;
6-(etilsulfonil)-2,2-dimetil-8-(6-metil-7-okso-6,7-dihidro-1H-pirolo[2,3-c]piridin-4-il)-2H-1,4-benzoksazin-3(4H)-on;
6-(izopropilsulfonil)-2,2-dimetil-8-(6-metil-7-okso-6,7-dihidro-1H-pirolo[2,3-c]piridin-4-il)-2H-1,4-benzoksazin-3(4H)-on;
6-acetil-2,2-dimetil-8-(6-metil-7-okso-6,7-dihidro-1H-pirolo[2,3-c]piridin-4-il)-2H-1,4-benzoksazin-3(4H)-on;
6-(1-hidroksietil)-2,2-dimetil-8-(6-metil-7-okso-6,7-dihidro-1H-pirolo[2,3-c]piridin-4-il)-2H-1,4-benzoksazin-3(4H)-on;
6-acetil-2,2,4-trimetil-8-(6-metil-7-okso-6,7-dihidro-1H-pirolo[2,3-c]piridin-4-il)-2H-1,4-benzoksazin-3(4H)-on;
6-(1-hidroksietil)-2,2,4-trimetil-8-(6-metil-7-okso-6,7-dihidro-1H-pirolo[2,3-c]piridin-4-il)-2H-1,4-benzoksazin-3(4H)-on; i
2-izopropil-8-(6-metil-7-okso-6,7-dihidro-1H-pirazolo[3,4-c]piridin-4-il)-6- (metilsulfonil)-2H-1,4-benzoksazin-3(4H)-on;
ili farmaceutski prihvatljiva sol od bilo kojega od predstojeฤih;
pri ฤemu se navedeno kemoterapeutsko sredstvo bira od sljedeฤih: abareliks, aldesleukin, alemtuzumab, alitretinoin, alopurinol, altretamin, anastrozol, arsenski trioksid, asparaginaza, azacitidin, bevacizumab, beksaroten, bleomicin, bortezombi, bortezomib, intravenozni busulfan, oralni busulfan, kalusteron, kapecitabin, karboplatin, karmustin, cetuksimab, klorambucil, cisplatin, kladribin, klofarabin, ciklofosfamid, citarabin, dakarbazin, daktinomicin, dalteparin natrij, dasatinib, daunorubicin, decitabin, denileukin, denileukin diftitoks, deksrazoksan, docetaksel, doksorubicin, dromostanolon propionat, ekulizumab, epirubicin, erlotinib, estramustin, etopozid fosfat, etopozid, eksemestan, fentanil citrat, filgrastim, floksuridin, fludarabin, fluorouracil, fulvestrant, gefitinib, gemcitabin, gemtuzumab ozogamicin, goserelin acetat, histrelin acetat, ibritumomab tiuksetan, idarubicin, ifosfamid, imatinib mesilat, interferon alfa 2a, irinotekan, lapatinib ditosilat, lenalidomid, letrozol, leukovorin, leuprolid acetat, levamisol, lomustin, mekloretamin, megestrol acetat, melfalan, merkaptopurin, metotreksat, metoksalen, mitomicin C, mitotan, mitoksantron, nandrolon fenpropionat, nelarabin, nofetumomab, oksaliplatin, paklitaksel, pamidronat, panitumumab, pegaspargas, pegfilgrastim, pemetreksed dinatrij, pentostatin, pipobroman, plikamicin, prokarbazin, kvinakrin, rasburikaza, rituksimab, sorafenib, streptozocin, sunitinib, sunitinib maleat, tamoksifen, temozolomid, tenipozid, testolakton, talidomid, tiogvanin, tiotepa, topotekan, toremifen, tositumomab, trastuzumab, tretinoin, uracil mustard, valrubicin, vinblastin, vinkristin, vinorelbin, vorinostat, i zoledronat.
10. Inhibitor BET proteina prema patentnom zahtjevu 7, ili kombinacija inhibitora BET proteina i kemoterapeutskog sredstva prema patentnom zahtjevu 8, ili kemoterapeutsko sredstvo prema patentnom zahtjevu 9, naznaฤeni time, da spomenuti rak je hematoloลกki rak.
11. Inhibitor BET proteina prema patentnom zahtjevu 7, ili kombinacija inhibitora BET proteina i kemoterapeutskog sredstva prema patentnom zahtjevu 8, ili kemoterapeutsko sredstvo prema patentnom zahtjevu 9, naznaฤeni time, da se spomenuti rak bira od akutne mijeloiฤne leukemije ili difuznog limfoma velikih B stanica.
12. Inhibitor BET proteina prema bilo kojem od patentnih zahtjeva 7 i 10 do 11, ili kombinacija inhibitora BET proteina i kemoterapeutskog sredstva prema bilo kojem od patentnih zahtjeva 8 i 10 do 11, ili kemoterapeutsko sredstvo prema bilo kojem od patentnih zahtjeva 9 do 11, naznaฤeni time, da spomenuti inhibitor BET proteina je 2,2,4-trimetil-8-(6-metil-7-okso-6,7-dihidro-1H-pirolo[2,3-c]piridin-4-il)-6-(metilsulfonil)-2H-1,4-benzoksazin-3(4H)-on, i njegove farmaceutski prihvatljive soli.
13. Inhibitor BET proteina prema bilo kojem od patentnih zahtjeva 7 i 10 do 12, ili kombinacija inhibitora BET proteina i kemoterapeutskog sredstva prema bilo kojem od patentnih zahtjeva 8 i 10 do 12, ili kemoterapeutsko sredstvo prema bilo kojem od patentnih zahtjeva 9 do 12, naznaฤeni time, da se spomenuto kemoterapeutsko sredstvo i spomenuti inhibitor BET proteina daju istovremeno.
14. Inhibitor BET proteina prema bilo kojem od patentnih zahtjeva 7 i 10 do 12, ili kombinacija inhibitora BET proteina i kemoterapeutskog sredstva prema bilo kojem od patentnih zahtjeva 8 i 10 do 12, ili kemoterapeutsko sredstvo prema bilo kojem od patentnih zahtjeva 9 do 12, naznaฤeni time, da se spomenuto kemoterapeutsko sredstvo i spomenuti inhibitor BET proteina daju uzastopno.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201461983289P | 2014-04-23 | 2014-04-23 | |
EP20156599.1A EP3674302B1 (en) | 2014-04-23 | 2015-04-22 | 1h-pyrrolo[2,3-c]pyridin-7(6h)-ones and pyrazolo[3,4-c]pyridin-7(6h)-ones as inhibitors of bet proteins |
Publications (1)
Publication Number | Publication Date |
---|---|
HRP20230340T1 true HRP20230340T1 (hr) | 2023-06-09 |
Family
ID=53055117
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
HRP20230340TT HRP20230340T1 (hr) | 2014-04-23 | 2015-04-22 | 1-h-pirolo[2,3-c]piridin-7(6h)-oni i pirazolo[3,4-c]piridin-7(6h)-oni kao inhibitori bet proteina |
HRP20200564TT HRP20200564T1 (hr) | 2014-04-23 | 2020-04-07 | 1h-pirolo[2,3-c]piridin-7(6h)-oni i pirazolo[3,4-c]piridin-7(6h)-oni kao inhibitori bet proteina |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
HRP20200564TT HRP20200564T1 (hr) | 2014-04-23 | 2020-04-07 | 1h-pirolo[2,3-c]piridin-7(6h)-oni i pirazolo[3,4-c]piridin-7(6h)-oni kao inhibitori bet proteina |
Country Status (36)
Country | Link |
---|---|
US (7) | US9540368B2 (hr) |
EP (3) | EP3134403B1 (hr) |
JP (2) | JP6572237B2 (hr) |
KR (2) | KR20220113552A (hr) |
CN (1) | CN106414442B (hr) |
AR (1) | AR100160A1 (hr) |
AU (3) | AU2015249810B2 (hr) |
BR (1) | BR112016024626B1 (hr) |
CA (1) | CA2946731C (hr) |
CL (1) | CL2016002681A1 (hr) |
CR (2) | CR20200231A (hr) |
CY (2) | CY1122948T1 (hr) |
DK (2) | DK3674302T3 (hr) |
EA (2) | EA034972B1 (hr) |
EC (1) | ECSP16088983A (hr) |
ES (2) | ES2784846T3 (hr) |
FI (1) | FI3674302T3 (hr) |
HR (2) | HRP20230340T1 (hr) |
HU (2) | HUE061770T2 (hr) |
IL (3) | IL248415B (hr) |
LT (2) | LT3674302T (hr) |
MA (1) | MA39985B1 (hr) |
ME (1) | ME03763B (hr) |
MX (2) | MX2016013851A (hr) |
MY (1) | MY180775A (hr) |
NZ (3) | NZ763740A (hr) |
PE (1) | PE20170144A1 (hr) |
PH (1) | PH12016502115B1 (hr) |
PL (2) | PL3134403T3 (hr) |
PT (2) | PT3674302T (hr) |
RS (2) | RS60139B1 (hr) |
SG (2) | SG10201809353TA (hr) |
SI (2) | SI3134403T1 (hr) |
TW (2) | TWI735002B (hr) |
UA (1) | UA119870C2 (hr) |
WO (1) | WO2015164480A1 (hr) |
Families Citing this family (46)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR102355670B1 (ko) | 2013-03-15 | 2022-02-08 | ์ธ์ฌ์ดํธ ํ๋ฉ์ค ์ฝํฌ๋ ์ด์ | Bet ๋จ๋ฐฑ์ง ์ ํด์ ๋ก์์ ์ผํ์ ๋ณต์ํ |
US9290514B2 (en) | 2013-07-08 | 2016-03-22 | Incyte Holdings Corporation | Tricyclic heterocycles as BET protein inhibitors |
WO2015081203A1 (en) | 2013-11-26 | 2015-06-04 | Incyte Corporation | Bicyclic heterocycles as bet protein inhibitors |
US9315501B2 (en) | 2013-11-26 | 2016-04-19 | Incyte Corporation | Bicyclic heterocycles as BET protein inhibitors |
US9309246B2 (en) | 2013-12-19 | 2016-04-12 | Incyte Corporation | Tricyclic heterocycles as BET protein inhibitors |
ME03763B (me) | 2014-04-23 | 2021-04-20 | Incyte Corp | 1h-pirrolo[2,3-c]piridin-7(6h)-oni i pirazolo[3,4-c]piridin-7(6h)-oni kao inhibitori bet proteina |
EP3194406B8 (en) | 2014-09-15 | 2021-03-31 | Incyte Corporation | Tricyclic heterocycles for use as bet protein inhibitors |
MA40943A (fr) | 2014-11-10 | 2017-09-19 | Constellation Pharmaceuticals Inc | Pyrrolopyridines substituรฉes utilisรฉes en tant qu'inhibiteurs de bromodomaines |
MA40940A (fr) | 2014-11-10 | 2017-09-19 | Constellation Pharmaceuticals Inc | Pyrrolopyridines substituรฉes utilisรฉes en tant qu'inhibiteurs de bromodomaines |
WO2016077375A1 (en) | 2014-11-10 | 2016-05-19 | Genentech, Inc. | Bromodomain inhibitors and uses thereof |
JP6709792B2 (ja) | 2015-01-29 | 2020-06-17 | ใธใงใใณใใใฏ๏ผ ใคใณใณใผใใฌใคใใใ | ๆฒป็็จๅๅ็ฉใใใณใใฎไฝฟ็จ |
AR104259A1 (es) | 2015-04-15 | 2017-07-05 | Celgene Quanticel Res Inc | Inhibidores de bromodominio |
WO2017024406A1 (en) * | 2015-08-11 | 2017-02-16 | Neomed Institute | N-substituted bicyclic lactams, their preparation and their use as pharmaceuticals |
WO2017024408A1 (en) * | 2015-08-11 | 2017-02-16 | Neomed Institute | Aryl-substituted dihydroquinolinones, their preparation and their use as pharmaceuticals |
JP6912039B2 (ja) | 2015-08-12 | 2021-07-28 | ใใชใกใ ใคใณในใใฃใใฅใผใ๏ผฎ๏ฝ ๏ฝ๏ฝ๏ฝ ๏ฝ ๏ผฉ๏ฝ๏ฝ๏ฝ๏ฝ๏ฝ๏ฝ๏ฝ๏ฝ | ็ฝฎๆใใณใพใคใใใพใผใซใใใใใฎ่ชฟ่ฃฝๅใณๅป่ฌๅใจใใฆใฎใใใใฎไฝฟ็จ |
WO2017066876A1 (en) | 2015-10-21 | 2017-04-27 | Neomed Institute | Substituted imidazopyridines, their preparation and their use as pharmaceuticals |
TW201722966A (zh) | 2015-10-29 | 2017-07-01 | ่ฑๅก็นๅ ฌๅธ | Bet่็ฝ่ณชๆๅถๅไน้ๆถๅบ้ซๅฝขๅผ |
WO2017127930A1 (en) | 2016-01-28 | 2017-08-03 | Neomed Institute | Substituted [1,2,4]triazolo[4,3-a]pyridines, their preparation and their use as pharmaceuticals |
DK3442972T3 (da) | 2016-04-15 | 2020-04-27 | Abbvie Inc | Bromdomรฆnehรฆmmere |
PE20190623A1 (es) | 2016-06-20 | 2019-04-26 | Incyte Corp | Formas solidas cristalinas de un inhibidor de bet |
JP2019534306A (ja) | 2016-11-10 | 2019-11-28 | ็พ ๆฌฃ่ฌๆฅญ๏ผไธๆตท๏ผๆ้ๅ ฌๅธ๏ผฌ๏ฝ๏ฝ๏ฝ๏ฝ๏ฝ ๏ผฐ๏ฝ๏ฝ๏ฝ๏ฝ๏ฝ๏ฝ๏ฝ ๏ฝ๏ฝ๏ฝ๏ฝ๏ฝ๏ฝ๏ผ๏ผณ๏ฝ๏ฝ๏ฝ๏ฝ๏ฝ๏ฝ๏ฝ๏ผ ๏ผฃ๏ฝ๏ผ๏ผ ๏ผฌ๏ฝ๏ฝ๏ผ | ็ช็ด ๅซๆๅคงๅก็ฐ็ณปๅๅ็ฉใใใฎ่ฃฝ้ ๆนๆณใ่ฌ็ฉ็ตๆ็ฉใใใณไฝฟ็จ |
WO2018130174A1 (zh) * | 2017-01-11 | 2018-07-19 | ๆฑ่่ฑชๆฃฎ่ฏไธ้ๅขๆ้ๅ ฌๅธ | ๅกๅฏๅนถ[2,3-c]ๅกๅถ็ฑป่ก็็ฉใๅ ถๅถๅคๆนๆณๅๅ ถๅจๅป่ฏไธ็ๅบ็จ |
CA3070073A1 (en) | 2017-07-18 | 2019-01-24 | Nuvation Bio Inc. | 1,8-naphthyridinone compounds and uses thereof |
US11028058B2 (en) | 2017-07-18 | 2021-06-08 | Nuvation Bio Inc. | Heterocyclic compounds as adenosine antagonists |
CA3081753A1 (en) * | 2017-11-06 | 2019-05-09 | Centre National De La Recherche Scientifique | Xanthine derivatives and uses thereof as inhibitors of bromodomains of bet proteins |
IL275478B1 (en) | 2017-12-20 | 2024-02-01 | Betta Pharmaceuticals Co Ltd | A preparation that functions as a bromodomain protein inhibitor, and the composition |
DK3728207T3 (da) | 2017-12-21 | 2023-03-13 | Ribon Therapeutics Inc | Quinazolinoner som parp14-inhibitorer |
WO2019154329A1 (zh) * | 2018-02-06 | 2019-08-15 | ไธๆตทๆตทๅ่ฏ็ฉ็ ็ฉถๅผๅๆ้ๅ ฌๅธ | ๅ ทๆbetๆๅถๆดปๆง็ๅๅ็ฉๅๅ ถๅถๅคๆนๆณๅ็จ้ |
CN110776508B (zh) * | 2018-07-27 | 2021-07-16 | ๆตทๅ่ฏไธ่กไปฝๆ้ๅ ฌๅธ | ไธ็งbrd4ๆๅถๅๅๅ ถๅถๅคๆนๆณๅ็จ้ |
CN109580433B (zh) * | 2018-10-26 | 2021-05-28 | ไธญๅฝ่พๅฐ้ฒๆค็ ็ฉถ้ข | ไธ็งๅธธ่ง็็ธๆพๅฐๆงๆฐๆบถ่ถๆฉๆฃ็ๆบ้กนไผฐ็ฎๆนๆณ |
JP2022509534A (ja) | 2018-10-30 | 2022-01-20 | ใใฅใผใใคใทใงใณใปใใคใชใปใคใณใณใผใใฌใคใใใ | ๏ผข๏ฝ ๏ฝ้ปๅฎณๅคใจใใฆใฎใใใญ็ฐๅผๅๅ็ฉ |
CN109432093A (zh) * | 2018-12-23 | 2019-03-08 | ้ปๆณณๅ | ็ฑๅกๅๅนถๅกๅถ้ ฎ็ฑปๅๅ็ฉๆๆ็ไน้ ฐ่็ขฑ้ ฏ้ ถๆๅถๅ็ๅขๆไฝ็ณป |
CN113939291A (zh) | 2019-01-18 | 2022-01-14 | ่ฏบ็ปด้็็ฉ่กไปฝๆ้ๅ ฌๅธ | 1,8-่ๅถ้ ฎๅๅ็ฉๅๅ ถ็จ้ |
BR112021013936A2 (pt) | 2019-01-18 | 2021-09-21 | Nuvation Bio Inc. | Compostos heterocรญclicos como antagonistas de adenosina |
KR20210139378A (ko) * | 2019-03-17 | 2021-11-22 | ์ํ์ด ๋ฆฐ์ง ๋ฐ์ด์คํ๋ง ์จ์ค., ์ํฐ๋. | ํผ๋กค์๋ฏธ๋ํผ๋ฆฌ๋๊ณ ํํฉ๋ฌผ, ์ ์กฐ๋ฐฉ๋ฒ ๋ฐ ์ฉ๋ |
CN110003204B (zh) * | 2019-04-30 | 2020-08-11 | ไธๆตทๅๅๅป่ฏ็งๆๆ้ๅ ฌๅธ | ไธ็งbet่็ฝๆๅถๅใๅ ถๅถๅคๆนๆณๅ็จ้ |
WO2020253711A1 (zh) * | 2019-06-17 | 2020-12-24 | ไธญๅฝ็งๅญฆ้ขไธๆตท่ฏ็ฉ็ ็ฉถๆ | ไธ็งๅกๅฏๅนถๅกๅถ้ ฎ็ฑปๅๅ็ฉใๅ ถๅถๅคๆนๆณใๅ ถ็ปๅ็ฉๅ็จ้ |
AU2020296063A1 (en) * | 2019-06-19 | 2021-12-23 | Ribon Therapeutics, Inc. | Targeted protein degradation of PARP14 for use in therapy |
EP3997070A4 (en) | 2019-07-02 | 2023-07-26 | Nuvation Bio Inc. | HETEROCYCLIC COMPOUNDS USED AS BET INHIBITORS |
CN112625036A (zh) * | 2019-10-08 | 2021-04-09 | ไธๆตทๆตทๅ่ฏ็ฉ็ ็ฉถๅผๅ่กไปฝๆ้ๅ ฌๅธ | ไธ็ฑปๅ ทๆbrd4ๆๅถๆดปๆง็ๅๅ็ฉใๅ ถๅถๅคๆนๆณๅ็จ้ |
IL294198A (en) | 2019-12-27 | 2022-08-01 | Lupin Ltd | Transmuted tricyclic compounds |
US11833155B2 (en) | 2020-06-03 | 2023-12-05 | Incyte Corporation | Combination therapy for treatment of myeloproliferative neoplasms |
MX2022015220A (es) | 2020-06-03 | 2023-03-08 | Incyte Corp | Terapia de combinacion para tratamiento de neoplasias mieloproliferativas. |
AU2021392700B2 (en) * | 2020-12-01 | 2023-11-23 | Chengdu Easton Biopharmaceuticals Co., Ltd. | Novel n-heterocyclic bet bromodomain inhibitor, and preparation method therefor and medical use thereof |
WO2022132049A1 (en) * | 2020-12-17 | 2022-06-23 | National University Of Singapore | Treating cancers using bet inhibitors |
CA3203205A1 (en) | 2021-01-19 | 2022-07-28 | Mandar Ramesh Bhonde | Pharmaceutical combinations of sos1 inhibitors for treating and/or preventing cancer |
Family Cites Families (167)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
FR2404E (fr) | 1899-12-05 | 1904-03-26 | Louis Olivier Victor Parmentie | Machine ร copier les lettres |
JPS59170313A (ja) | 1983-03-14 | 1984-09-26 | Kurimoto Iron Works Ltd | ในใฏใชโใณใฒโใ |
JPS6053449A (ja) | 1983-09-01 | 1985-03-27 | M K Seikou Kk | ๆด่ปๆฉ |
JPS6085739U (ja) | 1983-11-18 | 1985-06-13 | ใฏใฉใชใชใณๆ ชๅผไผ็คพ | ใโใใฌใณโใใซใใใใใณใใญโใฉ่ฃ ็ฝฎ |
JPS6243003U (hr) | 1985-09-05 | 1987-03-14 | ||
JPH0314566A (ja) | 1989-06-09 | 1991-01-23 | Sankyo Co Ltd | ใใณใบใคใใใพใผใซ่ชๅฐไฝ |
US5244912A (en) | 1991-03-28 | 1993-09-14 | Eli Lilly And Company | 6-heterocyclic-4-amino-1,3,4,5-tetrahydrobenz(cd)indoles and pharmaceutical use thereof |
FR2710915B1 (fr) | 1993-10-04 | 1995-11-24 | Synthelabo | Dรฉrivรฉs de pipรฉridine, leur prรฉparation et leur utilisation en thรฉrapeutique. |
GB9410469D0 (en) | 1994-05-25 | 1994-07-13 | Erba Farmitalia | Imidazolylalkyl derivatives of imidazo (5,1-c) (1,4) benzoxazin-1-one and process for their preparation |
FR2731708B1 (fr) | 1995-03-13 | 1997-04-30 | Synthelabo | Derives de piperidine, leur procede de preparation et leur application en therapeutique |
FR2747678B1 (fr) | 1996-04-22 | 1998-05-22 | Synthelabo | Composes derives d'imidazobenzoxazine, leurs procedes de preparation et leurs utilisations en therapeutique |
US6287693B1 (en) | 1998-02-25 | 2001-09-11 | John Claude Savoir | Stable shaped particles of crystalline organic compounds |
WO2001081343A2 (en) | 2000-04-21 | 2001-11-01 | Pharmacia & Upjohn Company | Compounds for treating fibromyalgia and chronic fatigue syndrome |
NZ522783A (en) | 2000-06-28 | 2004-07-30 | Smithkline Beecham P | Wet milling process for pharmaceuticals with agitator or chamber having nylon with internal lubricant |
DE60107859T2 (de) | 2000-08-08 | 2005-12-22 | Sanofi-Aventis | Benzimidazolderivate, ihre herstellung und therapeutische verwendung |
FR2816619B1 (fr) | 2000-11-15 | 2003-01-31 | Sanofi Synthelabo | Derives de benzimidazole, leur preparation et leur application en therapeutique |
US6919334B2 (en) | 2002-09-12 | 2005-07-19 | Wyeth | Antidepressant azaheterocyclymethyl derivatives of 4,5-dihydroimidazo[1,4,5-de][1,4]benzoxazine |
JP3988830B2 (ja) | 2002-11-22 | 2007-10-10 | ๆฅๆฌใใฐใ็ฃๆฅญๆ ชๅผไผ็คพ | ็ธฎๅไบ็ฐๅผ็ช็ด ๅซๆ่ค็ด ็ฐ |
EP1462103A1 (en) | 2003-03-25 | 2004-09-29 | Faust Pharmaceuticals | NO donors, combination products and uses as modulators of neurotransmitter release |
CA2554774A1 (en) | 2004-02-23 | 2005-09-01 | Dainippon Sumitomo Pharma Co., Ltd. | Novel heterocyclic compound |
CA2562244A1 (en) | 2004-04-07 | 2005-10-27 | Takeda Pharmaceutical Company Limited | Cyclic compounds |
US7713954B2 (en) | 2004-09-30 | 2010-05-11 | Roche Palo Alto Llc | Compositions and methods for treating cognitive disorders |
DE102005011058A1 (de) | 2005-03-10 | 2006-09-14 | Merck Patent Gmbh | Substituierte Tetrahydro-pyrrolo-chinolinderivate |
WO2006124874A2 (en) | 2005-05-12 | 2006-11-23 | Kalypsys, Inc. | Inhibitors of b-raf kinase |
BRPI0614168A2 (pt) | 2005-08-05 | 2017-07-25 | Astrazeneca Ab | Composto ou um sal, hidrato, solvato, isoforma, tautรดmero, isรดmero รณptico farmaceuticamente aceitรกvel ou uma combinaรงรฃo dos mesmos, composiรงรฃo farmacรชutica, mรฉtodo para o tratamento ou prevenรงรฃo de distรบrbios neurolรณgicos e psquiรกtricos, uso de um composto, e, processo para a preparaรงรฃo de um composto |
EP2147310A4 (en) | 2007-04-27 | 2010-09-08 | Univ Rochester | COMPOSITIONS AND METHODS FOR INHIBITING G PROTEIN SIGNALING |
US9603848B2 (en) | 2007-06-08 | 2017-03-28 | Senomyx, Inc. | Modulation of chemosensory receptors and ligands associated therewith |
US8633186B2 (en) | 2007-06-08 | 2014-01-21 | Senomyx Inc. | Modulation of chemosensory receptors and ligands associated therewith |
US7928111B2 (en) | 2007-06-08 | 2011-04-19 | Senomyx, Inc. | Compounds including substituted thienopyrimidinone derivatives as ligands for modulating chemosensory receptors |
WO2009020559A2 (en) | 2007-08-03 | 2009-02-12 | The J. David Gladstone Institutes | Agents that inhibit p-tefb interactions and methods of use thereof |
JP5478262B2 (ja) | 2007-12-28 | 2014-04-23 | ็ฐ่พบไธ่ฑ่ฃฝ่ฌๆ ชๅผไผ็คพ | ๆ็ๅค |
DE102008052618A1 (de) | 2008-10-21 | 2010-04-22 | Henkel Ag & Co. Kgaa | Tricyclische Aldehyde und C,H-acide Verbindungen |
WO2010111626A2 (en) | 2009-03-27 | 2010-09-30 | Takeda Pharmaceutical Company Limited | Poly (adp-ribose) polymerase (parp) inhibitors |
TW201103941A (en) | 2009-06-10 | 2011-02-01 | Janssen Pharmaceutica Nv | Benzimidazole derivatives useful as TRPM8 channel modulators |
TW201105681A (en) | 2009-06-10 | 2011-02-16 | Janssen Pharmaceutica Nv | Benzimidazole derivatives useful as TRPM8 channel modulators |
WO2011024987A1 (ja) | 2009-08-31 | 2011-03-03 | ๅกฉ้็พฉ่ฃฝ่ฌๆ ชๅผไผ็คพ | ่ณ้ฆๆ็ธฎๅใธใใญ็ฐ่ชๅฐไฝใใใณใใใใๅซๆใใๅป่ฌ็ตๆ็ฉ |
GB0919431D0 (en) | 2009-11-05 | 2009-12-23 | Glaxosmithkline Llc | Novel compounds |
GB0919434D0 (en) | 2009-11-05 | 2009-12-23 | Glaxosmithkline Llc | Novel compounds |
EP2955524A3 (en) | 2009-11-05 | 2016-03-23 | GlaxoSmithKline LLC | Novel process |
EP2496582B1 (en) | 2009-11-05 | 2016-01-27 | GlaxoSmithKline LLC | Benzodiazepine bromodomain inhibitor |
GB0919423D0 (en) | 2009-11-05 | 2009-12-23 | Glaxosmithkline Llc | Novel compounds |
GB0919426D0 (en) | 2009-11-05 | 2009-12-23 | Glaxosmithkline Llc | Novel compounds |
GB0919432D0 (en) | 2009-11-05 | 2009-12-23 | Glaxosmithkline Llc | Use |
ES2652304T3 (es) | 2009-11-05 | 2018-02-01 | Glaxosmithkline Llc | Compuesto de benzodiacepina novedoso |
KR20130069640A (ko) | 2010-04-23 | 2013-06-26 | ํค๋คํ, ์ธํฌ. | ํญ-๋ฐ์ด๋ฌ์ค ํํฉ๋ฌผ |
CA2799403C (en) | 2010-05-14 | 2020-01-21 | Dana-Farber Cancer Institute, Inc. | Compositions and methods for treating leukemia |
WO2011143651A1 (en) | 2010-05-14 | 2011-11-17 | Dana-Farber Cancer Institute, Inc. | Compositions and methods for modulating metabolism |
BR112012029005A2 (pt) | 2010-05-14 | 2016-07-26 | Dana Farber Cancer Inst Inc | composiรงรตes e mรฉtodos de tratamento de neoplasia, doenรงa inflamatรณria e outros distรบrbios |
CN103180318B (zh) | 2010-05-14 | 2017-05-10 | ่พพ้ฃ-ๆณไผฏ็็็ ็ฉถๆ | ้ๆง้ฟๅญ็ปๅ็ฉไปฅๅไฝฟ็จๆนๆณ |
ES2526671T3 (es) | 2010-06-22 | 2015-01-14 | Glaxosmithkline Llc | Compuestos de benzotriazoldiazepina inhibidores de bromodominios |
US9249161B2 (en) | 2010-12-02 | 2016-02-02 | Constellation Pharmaceuticals, Inc. | Bromodomain inhibitors and uses thereof |
AR084070A1 (es) | 2010-12-02 | 2013-04-17 | Constellation Pharmaceuticals Inc | Inhibidores del bromodominio y usos de los mismos |
KR20130116358A (ko) | 2011-02-09 | 2013-10-23 | ์ํ. ํธํ๋ง-๋ผ ๋ก์ ์๊ฒ | Pi3 ํค๋์์ ์ต์ ์ ๋ก์ ํคํ ๋ก์ฌ์ดํด๋ฆญ ํํฉ๋ฌผ |
CA2828212A1 (en) | 2011-02-23 | 2012-08-30 | Shiraz Mujtaba | Inhibitors of bromodomains as modulators of gene expression |
KR20140032383A (ko) | 2011-03-21 | 2014-03-14 | ์ํ. ํธํ๋ง-๋ผ ๋ก์ ์๊ฒ | Pi3k p110 ๋ธํ์ ๋ํ์ฌ ์ ํ์ ์ธ ๋ฒค์ฆ์ฅ์ฌ์ ํ ํํฉ๋ฌผ ๋ฐ ์ด์ ์ฌ์ฉ ๋ฐฉ๋ฒ |
GB201106743D0 (en) | 2011-04-21 | 2011-06-01 | Glaxosmithkline Llc | Novel compounds |
GB201106750D0 (en) | 2011-04-21 | 2011-06-01 | Glaxosmithkline Llc | Novel compounds |
GB201106799D0 (en) | 2011-04-21 | 2011-06-01 | Glaxosmithkline Llc | Novel compounds |
EP2705039B1 (en) | 2011-05-04 | 2017-07-26 | Constellation Pharmaceuticals, Inc. | Bromodomain inhibitors and uses thereof |
GB201107325D0 (en) | 2011-05-04 | 2011-06-15 | Glaxosmithkline Llc | Novel compounds |
US9328117B2 (en) | 2011-06-17 | 2016-05-03 | Constellation Pharmaceuticals, Inc. | Bromodomain inhibitors and uses thereof |
US20150197497A1 (en) | 2011-06-24 | 2015-07-16 | Dana-Farber Cancer Institute, Inc. | Selective inhibitors of histone deacetylase isoform 6 and methods thereof |
JP2013010719A (ja) | 2011-06-30 | 2013-01-17 | Dainippon Sumitomo Pharma Co Ltd | ใใณใบใคใใใพใญใณใใใณใชใญใทใคใณใใผใซ่ชๅฐไฝใชใใณใซใใใใฎๅป่ฌ็จ้ |
JP2014524409A (ja) | 2011-07-29 | 2014-09-22 | ใถใปใใซใใฌใณใบใปใในใใฟใซใปใชใใปใใฃใฉใใซใใฃใข | ๏ผจ๏ฝ๏ฝใฎๆฒป็ใฎใใใฎ็ตๆ็ฉใใใณๆนๆณ |
GB201114103D0 (en) | 2011-08-17 | 2011-09-28 | Glaxosmithkline Llc | Novel compounds |
WO2013027168A1 (en) | 2011-08-22 | 2013-02-28 | Pfizer Inc. | Novel heterocyclic compounds as bromodomain inhibitors |
WO2013033269A1 (en) | 2011-08-29 | 2013-03-07 | Coferon, Inc. | Bioorthogonal monomers capable of dimerizing and targeting bromodomains and methods of using same |
WO2013033268A2 (en) | 2011-08-29 | 2013-03-07 | Coferon, Inc. | Bivalent bromodomain ligands, and methods of using same |
TWI606044B (zh) | 2011-08-31 | 2017-11-21 | ๅคงๅก่ฃฝ่ฅ่กไปฝๆ้ๅ ฌๅธ | ๅนๅ้ ฎๅๅ็ฉ |
DE102011082013A1 (de) | 2011-09-01 | 2013-03-07 | Bayer Pharma AG | 6H-Thieno[3,2-f][1,2,4]triazolo[4,3-a][1,4]diazepine |
EP2757887B1 (en) | 2011-09-22 | 2017-04-26 | VIIV Healthcare UK Limited | Pyrrolopyridinone compounds and methods for treating hiv |
CN103857391B (zh) | 2011-09-30 | 2016-06-08 | ๆฒ้ณ่ๆกๅป่ฏ็็ฉๆๆฏ็ ๅๆ้ๅ ฌๅธ | ๅซๆ็ๅฉๆ ผๅ ้ ฏ็่ฏ็ฉ็ปๅ็ฉๅๅ ถๅบ็จ |
WO2013060636A1 (en) | 2011-10-25 | 2013-05-02 | Sanofi | 6-(4-hydroxy-phenyl)-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors |
CN103945848B (zh) | 2011-11-01 | 2016-09-07 | ้ทๆฏ้ฆๆดๅๅ ๆฏๅ ฌๅธ | ่ขซๅไปฃ็ๅนๅๅ้ ฎ็ๅฃๆๅณ้ๅถๅ |
WO2013097052A1 (en) | 2011-12-30 | 2013-07-04 | Abbott Laboratories | Bromodomain inhibitors |
US20150133434A1 (en) | 2012-03-28 | 2015-05-14 | The J. David Gladstone Institutes | Compositions and Methods for Reactivating Latent Immunodeficiency Virus |
US20130281398A1 (en) | 2012-04-19 | 2013-10-24 | Rvx Therapeutics Inc. | Treatment of diseases by epigenetic regulation |
US20130281397A1 (en) | 2012-04-19 | 2013-10-24 | Rvx Therapeutics Inc. | Treatment of diseases by epigenetic regulation |
US20130281399A1 (en) | 2012-04-19 | 2013-10-24 | Rvx Therapeutics Inc. | Treatment of diseases by epigenetic regulation |
US20130281396A1 (en) | 2012-04-19 | 2013-10-24 | Rvx Therapeutics Inc. | Treatment of diseases by epigenetic regulation |
JP5989229B2 (ja) | 2012-04-20 | 2016-09-07 | ใขใใดใฃใปใคใณใณใผใใฌใคใใใ | ใคใฝใคใณใใญใณ่ชๅฐไฝ |
TWI602820B (zh) | 2012-06-06 | 2017-10-21 | ๆๅฎฟ่ฅ็ฉๅ ฌๅธ | ๆบดๅๆๅถๅๅๅ ถ็จ้ |
US9624244B2 (en) | 2012-06-06 | 2017-04-18 | Constellation Pharmaceuticals, Inc. | Benzo [B] isoxazoloazepine bromodomain inhibitors and uses thereof |
CN104718201A (zh) | 2012-06-12 | 2015-06-17 | ่พไผฏ็ปดๅ ฌๅธ | ๅกๅถ้ ฎๅๅๅช้ ฎ่ก็็ฉ |
BR112014032105A2 (pt) | 2012-06-25 | 2017-08-01 | Oncoethix Sa | mรฉtodo para o tratamento de cรขncer |
WO2014015175A1 (en) | 2012-07-18 | 2014-01-23 | Massachusetts Institute Of Technology | Compositions and methods for modulating brd4 bioactivity |
JP2015524847A (ja) | 2012-08-16 | 2015-08-27 | ใฐใฉใฏใฝในใในใฏใฉใคใณใปใชใใใใใปใฉใคใขใใชใใฃใปใซใณใใใผ๏ผง๏ฝ๏ฝ๏ฝ๏ฝ๏ผณ๏ฝ๏ฝ๏ฝ๏ฝ๏ผซ๏ฝ๏ฝ๏ฝ๏ฝ ๏ผฌ๏ผฌ๏ผฃ | ๅฐ็ดฐ่่บใใใๆฒป็ใใใใใฎใใณใพใธใขใผใใณ |
EA201590356A1 (ru) | 2012-08-16 | 2015-07-30 | ะะฐะนะตั ะคะฐัะผะฐ ะะบัะธะตะฝะณะตะทะตะปััะฐัั | 2,3-ะฑะตะฝะทะพะดะธะฐะทะตะฟะธะฝั |
WO2014068402A2 (en) | 2012-09-28 | 2014-05-08 | Oncoethix Sa | Pharmaceutical formulation containing thienotriazolodiazepine compounds |
JP6276277B2 (ja) | 2012-09-28 | 2018-02-07 | ใใคใจใซ ใใกใผใ ใขใฏใใจใณใฒใผใซใทใฃใใ | ๏ผข๏ฝ ๏ฝใฟใณใใฏ่ณช้ปๅฎณๆงใฎ๏ผโใขใชใผใซใใชใขใพใญใขใผใใณ |
KR20150079968A (ko) | 2012-11-09 | 2015-07-08 | ์์ฝ๋ฒ์ค ํ๋ง์ํฐ์ปฌ ์ปดํจ๋, ์ธ์ฝํฌ๋ ์ดํฐ๋ | ํคํ ๋ก์๋ฆด ์ ๋์ฒด ๋ฐ ๊ทธ์ ์ฉ๋ |
US9422290B2 (en) | 2012-11-13 | 2016-08-23 | Boehringer Ingelheim International Gmbh | Triazolopyridazine |
EP2920183B1 (en) | 2012-11-14 | 2017-03-08 | Glaxosmithkline LLC | Thieno[3,2-c]pyridin-4(5h)-ones as bet inhibitors |
US9765039B2 (en) | 2012-11-21 | 2017-09-19 | Zenith Epigenetics Ltd. | Biaryl derivatives as bromodomain inhibitors |
US9073878B2 (en) | 2012-11-21 | 2015-07-07 | Zenith Epigenetics Corp. | Cyclic amines as bromodomain inhibitors |
WO2014095774A1 (de) | 2012-12-20 | 2014-06-26 | Bayer Pharma Aktiengesellschaft | Bet-proteininhibitorische dihydropyridopyrazinone |
WO2014095775A1 (de) | 2012-12-20 | 2014-06-26 | Bayer Pharma Aktiengesellschaft | Bet-proteininhibitorische dihydrochinoxalinone |
CN105073744B (zh) | 2012-12-21 | 2019-11-08 | ้ฝๅฐผๆ่กจ่ง้ไผ ๅญฆๆ้ๅ ฌๅธ | ไฝไธบๆบด็ปๆๅๆๅถๅ็ๆฐๅๆ็ฏๅๅ็ฉ |
WO2014128655A1 (en) | 2013-02-25 | 2014-08-28 | Aurigene Discovery Technologies Limited | Substituted imidazo[4,5-c]quinoline derivatives as bromodomain inhibitors |
US9492460B2 (en) | 2013-02-27 | 2016-11-15 | Bristol-Myers Squibb Company | Carbazole compounds useful as bromodomain inhibitors |
WO2014134267A1 (en) | 2013-02-27 | 2014-09-04 | Bristol-Myers Squibb Company | Carbazole compounds useful as bromodomain inhibitors |
US9675697B2 (en) | 2013-03-11 | 2017-06-13 | The Regents Of The University Of Michigan | BET bromodomain inhibitors and therapeutic methods using the same |
AU2014249025A1 (en) | 2013-03-11 | 2015-09-17 | Abbvie Inc. | Bromodomain inhibitors |
EP2970285B1 (en) | 2013-03-11 | 2019-04-17 | AbbVie Inc. | Fused tetracyclic bromodomain inhibitors |
MX2015011984A (es) | 2013-03-12 | 2015-12-15 | Abbvie Inc | Inhibidores de bromodominio de dihidro-pirrolopiridinona. |
CN108440528A (zh) | 2013-03-12 | 2018-08-24 | ่พไผฏ็ปดๅ ฌๅธ | ๅ็ฏๅธ็ฝ่ซ็ปๆๅๆๅถๅ |
AU2014248647A1 (en) | 2013-03-12 | 2015-10-01 | Abbvie Inc. | Pyrrole amide inhibitors |
AU2014230816B9 (en) | 2013-03-14 | 2016-12-15 | Glaxosmithkline Intellectual Property (No.2) Limited | Furopyridines as bromodomain inhibitors |
SG11201506245QA (en) | 2013-03-14 | 2015-09-29 | Glaxosmithkline Ip No 2 Ltd | 2,3-disubstituted 1 -acyl-4-amino-1,2,3,4-tetrahydroquinoline derivatives and their use as bromodomain inhibitors |
WO2014159392A1 (en) | 2013-03-14 | 2014-10-02 | Dana-Farber Cancer Institute, Inc. | Bromodomain binding reagents and uses thereof |
CN105407894A (zh) | 2013-03-14 | 2016-03-16 | ๅบทๅจๅบๅ ๆ้ๅ ฌๅธ | ็จไบๆๅถๅซๅธ็ฝ่ซ็ปๆๅ็่็ฝ่ดจ็ๆนๆณๅ็ปๅ็ฉ |
KR102355670B1 (ko) | 2013-03-15 | 2022-02-08 | ์ธ์ฌ์ดํธ ํ๋ฉ์ค ์ฝํฌ๋ ์ด์ | Bet ๋จ๋ฐฑ์ง ์ ํด์ ๋ก์์ ์ผํ์ ๋ณต์ํ |
US20160039842A1 (en) | 2013-03-15 | 2016-02-11 | Epigenetix, Inc. | Oxazolo[5,4-c]quinolin-2-one compounds as bromodomain inhibitors |
PL2970265T3 (pl) | 2013-03-15 | 2018-11-30 | Plexxikon Inc. | Heterocykliczne zwiฤ zki i ich zastosowania |
JP6370368B2 (ja) | 2013-03-27 | 2018-08-08 | ใใผใชใณใฌใผ ใคใณใฒใซใใคใ ใคใณใฟใผใใทใงใใซ ใฒใผใซใทใฃใใ ใใใ ใใทใฅใฌใณใฏใใซ ใใใใณใฐ | ๏ผข๏ฝ๏ฝ๏ผ้ปๅฎณๅคใจใใฆใฎใคใณใใชใใณ้กไผผไฝ |
JP6453845B2 (ja) | 2013-03-27 | 2019-01-16 | ใใผใชใณใฌใผ ใคใณใฒใซใใคใ ใคใณใฟใผใใทใงใใซ ใฒใผใซใทใฃใใ ใใใ ใใทใฅใฌใณใฏใใซ ใใใใณใฐ | ๏ผข๏ฝ๏ฝ๏ผ้ปๅฎณ่ฌใจใใฆใฎใธใใใญใญใใพใชใใณ้กไผผไฝ |
TWI530499B (zh) | 2013-03-28 | 2016-04-21 | ๅๆๅพท็งๅญธ่กไปฝๆ้ๅ ฌๅธ | ไฝ็บๆบด็ตๆงๅ๏ผ๏ฝ๏ฝ๏ฝ๏ฝ๏ฝ๏ฝ๏ฝ๏ฝ๏ฝ๏ฝ๏ฝ๏ผๆๅถๅไน่ฏไธฆๅชๅ้ ฎ่ก็็ฉ้ก |
US10435364B2 (en) | 2013-04-17 | 2019-10-08 | Albert Ludwigs Universitรคt Freiburg | Compounds for use as bromodomain inhibitors |
MX366623B (es) | 2013-04-26 | 2019-07-16 | Beigene Ltd | 5-(3,5-dimetilisoxazol-4-il)indolina-2-onas sustituidas. |
TWI527811B (zh) | 2013-05-09 | 2016-04-01 | ๅๆๅพท็งๅญธ่กไปฝๆ้ๅ ฌๅธ | ไฝ็ฒๆบด็ตๆงๅๆๅถๅ็่ฏไธฆๅชๅ่ก็็ฉ |
EA029312B1 (ru) | 2013-05-27 | 2018-03-30 | ะะพะฒะฐััะธั ะะณ | ะัะพะธะทะฒะพะดะฝัะต ะธะผะธะดะฐะทะพะฟะธััะพะปะธะดะธะฝะพะฝะฐ ะธ ะธั ะฟัะธะผะตะฝะตะฝะธะต ะฟัะธ ะปะตัะตะฝะธะธ ะทะฐะฑะพะปะตะฒะฐะฝะธะน |
US8975417B2 (en) | 2013-05-27 | 2015-03-10 | Novartis Ag | Pyrazolopyrrolidine derivatives and their use in the treatment of disease |
AU2014272695B2 (en) | 2013-05-28 | 2016-10-20 | Novartis Ag | Pyrazolo-pyrrolidin-4-one derivatives as BET inhibitors and their use in the treatment of disease |
PT3004112T (pt) | 2013-05-28 | 2017-12-11 | Novartis Ag | Derivados de pirazolo-pirrolidin-4-ona e sua utilizaรงรฃo no tratamento de doenรงa |
CA2915419A1 (en) | 2013-06-17 | 2014-12-24 | Bayer Pharma Aktiengesellschaft | Substituted phenyl-2,3-benzodiazepines |
ITMI20130991A1 (it) | 2013-06-17 | 2014-12-18 | Industrie De Nora Spa | Sistema per la misurazione di correnti presenti sugli elettrodi in celle elettrolitiche interconnesse. |
ES2661437T3 (es) | 2013-06-21 | 2018-04-02 | Zenith Epigenetics Corp. | Nuevos compuestos bicรญclicos sustituidos como inhibidores de bromodominio |
JP6461121B2 (ja) | 2013-06-21 | 2019-01-30 | ใผใในใปใจใใธใงใใใฃใฏในใปใชใใใใ๏ผบ๏ฝ ๏ฝ๏ฝ๏ฝ๏ฝ ๏ผฅ๏ฝ๏ฝ๏ฝ๏ฝ ๏ฝ๏ฝ ๏ฝ๏ฝ๏ฝ๏ฝ ๏ผฌ๏ฝ๏ฝ๏ผ | ๆฐ่ฆใฎไบ็ฐๅผใใญใขใใกใคใณ้ปๅฎณๅค |
SG11201510678TA (en) | 2013-06-28 | 2016-01-28 | Abbvie Inc | Bromodomain inhibitors |
AR096758A1 (es) | 2013-06-28 | 2016-02-03 | Abbvie Inc | Inhibidores cristalinos de bromodominios |
US9290514B2 (en) | 2013-07-08 | 2016-03-22 | Incyte Holdings Corporation | Tricyclic heterocycles as BET protein inhibitors |
PL3022191T3 (pl) | 2013-07-16 | 2017-08-31 | Basf Se | Chwastobรณjcze azyny |
US9975896B2 (en) | 2013-07-25 | 2018-05-22 | Dana-Farber Cancer Institute, Inc. | Inhibitors of transcription factors and uses thereof |
KR101672096B1 (ko) | 2013-09-30 | 2016-11-02 | ์ฃผ์ํ์ฌ ์์งํํ | ํคํ ๋กํ ํํฉ๋ฌผ ๋ฐ ์ด๋ฅผ ํฌํจํ๋ ์ ๊ธฐ ๋ฐ๊ด ์์ |
RS60136B1 (sr) | 2013-10-18 | 2020-05-29 | Celgene Quanticel Research Inc | Inhibitori bromodomena |
WO2015081246A1 (en) | 2013-11-26 | 2015-06-04 | Incyte Corporation | Bicyclic heterocycles as bet protein inhibitors |
WO2015081203A1 (en) | 2013-11-26 | 2015-06-04 | Incyte Corporation | Bicyclic heterocycles as bet protein inhibitors |
US9315501B2 (en) | 2013-11-26 | 2016-04-19 | Incyte Corporation | Bicyclic heterocycles as BET protein inhibitors |
MX2016007346A (es) | 2013-12-09 | 2016-09-13 | Abbvie Inc | Derivados de dihidropiridinona y dihidropiridazinona utiles como inhibidores de bromodominio. |
US9309246B2 (en) | 2013-12-19 | 2016-04-12 | Incyte Corporation | Tricyclic heterocycles as BET protein inhibitors |
WO2015095445A1 (en) | 2013-12-20 | 2015-06-25 | Merck Sharp & Dohme Corp. | Thiazole-substituted aminoheteroaryls as spleen tyrosine kinase inhibitors |
PE20161021A1 (es) | 2014-01-09 | 2016-11-09 | Orion Corp | Derivados heterociclicos biciclicos como inhibidores de bromodominio |
AU2015222887B2 (en) | 2014-02-28 | 2019-06-27 | The Regents Of The University Of Michigan | 9H-pyrimido[4,5-b]indoles and related analogs as BET bromodomain inhibitors |
WO2015162169A1 (en) | 2014-04-23 | 2015-10-29 | Basf Se | Diaminotriazine compounds as herbicides |
ME03763B (me) * | 2014-04-23 | 2021-04-20 | Incyte Corp | 1h-pirrolo[2,3-c]piridin-7(6h)-oni i pirazolo[3,4-c]piridin-7(6h)-oni kao inhibitori bet proteina |
SI3134386T1 (sl) | 2014-04-23 | 2020-10-30 | Takeda Pharmaceutical Company Limited | Izoindolin-1-onski derivati kot holinergiฤni muskarinski M1 receptor pozitivna alosteriฤna modulatorna aktivnost za zdravljenje Alzheimerjeve bolezni |
RU2016146099A (ru) | 2014-05-02 | 2018-06-05 | ะะฝะบะพััะธะบั ะะผะฑั | ะกะฟะพัะพะฑ ะปะตัะตะฝะธั ะพัััะพะณะพ ะผะธะตะปะพะธะดะฝะพะณะพ ะปะตะนะบะพะทะฐ ะธ/ะธะปะธ ะพัััะพะณะพ ะปะธะผัะพะฑะปะฐััะฝะพะณะพ ะปะตะนะบะพะทะฐ ั ะฟะพะผะพััั ัะธะตะฝะพััะธะฐะทะพะปะพะดะธะฐะทะตะฟะธะฝะพะฒัั ัะพะตะดะธะฝะตะฝะธะน |
CA2947593A1 (en) | 2014-05-02 | 2015-11-05 | Oncoethix Gmbh | Method of treating resistant non-hodgkin lymphoma, medulloblastoma, and/or alk+non-small cell lung cancer using thienotriazolodiazepine compounds |
WO2015169953A1 (en) | 2014-05-08 | 2015-11-12 | Oncoethix Gmbh | Method of treating glioma using thienotriazolodiazepine compounds |
EP3139959A1 (en) | 2014-05-08 | 2017-03-15 | Oncoethix GmbH | Method of treating triple-negative breast cancer using thienotriazolodiazepine compounds |
WO2015184257A2 (en) | 2014-05-30 | 2015-12-03 | Icahn School Of Medicine At Mount Sinai | Small molecule transcription modulators of bromodomains |
US9969747B2 (en) | 2014-06-20 | 2018-05-15 | Constellation Pharmaceuticals, Inc. | Crystalline forms of 2-((4S)-6-(4-chlorophenyl)-1-methyl-4H-benzo[C]isoxazolo[4,5-e]azepin-4-yl)acetamide |
EP3194406B8 (en) | 2014-09-15 | 2021-03-31 | Incyte Corporation | Tricyclic heterocycles for use as bet protein inhibitors |
EA034931B1 (ru) | 2014-10-24 | 2020-04-08 | ะัะธััะพะป-ะะฐะนะตัั ะกะบะฒะธะฑะฑ ะะพะผะฟะฐะฝะธ | ะะฝะดะพะปะบะฐัะฑะพะบัะฐะผะธะดะฝัะต ัะพะตะดะธะฝะตะฝะธั |
MA40943A (fr) | 2014-11-10 | 2017-09-19 | Constellation Pharmaceuticals Inc | Pyrrolopyridines substituรฉes utilisรฉes en tant qu'inhibiteurs de bromodomaines |
US10259809B2 (en) | 2015-02-03 | 2019-04-16 | Trillium Therapeutics Inc. | Fluorinated imidazo[4,5-C]quinoline derivatives as inhibitors of bromodomain containing proteins |
WO2016186453A1 (en) | 2015-05-20 | 2016-11-24 | Kainos Medicine, Inc. | Quinoline derivatives as bromodomain inhibitors |
KR20180011267A (ko) | 2015-05-29 | 2018-01-31 | ์์ค๋ ธ๊ธฐ ์ค๋ ์ปดํ๋, ๋ฆฌ๋ฏธํฐ๋ | Hiv ๋ณต์ ์ ํด ์์ฉ์ ๊ฐ๋ ํจ์ง์ 3ํ์ฑ ์ ๋์ฒด |
CN105039258B (zh) | 2015-07-03 | 2018-04-17 | ๅไบฌๅคงๅญฆ | ๅฐ้็ฅ็ปๅ ็ป่้็ผ็จไธบ็ฅ็ปๅ ๆ ท็ป่็ๆนๆณๅ็ปๅ็ฉ |
TW201722966A (zh) | 2015-10-29 | 2017-07-01 | ่ฑๅก็นๅ ฌๅธ | Bet่็ฝ่ณชๆๅถๅไน้ๆถๅบ้ซๅฝขๅผ |
CN105254635A (zh) | 2015-10-30 | 2016-01-20 | ไธญๅฝ่ฏ็งๅคงๅญฆ | ไธ็ฑปๅชๅๅนถๅกๅช็ฑปๅๅ็ฉๅๅ ถ่ฏ็ฉ็ปๅ็ฉๅ็จ้ |
US20170127985A1 (en) | 2015-11-11 | 2017-05-11 | Medtronic Minimed, Inc. | Sensor set |
CA3007168A1 (en) | 2015-12-14 | 2017-06-22 | Zenith Epigenetics Ltd. | 1h-imidazo[4,5-b]pyridinyl and 2-oxo-2,3-dihydro-1h-imidazo[4,5-b]pyridinyl heterocyclic bet bromodomain inhibitors |
WO2017127930A1 (en) | 2016-01-28 | 2017-08-03 | Neomed Institute | Substituted [1,2,4]triazolo[4,3-a]pyridines, their preparation and their use as pharmaceuticals |
WO2017133681A1 (zh) | 2016-02-05 | 2017-08-10 | ๆญฃๅคงๅคฉๆด่ฏไธ้ๅข่กไปฝๆ้ๅ ฌๅธ | ๆบดๅบ็ปๆๅ่็ฝๆๅถๅ็ไธ็ฏ็ฑปๅๅ็ฉๅๅ ถๅถๅคใ่ฏ็ฉ็ปๅ็ฉๅ็จ้ |
PE20190623A1 (es) | 2016-06-20 | 2019-04-26 | Incyte Corp | Formas solidas cristalinas de un inhibidor de bet |
CN108069958A (zh) | 2016-11-10 | 2018-05-25 | ๅฏๆ ็งๆๅๅฑ(ไธๆตท)ๆ้ๅ ฌๅธ | ไธ็งๅซๆฐฎๆ็ฏ็ฑปๅๅ็ฉใๅ ถๅถๅคๆนๆณใ่ฏ็ฉ็ปๅ็ฉๅๅบ็จ |
-
2015
- 2015-04-22 ME MEP-2020-64A patent/ME03763B/me unknown
- 2015-04-22 LT LTEP20156599.1T patent/LT3674302T/lt unknown
- 2015-04-22 DK DK20156599.1T patent/DK3674302T3/da active
- 2015-04-22 MX MX2016013851A patent/MX2016013851A/es active IP Right Grant
- 2015-04-22 CR CR20200231A patent/CR20200231A/es unknown
- 2015-04-22 LT LTEP15721085.7T patent/LT3134403T/lt unknown
- 2015-04-22 ES ES15721085T patent/ES2784846T3/es active Active
- 2015-04-22 EP EP15721085.7A patent/EP3134403B1/en active Active
- 2015-04-22 KR KR1020227026808A patent/KR20220113552A/ko not_active Application Discontinuation
- 2015-04-22 CN CN201580025765.3A patent/CN106414442B/zh active Active
- 2015-04-22 UA UAA201611803A patent/UA119870C2/uk unknown
- 2015-04-22 KR KR1020167032545A patent/KR102430144B1/ko active IP Right Grant
- 2015-04-22 RS RS20200395A patent/RS60139B1/sr unknown
- 2015-04-22 PT PT201565991T patent/PT3674302T/pt unknown
- 2015-04-22 CA CA2946731A patent/CA2946731C/en active Active
- 2015-04-22 SG SG10201809353TA patent/SG10201809353TA/en unknown
- 2015-04-22 HU HUE20156599A patent/HUE061770T2/hu unknown
- 2015-04-22 US US14/693,424 patent/US9540368B2/en active Active
- 2015-04-22 MA MA39985A patent/MA39985B1/fr unknown
- 2015-04-22 NZ NZ763740A patent/NZ763740A/en unknown
- 2015-04-22 DK DK15721085.7T patent/DK3134403T3/da active
- 2015-04-22 AU AU2015249810A patent/AU2015249810B2/en active Active
- 2015-04-22 NZ NZ763737A patent/NZ763737A/en unknown
- 2015-04-22 BR BR112016024626-8A patent/BR112016024626B1/pt active IP Right Grant
- 2015-04-22 TW TW108123445A patent/TWI735002B/zh active
- 2015-04-22 AR ARP150101214A patent/AR100160A1/es active IP Right Grant
- 2015-04-22 WO PCT/US2015/027047 patent/WO2015164480A1/en active Application Filing
- 2015-04-22 PL PL15721085T patent/PL3134403T3/pl unknown
- 2015-04-22 TW TW104112916A patent/TWI672301B/zh active
- 2015-04-22 JP JP2016563976A patent/JP6572237B2/ja active Active
- 2015-04-22 PE PE2016002116A patent/PE20170144A1/es active IP Right Grant
- 2015-04-22 SG SG11201608843TA patent/SG11201608843TA/en unknown
- 2015-04-22 SI SI201531116T patent/SI3134403T1/sl unknown
- 2015-04-22 SI SI201531941T patent/SI3674302T1/sl unknown
- 2015-04-22 EP EP23157487.2A patent/EP4218766A1/en active Pending
- 2015-04-22 PL PL20156599.1T patent/PL3674302T3/pl unknown
- 2015-04-22 RS RS20230379A patent/RS64231B1/sr unknown
- 2015-04-22 EA EA201692134A patent/EA034972B1/ru unknown
- 2015-04-22 EA EA202090371A patent/EA039678B1/ru unknown
- 2015-04-22 HR HRP20230340TT patent/HRP20230340T1/hr unknown
- 2015-04-22 HU HUE15721085A patent/HUE049627T2/hu unknown
- 2015-04-22 PT PT157210857T patent/PT3134403T/pt unknown
- 2015-04-22 FI FIEP20156599.1T patent/FI3674302T3/fi active
- 2015-04-22 MY MYPI2016001898A patent/MY180775A/en unknown
- 2015-04-22 CR CR20160542A patent/CR20160542A/es unknown
- 2015-04-22 ES ES20156599T patent/ES2942723T3/es active Active
- 2015-04-22 EP EP20156599.1A patent/EP3674302B1/en active Active
- 2015-04-22 NZ NZ725930A patent/NZ725930A/en unknown
-
2016
- 2016-10-20 IL IL248415A patent/IL248415B/en active IP Right Grant
- 2016-10-21 CL CL2016002681A patent/CL2016002681A1/es unknown
- 2016-10-21 MX MX2020011035A patent/MX2020011035A/es unknown
- 2016-10-21 PH PH12016502115A patent/PH12016502115B1/en unknown
- 2016-11-17 US US15/354,223 patent/US9957268B2/en active Active
- 2016-11-18 EC ECIEPI201688983A patent/ECSP16088983A/es unknown
-
2018
- 2018-03-21 US US15/927,170 patent/US10472358B2/en active Active
-
2019
- 2019-07-15 AU AU2019205984A patent/AU2019205984B2/en active Active
- 2019-08-09 JP JP2019147776A patent/JP6745390B2/ja active Active
- 2019-10-21 US US16/658,445 patent/US10781209B2/en active Active
-
2020
- 2020-03-04 IL IL273049A patent/IL273049B/en active IP Right Grant
- 2020-04-07 HR HRP20200564TT patent/HRP20200564T1/hr unknown
- 2020-04-27 CY CY20201100382T patent/CY1122948T1/el unknown
- 2020-08-14 US US16/994,172 patent/US11059821B2/en active Active
-
2021
- 2021-01-22 AU AU2021200450A patent/AU2021200450B2/en active Active
- 2021-03-04 IL IL281263A patent/IL281263B/en unknown
- 2021-06-04 US US17/339,546 patent/US11702416B2/en active Active
-
2023
- 2023-05-18 CY CY20231100237T patent/CY1126052T1/el unknown
- 2023-05-31 US US18/204,136 patent/US20240002381A1/en active Pending
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
HRP20230340T1 (hr) | 1-h-pirolo[2,3-c]piridin-7(6h)-oni i pirazolo[3,4-c]piridin-7(6h)-oni kao inhibitori bet proteina | |
AU2020233606A1 (en) | Combination therapy with 7-benzyl-10-(2-methylbenzyl)-2,6,7,8,9,10-hexahydroimidazo[1,2-a]pyrido[4,3-d]pyrimidin-5(3h)-one | |
ES2873895T3 (es) | Compuestos y derivados de espiro[3H-indol-3,2-pirrolidin]-2(1H)-ona como inhibidores de MDM2-p53 | |
US20200038406A1 (en) | 7-benzyl-4-(methylbenzyl)-2,4,6,7,8,9-hexahydroimidazo[1,2-a]pyrido[3,4-e]pyrimidin-5 (1h)-one, salts thereof and methods of using the same in combination therapy | |
AU2020200875B2 (en) | 7-benzyl-4-(2-methylbenzyl)-2,4,6,7,8,9-hexahydroimidazo[1,2-a]pyrido[3,4-e]pyrimidin-5(1h)-one, salts thereof and methods of use | |
JP2015510944A5 (hr) | ||
WO2016001376A1 (en) | New spiro[3h-indole-3,2ยด-pyrrolidin]-2(1h)-one compounds and derivatives as mdm2-p53 inhibitors | |
CA2851151A1 (en) | Aminoquinazoline derivatives and their salts and methods of use | |
US10045992B2 (en) | 7-benzyl-4-(methylbenzyl)-2,4,6,7,8,9-hexahydroimidazo[1,2-a]pyrido[3,4-e]pyrimidin-5 (1h)-one, salts thereof and methods of using the same in combination therapy | |
WO2015073072A1 (en) | 7-benzyl-4-(2-methylbenzyl)-2,4,6,7,8,9-hexahydroimidazo[1,2-a]pyrido[3,4-e]pyrimidin-5(1h)-one | |
EP3927433A1 (en) | Pyrido-pyrimidinyl compounds and methods of use | |
AU2019355057A1 (en) | Method for preparing and delivering bisantrene formulations | |
EP4351583A1 (en) | Therapeutics for the degradation of mutant braf | |
AU2022280070A1 (en) | Egfr degraders to treat cancer metastasis to the brain or cns | |
WO2022170198A1 (en) | Ubiquitin-specific protease 7 (usp7) inhibitors and uses thereof |